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Many anticancer and antibacterial therapies are based on the interaction of small 
molecule drugs with DNA. Increasing interest in the development of DNA-interactive 
agents has fostered the need for sensitive and versatile analytical techniques that are 
capable of characterizing the DNA/ligand interactions and are compatible with library-
based screening methods. Electrospray ionization mass spectrometry (ESI-MS) has 
emerged as a useful technique for the analysis of non-covalent complexes formed 
between DNA and small molecules due to its low sample consumption and fast analysis 
time. The work presented in this dissertation is aimed at exploring, optimizing, and 
validating ESI-MS methods for characterizing DNA-ligand interactions.  
ESI-MS is first used to assess the binding of threading bis-intercalators to 
duplexes containing different sequences to determine high affinity binding sites of the 
ligands. Preliminary DNAse footprinting experiments identified possible specific binding 
sites of the ligands and ESI-MS experiments revealed that the ligands bound to DNA 
duplexes containing the respective specific binding sequences. The metal-mediated 
 vii
binding of benzoxazole ligands with different side chains to duplex DNA is also 
examined. Cu2+ and Ni2+ were found to promote the most dramatic increase in ligand 
binding, and ligands exhibiting the most dramatic metal-mediated or metal-enhanced 
binding were also determined to be the most cytotoxic.  
The quadruplex DNA binding selectivity of perylene diimides is evaluated by 
screening the binding of the ligands to quadruplex, duplex and single strand DNA by 
ESI-MS. Three ligands, one containing basic side chains, one containing anionic side-
chains, and one benzannulated compound were determined to be the most-quadruplex 
selective. The ESI-MS results correlated well with spectroscopic experiments. The 
relative gas-phase stabilities of different quadruplex DNA structures were investigated 
using molecular dynamics simulations and ESI-MS. The stabilities from the E1/2 values 
generally paralleled the RMSD and relative free energies of the quadruplexes based on 
MD energy analysis. Finally an ESI-MS technique employing the KMnO4 reaction with 
DNA to determine conformational changes to the duplex structure upon ligand binding is 
detailed. Thymines in most intercalator/duplex complexes are more susceptible to 
oxidation by KMnO4 than those in duplex DNA. CAD and IRMPD experiments are used 
to identify the site of oxidation. 
 viii
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Chapter 1: Introduction 
The therapeutic basis of many anticancer and antibacterial drugs is the non-
covalent binding of small molecules to nucleic acid substrates.1,2 Increased interest in the 
development and characterization of DNA-interactive agents has fostered the need for 
sensitive and versatile analytical techniques that are capable of characterizing the binding 
of these compounds. ESI-MS has emerged as a useful tool for the analysis of non-
covalent drug/DNA complexes due to its high sensitivity and fast analysis time making it 
adaptable to high throughput screening techniques. In gently transferring non-covalent 
complexes in solution to the gas-phase, ESI-MS allows for the characterization of many 
aspects of the drug/DNA binding interaction including complex binding stoichiometries, 
ligand sequence selectivities and relative binding affinities. 
The development of ESI-MS as an analytical tool for the analysis of non-covalent 
drug/DNA complexes is the focus of this dissertation. A review of the different types of 
DNA-interactive compounds and the development of ESI-MS as a technique for the 
evaluation of drug/DNA complexes is presented in this introduction. This chapter 
concludes with an overview of the chapters to follow. 
1.1 DNA-INTERACTIVE COMPOUNDS 
The development of ligands that bind non-covalently to DNA structures 
represents an important area of medicinal chemistry and pharmaceutical research.1,2 
DNA-interactive compounds are used therapeutically to treat wide range of diseases 
including malaria,3 hepatitis,4 HIV,5 as well as numerous bacterial infections6,7 and 
cancers.8-10 The primary mode of action of many of these drugs is to cause conformational 
changes or damage to the DNA targets, which ultimately interferes with DNA 
transcription or hinders replication, thereby interrupting cell growth and proliferation.1 
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While the clinical importance of these types of compounds has been demonstrated, the 
study of drug/DNA interactions remains an important area of medicinal chemistry 
research. The desire to more fully understand the mode of action of many current drugs, 
and to develop new compounds that are capable of selectively targeting cells directly 
affected by the disease, thereby reducing many negative side effects of the treatments, 
drive much of the current research.  
1.1.1 Duplex DNA-Interactive Drugs 
Until recently, the primary focus of drug-DNA research was on compounds that 
targeted duplex DNA. The two primary modes of binding by small molecules to duplex 
DNA are by intercalation and minor groove binding.11 Intercalators comprise a class of 
compounds that are characterized as containing one or more planar, aromatic moieties 
that are inserted between adjacent base pairs upon DNA binding.12 To accommodate the 
binding of a ligand in this manner, the duplex undergoes elongation due to a separation of 
base pairs, and unwinding around the site of intercalation.12,13 Intercalators typically bind 
to G/C rich sequences, with a general preference for CpG sites due to the lower energy of 
unstacking at this sequence. Once bound, the complex is stabilized by van der Waals 
interactions between the chromophore of the intercalator and the adjacent nucleobases.11 
The intercalator-induced distortion of the DNA duplex causes an interference in DNA-
protein interactions, ultimately disrupting transcription and replication.12  
Figure 1.1 shows the structures of acridine, daunomycin, and actinomycin-D 
which are common intercalating compounds. Some intercalators, like daunomycin and 
actinomycin-D, contain side-chains that enhance the interaction by associating with the 
minor grove of duplex after intercalation of the planar chromophore.14,15 Another way of 
increasing the binding constants of intercalators is by synthesizing polyintercalators, 
which contain multiple aromatic groups connected by chemical chains or scaffolds.12 
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When bound to DNA, the aromatic groups intercalate at multiple sites along the duplex, 
while the chemical linker interacts with the minor and/or major groove. The structure of 
echinomycin, one of the few commercially available bis-intercalators, is shown in Figure 
1.1. Echinomycin is characterized by two quinoxaline chromophores connected by a 
central bicyclic peptide that interacts with the DNA minor groove upon binding.16, 17 The 
potential advantages of polyintercalating ligands are increased binding constants, slower 



























































































































Figure 1.1:  DNA-interactive drug molecules. 
 In addition to the intercalators, minor groove binders comprise the other main 
class of duplex-interactive drugs. As demonstrated by the structures of Hoechst 33342 
and distamycin in Figure 1.1, minor groove binders are characterized by a crescent shape 
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which is similar to the curvature of the DNA minor groove.13,19,20 DNA complexes 
containing minor groove binders are stabilized by van der Waals and hydrophophic 
interactions, as well as hydrogen bonds formed between the ligand and DNA. In contrast 
to the intercalators, minor groove binders typically exhibit selectivity for A/T rich 
sequences, likely due to increased hydrogen bonding between the ligands and adenines 
and thymines, as well as the smaller width of the minor groove of A/T tracts which 
allows for better binding interactions.21 Upon complex formation, minor groove binders 
do not cause the significant conformational changes to the duplex that intercalators do, 
however they are effective at inhibiting protein binding usually by preventing the binding 
of transcription factors.13 
1.1.2 Quadruplex-DNA Interactive Drugs 
Traditionally, DNA-interactive compounds have targeted double stranded DNA, 
however there is increasing interest in the development of quadruplex DNA-interactive 
compounds.22-24 Hydrogen bonds can form between a planar arrangement of four guanine 
nucleobases to create a G-tetrad as shown in Figure 1.2. Quadruplex DNA forms when 
two or more G-quartets are stacked on top of one another and stabilized by monovalent 
cations such as Na+, K+, and NH4
+ coordinated to the central cavity of the quadruplex.22-24 
While a variety of sequences containing two or more tandem repeats of G-rich sequences 
are capable of forming quadruplex DNA, there is significant interest in examining the 
intramolecular quadruplex formation in  3’ overhangs of the human telomeric sequence, 
5-TTAGGG-3’.25 
 Telomeres are the DNA structures found on the terminal ends of chromosomes 
and are believed to play a key role in protecting DNA from degradation and fusion, 
ensuring the complete replication of DNA sequences and signaling cell senescence and 
death.26 In normal, somatic cells, the telomere length is shortened with each DNA 
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replication and subsequent cell division process. As the length of the telomeres is 
shortened, regions of coding DNA are not replicated, eventually leading to cell death.27 
However, in most tumor cells, the length of the telomeres is maintained by telomerase, a 
reverse transcriptase enzyme.28 The discovery that telomerase is over-expressed in 80-
90% of all human tumor cells established a promising link between cell immortality 






































Figure 1.2:  The structure of a G-tetrad. M+ represents a monovalent cation and the 
dashed lines show hydrogen bonds. 
Small molecules that bind to and stabilize the quadruplex structure in telomeric 
DNA have been found to inhibit telomerase activity and represent a promising area of 
anticancer drug research.22-24,30,31 Ethidium bromide was one of the first compounds that 
was discovered to bind to quadruplex DNA.32 Molecular models showed that this 
molecule binds by intercalation and undergoes pi-stacking interactions between the 
chromophore and the G-tetrad. Subsequent studies of related anthraquinone analogs 
found that adding flexible side chains to the molecule allowed for interaction with the 
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grooves of the quadruplex, and these analogs exhibited inhibition of telomerase 
activity.33,34  
Another mode of binding by small molecules to quadruplexes is by stacking on 
the ends of the tetrads.22,35 Several cationic porphyrin compounds, specifically para- and 
ortho- 5,10,15,20-tetra(N-methyl-4-pyridyl)porphine (H2TMPy), bind to quadruplexes 
and have a suspected end-stack binding mode, with -overlap between the aromatic 
moieties and the G-tetrads.36 The ortho-H2TMPy compound was also found to create 
“sandwich” complexes which are formed when one porphyrin molecule stacks on the 
ends of two quadruplexes. The perylene diimides comprise another promising class of 
quadruplex-interactive compounds with a suspected end-stacking and/or sandwich 
binding mode.22,23,30 As demonstrated by the structures of an early analog PIPER37 
(structure shown in Figure 1.1), these compounds are characterized by the perylene 
chromophore functionalized with the tetracarboxylic diimide groups with different side-
chains. Early studies found that PIPER exhibited telomerase inhibition,37 and more recent 
studies have focused on developing analogs that selectively bind to quadruplex DNA 
over duplex DNA in an attempt to reduce the cytotoxic side-effects of the compounds.38-41 
1.2 ANALYSIS OF DRUG/DNA COMPLEXES BY ESI-MS 
The therapeutic importance and structural diversity amongst DNA-interactive 
compound underscores the need for new analytical technologies capable of characterizing 
non-covalent drug/DNA complexes. ESI-MS has been established as a useful technique 
for this area of application due to its versatility, sensitivity and fast analysis time.42-44 The 
development of electrospray ionization greatly expanded the scope of mass spectrometry 
by allowing for the analysis of large biomolecules45 and the subsequent discovery that 
non-covalent complexes involving biomolecules, such as proteins and nucleic acids, were 
also preserved.46-49 ESI is well-suited for the analysis of these types of complexes because 
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it creates highly charged ions, allowing analytes with large molecular weights to be 
analyzed by robust and inexpensive mass analyzers with limited mass ranges, such as the 
quadrupole ion trap which has a typical m/z range of 2000.  ESI is also a gentle ionization 
technique allowing non-covalent complexes present in solution to be transferred to the 
gas-phase while maintaining many of the native binding interactions.  
Upon the discovery that ions of DNA duplexes50 and later, non-covalent 
complexes containing duplexes with minor groove binders,51 could be observed by ESI-
MS, interest in further examining the technique was stimulated. ESI-MS offers several 
advantages as a screening tool for the analysis of non-covalent drug/DNA complexes 
compared to traditional bioanalytical techniques such as surface plasmon resonance, 
fluorescence, circular dichroism, UV-Vis spectroscopy, NMR and crystallography. 
Compared to high resolution structural techniques such as NMR and crystallography, 
mass spectrometry is more sensitive, requiring micrograms of sample, compared to the 
milligrams typically required for those techniques. Another advantage is that ESI-MS 
does not require that ligands or DNA be labeled or tethered to a surface, which could 
affect ligand binding. This also reduces the time and complexity of an experiment. 
Finally, ESI-MS is well-suited for high throughput screening techniques due to its rapid 
analysis time and ability to be automated.44 
1.2.1 ESI-MS Analysis of Duplex DNA/Drug Complexes 
Early studies of drug/DNA complexes by ESI-MS focused on examining the 
binding of commercially available drugs to duplex DNA to determine if the binding 
behavior observed by mass spectrometry mirrored known solution activity. In seminal 
studies by Gale et al., complexes formed between minor groove binders including 
distamycin, pentamidine, and Hoechst 33258 and a self-complementary 12-mer duplex 
were examined.51,52 The binding stoichiometries of the DNA complexes containing the 
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minor groove binders observed in the mass spectra were consistent with previous NMR 
reports. For example, ESI-MS experiments found that at low distamycin/DNA molar 
ratios, 1:1 complexes were present, while 2:1 complexes emerged at higher molar ratios. 
This study also established experimental conditions required for the analysis of 
drug/DNA complexes by ESI-MS, including using low ESI voltages and heated capillary 
temperatures, as well as an ammonium acetate buffer instead of conventional alkali metal 
buffers.  Ammonium acetate is very amenable to ESI-MS because of the greater lability 
of the ammonium ion over Na+ and K+, thus reducing the extent of counterion adduction 
to the DNA ions.  
ESI-MS studies of the binding of intercalators daunomycin and nogalamycin to 
duplexes of  different sizes and sequence composition were also undertaken,53,54 with 
results suggesting that mass spectrometry can be used to assess sequence selectivity of 
drugs, as the intercalators formed complexes with greater relative abundance with 
duplexes with the largest GC-base pair composition. The binding of commercially 
available intercalators (ethidium bromide, amsacrine, and ascididemin) and minor groove 
binders (Hoechst 33258, netropsin, distamycin, berenil, and DAPI) was further examined 
by Gabelica at al.55 The DNA complexes containing the minor groove binders were found 
to have more well-defined 1:1 and 2:1 binding stoichiometries, while the complexes 
containing the intercalators had more variable binding stoichiometries that were 
suggestive of less specific binding compared to the groove binders. The binding of a 
series of commercially available minor groove binders and intercalators were also 
examined by Wan. et al.56 Differences in sequences selectivities of intercalators and 
minor groove binders were compared, with the intercalators exhibiting high affinity for 
GC-rich sequences, while minor groove binders displayed a preference for AT-rich 
sequences. These previous ESI-MS studies of non-covalent complexes of duplex DNA 
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with commercially available compounds indicated a good correlation between the mass 
spectral results and known solution behavior. 
1.2.2 ESI-MS Analysis of Quadruplex DNA/Drug Complexes 
The use of mass spectrometry has recently been extended to examine non-
covalent complexes containing quadruplex DNA after initial studies confirmed that 
quadruplexes stabilized by sodium57 and ammonium58 cations can be observed using ESI-
MS. Complexes formed between quadruplexes and a variety of ligands have been 
examined including the perylene diimides,59,60 ethidium bromide derivatives,61 
cyclo[n]pyrolles,62 pyridoacridines,63 cryptolepine and neocryptolepine,64 telomestatin,65 
and the bis-intercalator ditercalinium.66 In addition to confirming that ligand/quadruplex 
structures can be examined using ESI-MS, the binding selectivity of the ligands for 
quadruplexes over other DNA structures has been evaluated due to the desire to develop 
quadruplex-selective compounds. The results of these studies have shown good 
agreement between the ligand binding affinities for different DNA structures determined 
by ESI-MS with results from spectroscopic60 and competition dialysis experiments.61,63,64 
1.3 OVERVIEW OF CHAPTERS 
The objective of this dissertation is to (1) extend to use of ESI-MS for the analysis 
of new types drug/DNA complexes, and (2) develop new techniques for the evaluation of 
drug binding sites in DNA complexes. Chapter 2 is a brief description of the primary 
experimental methods used throughout this dissertation. Chapters 3 and 4 explore the use 
of ESI-MS to examine complexes containing novel drugs with duplex DNA. The binding 
of a series of threading bis-intercalators to duplex DNA is evaluated in Chapter 3. 
Binding affinities of the ligands for duplexes with different sequences were evaluated to 
assess possible specific binding, while the CAD spectra of the bis-intercalator/duplex 
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complexes were found to be unique from complexes containing commercially available 
monointercalators. 
Chapter 4 focuses on metal-mediated binding to duplex DNA. The binding of a 
series of benzoxazoles analogs with different amide- and ester-linked side chains to 
duplex DNA in the absence and presence of biologically relevant divalent metal cations 
is examined. The ligands with the shorter side chains only formed DNA complexes in the 
presence of metal cations, most notably with Cu2+. The ligand exhibiting the most 
dramatic metal-enhanced DNA binding also demonstrated the greatest cytotoxic activity. 
ESI-MS of quadruplex DNA is the focus of chapters 5 and 6. In chapter 5, the 
binding of a series of perylene diimides to quadruplex, duplex, and single strand DNA 
was examined to assess the quadruplex selectivity of each ligand. There was good 
correlation between solution-based spectroscopic binding studies and the ESI-MS 
analysis of G-quadruplex selectivity.  The collisional activated dissociation (CAD) 
spectra of the perylene diimide/quadruplex complexes were consistent with previous 
studies of ligands with an end-stack binding mode. The gas-phase stabilities of different 
G-quadruplexes were examined in Chapter 6 using energy-variable collisional activated 
dissociation and molecular dynamics (MD) simulations. The MD simulations found that 
the quadruplex structures are maintained in the gas-phase, while the stabilities of the 
quadruplexes determined by energy-variable experiments generally paralleled the RMSD 
and relative free energies of the quadruplexes based on the MD energy analysis. 
In the final chapter of this dissertation, Chapter 7, a technique that utilizes ESI-
MS with the KMnO4 oxidation of thymines to probe conformational changes to duplex 
DNA upon ligand binding is presented. In intercalator/DNA complexes, thymines around 
the ligand binding site are most susceptible to oxidation, allowing the binding sites to be 
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assessed. The site of oxidation is determined using CAD or infrared multiphoton 
dissociation (IRMPD).  
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Chapter 2: Experimental Methods 
The experiments described in this dissertation involve the analysis of DNA by 
electrospray ionization mass spectrometry (ESI-MS). A review of DNA nomenclature as 
well as brief descriptions of  the solution and instrument conditions used in the ESI-MS 
analysis of DNA and drug/DNA complexes are contained in this chapter. 
2.1 DNA NOMENCLATURE AND ANNEALING CONDITIONS 
DNA is a biopolymer that is composed of repeating units called nucleotides. Each 
nucleotide contains one of four nucleobases, guanine (G), cytosine (C), thymine (T), and 
adenine (A), linked to pentose ring and phosphate group. Multiple nucleotides are linked 
together to form an oligonucleotide.1 The ends of oligonucleotides are asymmetric and 
are labeled as the 5’ and 3’ end as demonstrated by the structure of 5’-GTAC-3’ shown in 
Figure 2.1 In in vivo environments, DNA typically exists as a double helix or duplex, 
which forms when there is hydrogen bonding between nucleobases on two different 
single strands that are arranged in an anti-parallel fashion, meaning the 5’ end of one 
strand is oriented to the 3’ end of the second strand.2 Hydrogen bonds are formed 
between complementary base pairs, with cytosines binding to guanines via three 
hydrogen bonds, and adenines binding to thymines by two hydrogen bonds as shown in 
Figure 2.2.1 
For the ESI-MS studies described herein, single strand oligonucleotides were 
ordered from Integrated DNA Technologies (Coralville, IA) or TriLink Biotechnologies 
Inc. (San Diego, CA), custom synthesized on the 1.0 µmole scale with reverse-phase 
HPLC purification. Stock solutions of each oligonucleotide were prepared at 2 mM 
concentration in 250 mM ammonium acetate. The concentration of the DNA strands were 
verified spectroscopically using Beer’s law and extinction coefficients provided by the 
DNA manufacturer. To prepare duplex DNA, solutions containing equimolar 
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concentrations of complementary strands were made in 250 mM ammonium acetate so 
that the final concentration of each oligonucleotide was 1 mM. The solution was then 
heated to 90 °C for 10 min., and then cooled to room temperature during a period of 7 
hours. Quadruplex DNA was annealed using a similar procedure. Solutions containing 
quadruplex forming oligonucleotides were prepared at 1 mM concentration in 150 mM 
ammonium acetate. The quadruplex solutions were heated to 90 °C for 10 min., followed 
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Figure 2.2:  Hydrogen bonding between DNA nucleobases. 
2.2 SOLUTION AND INSTRUMENT CONDITIONS FOR ESI-MS ANALYSIS OF DNA 
In these studies, analytical solutions were typically contained the single strand, 
duplex or quadruplex DNA at a concentration of 10 µM in a buffer containing 50 mM 
ammonium acetate with 25% (v/v) methanol. Methanol was included in the analytical 
solutions to increase the volatility of the aqueous solutions. The pH of the solutions was 
nominally 6.8. The samples were directly infused into a Thermo Finnigan LCQ Duo ion 
trap mass spectrometer (San Jose, CA) at flow rate of 3 µL/min using a Harvard 
Apparatus syringe pump (Holliston, MA). The Xcalibur software package (Thermo 
Finnigan, San Jose, CA) was used to control the instrument. The mass range of this 
instrument is 2000 mass units and a typical lower limit of concentration of DNA 
oligonucleotides using the LCQ is 2.5 µM. 
 Ions were generated in the negative ion mode using an ESI voltage of 3.5 kV, and 
a heated capillary temperature ranging from 90 to 120 °C. Due to the large aqueous 
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composition of the analytical solutions, nitrogen sheath and auxiliary gas flows of 40 and 
20 arbitrary units, respectively, were used to assist the desolvation. During operation of 
the instrument, the base pressure of the ion trap was 1 x 10-5 Torr with helium. Ion 
accumulation times of 50 to 100 ms were used and spectra were acquired by summing 
300 scans. 
During collisional activated dissociation (CAD) experiments, the desired 
precursor ion was isolated in the trap using resonance ejection. The collision energy 
applied to the trap (typically reported as a percentage of 5 V0-p) was increased, causing the 
trapped ions to undergo energetic collisions with background bath gas molecules 
(typically He). The default activation time of 30 ms and qz value of 0.25 was used. 
Typically, the CAD energy was increased until the abundance of the precursor ion was 
reduced to nominally 10% of its original abundance. 
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Chapter 3: Screening of Threading Bis-Intercalators Binding to Duplex 
DNA by Electrospray Ionization Tandem Mass Spectrometry 
 
3.1 INTRODUCTION   
Many anticancer, antitumor, and antibacterial therapies are based on the 
interaction of small molecules with DNA,1, 2 fostering the need for sensitive and versatile 
analytical techniques that are both capable of characterizing the ligand/DNA interactions 
and  compatible with library-based screening methods. Electrospray ionization mass 
spectrometry (ESI-MS) shows promise as a screening tool for the evaluation drug/DNA 
complexes due to its low sample consumption and rapid analysis time.3,4 During the 
electrospray process, non-covalent complexes are transferred to the gas-phase with 
minimal internal energy, allowing many of the binding interactions to be maintained. The 
preservation of these non-covalent complexes allows information about binding 
stoichiometry and selectivity to be elucidated from the mass spectra, while tandem mass 
spectrometry techniques,  such as collisional activation dissociation (CAD), can be 
used to examine the binding mode.  
One important class of DNA-interactive drugs are ligands that bind via 
intercalation of one or more aromatic groups between base pairs of duplex DNA.1, 2, 5 
There have been numerous ESI-MS studies that have examined the interaction between 
duplex DNA and well-studied, commercially available monointercalators such as the 
anthracyclines,6-11 porphyrins,12,13 ruthenium compounds,11-15 ethidium bromide,16-18 
actinomycin-D,12,13 and aureolic acids.19 Characteristics such as ligand binding 
stoichiometry,7,8,11-14,16 sequence selectivity,7,11,13,14,16,19 binding mode,12,13,15 and complex 
stability9,12,16 have been examined with promising results correlating the binding trends 
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observed in the mass spectra to known solution behavior. While the binding of many 
commercial monointercalators has been well-studied by ESI-MS, there has been only one 
study20 that has focused on a bisintercalator, ditercalinium.  Based on ESI-MS 
measurements of the complexation of ditercalinium to a series of DNA sequences, it was 
found that ditercalinum bound better to quadruplex structures than to duplexes.20 









































































































































































Scheme 3.1: Structures of intercalator ligands. Molecular weights of compounds in Da 
are given in parenthesis.   
The development of novel polyintercalating ligands is of interest because of the 
potential improvements in antitumor activity and sequence specificity. A novel class of 
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DNA polyintercalators that shows great promise for binding to long stretches of DNA 
with sequence specificity and high affinity contain 1,4,5,8-tetracarboxylic naphthalene 
diimide (NDI) units connected in a head-to-tail arrangement by flexible scaffolds21-24 (see 
Scheme 3.1). These compounds are known as threading polyintercalators because, upon 
intercalation, one of the functional groups attached to the diimide nitrogen resides in the 
DNA major groove, while the other is in the minor groove.21 The potential advantages of 
developing a compound that binds to duplex DNA by threading polyintercalation include 
enhanced sequence specificity due to ligand interactions with the major and minor 
groove, the ability to bind to longer DNA sequences with a relatively low molecular 
weight compound, disruption of protein-ligand interactions that occur in both DNA 
grooves, and lower binding off-rates,22  
A series of bis-intercalators, compounds that contain two NDI units, have been 
synthesized as precursors to longer compounds with more than two intercalation groups 
(Scheme 3.1). The primary objective of this study is to evaluate the binding behavior of 
trans-D1 and cis-C1 which are new ligands containing a rigid spiro-tricyclic scaffold in 
the trans- and cis- orientations, respectively. While few results have been reported for the 
newer ligands trans-D1 and cis-C1,25 the binding behavior of V1, the ligand containing 
the peptide scaffold, has been examined in extensive footprinting and NMR-based 
studies.22,23 In the present study, the binding behavior of the well-characterized compound 
V1 will be examined to establish that the binding behavior observed by ESI-MS can be 
correlated to the results of traditional solution-based experiments. After developing a 
framework with V1, the binding of the new compounds, trans-D1 and cis-C1, will be 
reported with an emphasis on comparing differences in binding behavior of the 
compounds that result from the trans- versus cis-orientations of the scaffold.  Here we 
examine binding stoichiometries, sequence selectivities, and concentration dependent 
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binding of the bis-intercalators, evaluate the CAD fragmentation patterns of the observed 
DNA/drug complexes, and compare the results to ones obtained by conventional 
footprinting techniques. The binding of the bis-intercalator, echinomycin (Scheme 3.1) 
was also assessed by ESI-MS to serve as a comparison to the results of V1, cis-C1, and 
trans-D1. We also will compare the results of our study to other ESI-MS based studies 
involving monointercalators. 
Another objective of this study is to demonstrate that mass spectrometry can be 
used as a screening tool for bis-intercalator ligands. To accomplish this aim, we 
demonstrate that the ESI-MS results mirror those established by traditional techniques 
such as NMR and DNAse I footprinting experiments to lend legitimacy to ESI-MS as an 
analysis tool for future studies involving novel polyintercalating compounds. It is not 
anticipated that ESI-MS will replace traditional techniques such as NMR and DNAse I 
footprinting, but instead that it be used as an initial screening tool. As drug discovery 
efforts shift to combinatorial synthesis of compound libraries, ESI-MS is suited to narrow 
down the pool of promising ligands that would then be examined in more detail using 
traditional methods.   
3.2 EXPERIMENTAL 
3.2.1 Chemicals  
Single strand oligodeoxynucleotides (ODNs), custom synthesized as ammonium 
salts on the 1.0 µmole or 250 nmole scale with purification by HPLC, were obtained from 
Integrated DNA Technologies (Coralville, IA) and used without further purification. 
Stock solutions of each ODN were prepared at 2 mM concentration in deionized water. A 
portion of the stock solutions were diluted to 1 mM and set aside for experiments 
involving single strand ODNs. Duplex DNA was annealed by preparing solutions 
containing two complementary single strand ODNs, each at 0.7 mM concentration in 250 
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mM ammonium acetate. The annealing solutions were heated to 90 °C and then slowly 
cooled over a period of 4 hours. Table 3.1 shows the sequences used in this study.  The 
synthesis of ligands V1,26 trans-D1,25 cis-C1,25 and NDI127 have been previously reported. 
Concentrations were determined spectroscopically using Beer’s law. The extinction 
coefficients for the DNA strands were provided by the manufacturer and those of the 
ligands are 26 300 M-1 cm-1 (385 nm) for cis-C1, 36,000 M-1 cm-1 (383 nm) for trans-D1, 
and 26 300 M-1 cm-1 (385 nm) for V1.25 
3.2.2 DNAse I Footprinting.  
Plasmid pBR322 (New England BioLabs, Ipswich, MA) was digested with NheI, 
dephosphorylated with CIAP, 5’-32P-end labeled with [ -32P]-ATP and T4 kinase, 
digested with EcoRI (all enzymes were purchased from New England Biolabs) and 
purified by native polyacrylamide gel electrophoresis (PAGE), following standard 
protocols.28 The 92 bp synthetic fragment (PAGE grade) was purchased from Midland 
Certified (Midland, TX) and labeled (32P) similarly. The DNAse I (Amersham 
Biosciences, Piscataway, NJ) footprinting was carried out according to the procedure 
described previously.29 The DNA fragments were separated on an 8% (231 bp) or 12% 
(92 bp) denaturing polyacrylamide gel. The gels were exposed on a phosphor screen and 






Table 3.1: DNA sequences used in this study. 
 
 
3.2.3 Mass Spectrometry  
Stock solutions of V1, trans-D1 and cis-C1 were prepared in deionized water at 1 
mM. Analytical solutions containing duplex or single strand DNA and one ligand were 
prepared at equimolar 10 µM concentration (unless noted otherwise) in 50 mM 
ammonium acetate with 25% methanol to enhance the volatility of the solution. After 
allowing the solutions to equilibrate for 30 min., they were directly infused into a 
ThermoFinnigan LCQ Duo mass spectrometer (San Jose, CA) using a Harvard syringe 
pump (Holliston, MA) at 3 µL/min. Ions were generated in the negative ion mode with an 
electrospray voltage of 3.5 kV. The temperature of the heated capillary was set at 90 to 
110 °C and nitrogen sheath and auxiliary gas flows of 10 and 40 arbitrary units, 
respectively, were used to aid in desolvation. The base pressure in the ion trap region was 
nominally ~1 x 10-5 torr. Instrument conditions were optimized for each complex using 
the automatic tuning function of the Xcalibur software package (Finnigan, San Jose, CA). 










Tandem mass spectrometry experiments were performed using collisional 
activated dissociation (CAD). The desired precursor ion was isolated in the trap using 
resonance ejection, followed by fragmentation induced by increasing the resonance 
voltage applied to the trap. An activation time of 30 ms was used for all experiments. The 
CAD energy was increased until the abundance of the precursor ion was reduced to ~10% 
relative abundance. These experiments required CAD energies of ~12 – 14%.  
3.3 RESULTS AND DISCUSSION 
3.3.1 Complexes with V1 
The DNA binding of ligand V1 has been previously examined by NMR and 
DNAse I footprinting techniques that identified the specific binding sites of this 
compound.23 V1 was found to have a binding preference for d(GGTACC)2 sequences with 
NMR results confirming that the –Gly3-Lys- peptide scaffold was located in the major 
groove.23 The V1-d(GGTACC)2 complex was formed with a dominant 1:1 binding 
stoichiometry.  
The binding of V1 to a DNA duplex containing the preferred binding sequence 
was evaluated by ESI-MS to confirm that results revealed in the mass spectra can be 
correlated to the solution binding behavior.  The 14-mer 
d(GGGCGGTACCGCGG/CCGCGGTACCGCCC) (ds1) was used for this study because 
it contains the specific binding sequence of V1 (GGTACC).  All of the duplex DNA 
sequences selected for this study were non-self-complementary to allow the duplex and 
single strand ions to be unambiguously distinguished in the mass spectra. Duplexes with 
14 base-pairs were selected for this study because previous ion mobility/molecular 
dynamics studies have reported that DNA duplexes greater than 12 base pairs maintain 
the helical conformations in the gas-phase better than smaller duplexes.30,31  Even larger 
duplexes were not chosen to ensure that there was only one high affinity binding site per 
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duplex, allowing different binding sequences to be assessed individually. Each duplex 
was designed to contain the proposed high affinity ligand binding site in the center of the 
sequence. The terminal ends of the duplexes were selected to be G/C rich to enable good 
annealing of the sequences, and the sequences directly adjacent to the proposed specific 
binding site were selected based on the flanking sequences identified in DNAse I 
footprinting experiments to maintain consistency. 
ESI mass spectra of solutions containing 10 µM of V1 and 10 µM of ds1 in an 
ammonium acetate/methanol buffer were evaluated first. Both the 5- and 6- charge states 
are prominent for the duplex/V1 complexes.  For a typical solution containing V1 and 
ds1, the only complexes present in the spectrum possess a ligand/DNA binding 
stoichiometry of 1:1 with 2:1 complexes being at less than 5% of the relative abundance 
of the 1:1 complexes.  
Concentration-dependent binding studies were undertaken to examine the extent 
of complexation changes as a result of varying the ligand/DNA ratios. Solutions 
containing ds1 at 10 µM and either 2.5, 5.0, 10, or 20 µM of V1 were analyzed by ESI-
MS (spectra not shown). As the ligand/DNA molar ratio was increased, the relative ion 
abundance of the 1:1 complexes in the 5- and 6- charge states increased, while that of the 
free duplex decreased. However, no 2:1 complexes emerged, even with excess ligand in 
solution. While it is possible that there are multiple sites on the duplexes for which V1 
could bind to form 2:1 complexes, binding of V1 at a second site is not anticipated to be 
as strong because the ligand bound at the high affinity site, GGTACC, would cover six 
base pairs and thus presumably hinder the bis-intercalative binding of a second ligand.  
These results are consistent with solution-based studies of V123 and suggest ESI-MS is a 
promising tool for the analysis of DNA complexes containing bis-intercalators. 
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3.3.2 Binding selectivities of trans-D1 and cis-C1 
To explore the effect of the scaffold on the binding specificity of the 
polyintercalators, two new bis-intercalators, trans-D1 and cis-C1, were synthesized 
containing a rigid spiro-tricyclic scaffold (Scheme 3.1). As shown in Scheme 3.1, trans-
D1 is a trans-oriented ligand, while cis-C1 is cis-oriented. While the design and synthesis 
of these compounds has been previously reported,25 less is known about the DNA duplex 
binding of these compounds. We aimed to compare the binding of these compounds in a 
mass spectrometry based study.  
To begin an ESI-MS evaluation of the binding behavior of trans-D1 and cis-C1, 
the complexation of each ligand with DNA duplexes containing varying A-T and G-C 
base pair composition was evaluated. The NDI intercalator unit has exhibited a 
preference for  G-G steps,23 so it was of interest to assess the binding selectivities of the 
new compounds. ESI mass spectra were obtained for solutions containing trans-D1 or 
cis-C1 with a series of three duplexes with varying amounts of G/C and A/T base pair 
content: d(GCGGGGATGGGGCG/CGCCCCATCCCCGC) (ds2), 
d(GCGGGAATTGGGCG/CGCCCAATTCCCGC) (ds3), and 
d(GCGGAAATTTGGCG/CGCCAAATTTCCGC) (ds4).  
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Figure 3.1  ESI mass spectra for complexes containing trans-D1 and equimolar (10 µM) 
amounts of (A) ds2, d(GCGGGGATGGGGCG/CGCCCCATCCCCGC) (B) 
ds3, d(GCGGGAATTGGGCG/CGCCCAATTCCCGC and (C) ds4, 
d(GCGGAAATTTGGCG/CGCCAAATTTCCGC). 
 
While both ligands exhibited GC base pair selectivity, the preference was more 
pronounced for trans-D1. As shown in Figure 3.1A, trans-D1 readily forms abundant 
complexes with ds2, with ligand/DNA binding stoichiometries of 2:1 and 1:1, and little 
unbound DNA is present in the spectrum. The mass spectrum of trans-D1 with ds3 
(Figure 3.1B) shows that the relative abundance of the 2:1 complexes is significantly 
decreased compared to Figure 3.1A, and the abundance of the unbound DNA has 
increased. The spectrum of trans-D1 with ds4, the duplex containing the most AT base 
 31
pairs, reveals that only 1:1 complexes are present and with significantly lower 
abundances relative to the duplex ion present at m/z 1705 (Figure 3.1C). As the AT-
content increases, both the binding stoichiometry and relative abundance of the 
complexes formed between trans-D1 and the duplex decrease dramatically. 
The extent of complexation was calculated by expressing the sum of the 
abundances of ions from DNA/ligand complexes as a fraction of the total abundances of 
all ions from DNA as has been previously reported for ligand/DNA complexes.32 Ions in 
the 5- and 6- charge states were used in this calculation. The binding results for trans-D1 
(discussed above) and those for cis-C1 (spectra not shown) with ds2, ds3, and ds4 are 
summarized in Table 3.2. 
Our results indicate that like trans-D1, cis-C1 also forms more abundant 
complexes with the GC-rich DNA duplexes, as demonstrated by a value of 0.52 for the 
fraction of bound DNA with ds2, compared to 0.39 with ds3 and 0.32 with ds4.  These 
results are consistent with solution dissociation kinetics experiments in which cis-C1 and 
trans-D1 demonstrated a strong preference for binding to poly (dGdC) over poly (dAdT) 
sequences.25 This is a trend that has been previously reported for NDI intercalation.21, 33 
The observed poly d(GdC) preference of the ligands may be the result of a variety of 
binding interactions. Increased hydrogen bonding between the intercalators and 
functional groups in the major and minor grooves of GC-rich sequences could account 
for this preference. The imide carbonyls on the NDI units may also undergo a favorable 
electrostatic interaction with the N2 amino group on G:C base pairs.33 Steric and 
hydrophobic interactions could also play roles.21-23 While the ligands demonstrate a 
general preference for GC-rich sequences, likely because of the NDI units, the functional 
linker imparts specific binding preferences. 
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Table 3.2: Fraction of bound DNAa for intercalator ligands and DNA duplexes.d,f 
 
aAll values +/- 0.05. This value was calculated to be the greatest standard deviation for the results of 
three experiments done with the samples.  bSequence contains proposed binding site of V1. cSequence 
contains proposed binding site of  cis-C1. dSequence contains proposed binding site of trans-D1. dThe 
abundances for all of the sodium adducts ions associated with a complex were included in the relative 
abundance calculations. e“n/a” indicates data was not collected because the results were not relevant to the 
study. fSolutions contained equimolar (10 µM) concentrations of ligand and DNA. 
 
3.3.3 DNAse I Footprinting 
 In addition to evaluating the GC versus AT sequence selectivity of trans-D1 and 
cis-C1, the binding of the compounds to duplexes containing potential specific binding 
sites was also evaluated by DNAse I footprinting and ESI-MS. It has been established 
that the naphthalenetetracarboxylic diimide based-intercalator units possess a preference 
for binding G-G steps.23 In order to investigate the specificity of binding, DNAse I 
footprinting studies with trans-D1, cis-C1 and reference ligand V1 were carried out using 
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Figure 3.2:  Footprinting of compounds cis-C1, trans-D1 and V1 on 92mer DNA with 
the (-) strand labeled on its 5’-end. Lane A represents Adenine-specific 
sequencing reaction. Lane Co contains DNA without DNAse I. For D1, V1, 
and C1, lanes 1-4 contain 0.5, 0.25, 0.125, and 0.062 µM ligand, 
respectively. Lane C contains DNA with DNAse but no compound. 
Sequences at 1: 5’-GGTACC; 2: 5’-GGATCC; 3: 5’-GGGCCC; 4: 5’-
GGCGCC; 5: 5’-GGGGCC. 
 
trans-D1 showed some non-specific binding behavior, from targeting less than 
six-base pairs to only binding at high concentration (> 0.25 µM) (Figure 3.2). cis-C1, 
however, shows very different binding characteristics from the others.  It not only binds 
to GGTACC with an even higher affinity than V1, but it also binds to other sequences 
with good affinity, such as GGGCCC and GGATCC. The variety of binding sites with 
 34
good binding affinity (Kd ~100 nM) demonstrates the potential of spiro-tricyclic scaffold 
as a “universal” scaffold for polyintercalators.  
To further investigate the binding specificity of trans-D1, a 231 bp EcoRI-NheI 
restriction fragment of plasmid pBR322 was chosen for a second round of footprinting 
experiments. This sequence was previously used to screen the binding specificity of NDI 
ligands.23 V1 was used as a reference compound. As expected, one binding site for V1 
was clearly seen with this DNA fragment at the GGTACC sequence (results not shown). 
For trans-D1, two potential binding sites were identified: CAGTGA and GGCGAC.    
3.3.4 ESI-MS Evaluation of trans-D1 and cis-C1 Binding Sequences 
After identifying some possible specific binding sequences of cis-C1 and trans-
D1 using DNAse I footprinting experiments, the binding of these ligands to DNA 
duplexes containing the most promising specific sequences were further evaluated by 
ESI-MS. Duplex ds1 contains the GGTACC sequence which is a potential specific 
binding site for cis-C1 and is the same sequence identified for V1, and duplex ds5 
contains a possible specific binding sequence CAGTGA for trans-D1. The full sequences 
of these duplexes are shown in Table 3.1. Additional experiments were done with ds6, 
which contains a second possible binding site for cis-C1, GGGCCC, and ds7, containing 
the second potential site for trans-D1, GGCGAT. 
The mass spectrum acquired for a solution containing cis-C1 and ds1 at equimolar 
concentrations in 50 mM ammonium acetate with 25% methanol demonstrates that cis-
C1 forms very abundant 1:1 complexes with this duplex (Figure 3.3A). The abundance of 
the unbound DNA ions are very low, suggesting cis-C1 undergoes extensive 
complexation with this duplex. In addition, there are no complexes with a 2:1 binding 
stoichiometry, which is expected since the duplex contains a specific binding site in the 
center of this sequence. Based on the abundances of the ions in Figure 3.3A, the fraction 
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of bound DNA for the solution of ds1 with cis-C1 was calculated to be 0.86 (Table 3.2). 
These results suggest that the binding of cis-C1 with ds1 is more extensive than the 
binding of V1 with the same duplex, as the fraction of bound DNA for V1 with the 
duplex (shown in Figure 3.1B) was found to be 0.66 (Table 3.2). The higher binding 
affinity between cis-C1 and the GGTACC sequence was also demonstrated in the 
footprinting experiments discussed above. cis-C1 was also found to form complexes with 
ds6, which contained the GGGCCC binding site (spectra not shown). However, the 
fraction of bound DNA for cis-C1 and ds6 was 0.51, which suggests less extensive 
complexation between the cis-C1 and ds6 compared to ds1 and indicates a preference for 
the GGTACC binding sequence by the ligand. 
 





































[ds1 + 2 x C1]6-




























Figure 3.3:  ESI mass spectra for complexes containing cis-C1 and equimolar (10 µM) 
amounts of (A) ds1 d(GGGCGGTACCGCGG/CCGCGGTACCGCCC) and 
(B) ds5, d(GGGACAGTGAGGGG/CCCCTCACTGTCCC). 
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Experiments aimed at evaluating the binding between cis-C1 and a DNA duplex 
that does not contain a target binding sequences were also undertaken. Duplex ds5 was 
selected for this experiment because the target binding sequence in the duplex, 
CAGTGA, was identified as a possible specific binding site for trans-D1 but not cis-C1. 
The ESI mass spectrum of a solution containing equimolar (10 µM) concentrations of cis-
C1 and ds5 is shown in Figure 3.3B. The extent of complexation between cis-C1 and the 
duplex is lower than what was observed in the spectra of solutions containing cis-C1 with 
ds1 (Figure 3.3A) and ds6 (spectra not shown). In Figure 3.3B the abundances of the 
unbound DNA ions are considerably greater than the abundance of the 1:1 complexes. 
The fraction of bound DNA was calculated to be 0.38 which is significantly lower than 
the fraction of bound DNA for cis-C1 with ds1 (0.86) and moderately lower than that of 
cis-C1 with ds6 (0.51). These results indicate cis-C1 forms more abundant complexes 
with ds1 and ds6 which is consistent with the specific binding site identified by DNAse I 
footprinting experiments. 
Similar experiments were undertaken involving trans-D1 and ds5 and ds7, each 
which contain a possible specific binding site of the ligand (CAGTGA and GGCGAC, 
respectively) and ds1, which was identified as a specific binding site for cis-C1 but not 
trans-D1. The results of these experiments (spectra not shown) are summarized in Table 
3.2, and they suggest that while the structures of trans-D1 and cis-C1 are similar, they 
exhibit different binding behavior with the duplexes. The fraction of bound DNA in the 
spectrum of trans-D1 with ds5 was calculated to be 0.78, which is much greater than the 
fraction of bound DNA of cis-C1 with the same duplex (0.38). trans-D1 also formed 
abundant complexes with ds7, as indicated by a fraction of bound DNA of 0.85 for the 
ligand with the duplex. Conversely, the fraction bound for ds1 with trans-D1 was only 
0.41 compared to 0.86 observed with cis-C1.  
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As a further comparison, the fraction of bound DNA of V1 with ds1 is also 
summarized in Table 3.2 since V1 and cis-C1 have the same possible specific binding 
sequence. The 0.66 value for fraction bound is not as great as that observed with cis-C1, 
suggesting cis-C1 might be an improvement over V1 in terms of forming abundant 
complexes with the GGTACC sequence. The fraction of bound DNA in a spectrum of V1 
with ds5, a duplex that does not contain a specific binding site for V1, is 0.52 which is 
lower than that with ds1. However, the difference in the fraction of bound DNA for V1 
with ds1 (containing the specific binding sequence) and ds5 (no specific binding 
sequence) is not as great as that observed with cis-C1. These results indicate that cis-C1 
shows the most promising selectivity for binding to its target sequences over other 
sequences and demonstrate that the relative binding behavior of the bis-intercalators 
observed by ESI-MS correlates with DNAase I footprinting results.   
Because NDI1 contains only one intercalating unit and lacks the scaffold 
designed to interact with the groove of duplex DNA, this compound functions as a 
monointercalator and was used as a reference ligand to compare its complexation with 
the same duplexes as used in the experiments above for cis-C1 and trans-D1.  The ESI-
mass spectra indicate the formation of 1:1 and 2:1 NDI1:duplex complexes, with the 
fractions bound for ds1 and ds5 summarized in Table 3.2.  The greater abundances of the 
2:1 NDI1:duplex complexes is consistent with a lower specificity of NDI1.    
3.3.5 Concentration Dependent Binding of trans-D1 and cis-C1 
To further explore how the complexation of trans-D1 and cis-C1 changes with 
ligand/DNA molar ratios, concentration dependent binding was assessed.  A series of 
solutions containing trans-D1 or cis-C1 with a duplex containing a proposed specific 
binding site (ds5 for trans-D1 and ds1 for cis-C1) were prepared with a DNA 
concentration of 10 µM and a variable ligand concentration of 2.5, 5.0, 10, or 20 µM. The 
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mass spectra of trans-D1 with ds5 at these molar ratios demonstrate that when the ligand 
concentration is increased relative to the DNA concentration, changes in the extent of 
ligand complexation are observed in the mass spectra.  At a trans-D1/ds5 molar ratio of 
0.25, complexes with 1:1 binding stoichiometry are present, but with low relative 
abundances compared to the unbound DNA ions. As the molar ratio is increased to 0.5, 
the relative abundance of the 1:1 complexes increases, and low abundance 2:1 complexes 
emerge while the abundance of the free DNA decreases. When the molar ratio is 
increased to 1:1 or even  2:1, the abundances of the 2:1 complexes increase further, while 
the abundance of the unbound DNA ions diminish.  
The appearance of the 2:1 complexes at higher trans-D1/ds5 molar ratios is 
notable since ds5 contains only one relatively high affinity binding site for trans-D1. The 
results imply that trans-D1 is able to bind to the DNA duplex in a non-specific manner 
when the ligand concentration is increased relative to the DNA. At this point, it is 
unknown how the 2:1 complexes are formed, but some possible scenarios include that the 
ligand may bind to the DNA via the intercalation of only one of the NDI units, two trans-
D1 ligands could be aggregating in solution and then binding to the DNA duplex, the 
second ligand may non-specifically aggregate to the DNA, or there could be two binding 
sites on the duplex that are mutually exclusive. This last scenario is the least likely since 
the duplex contains one proposed specific binding site at the center of the sequence and 
the ligand bound at the higher affinity site would hinder the binding of the second 
molecule. The presence of trans-D1 footprints that are less than six bases long in Figure 
3.2 suggest the ligand is able to partially bind to the duplex via one NDI unit.  Future 




Figure 3.4:  Summary plots of concentration dependent binding studies of (A) trans-D1 
with ds5, (B) cis-C1 with ds1, and (C) V1 with ds1, indicating distribution 
of free duplexes, 1:1 ligand:duplex complexes, and 2:1 ligand:duplex 
complexes. Solutions contained the specified duplex DNA at 10 µM and 
ligand at, 2.5 µM, 5.0 µM, 10 µM, and 20 µM. 
 
The results of the concentration dependent binding studies for trans-D1 with ds5, 
cis-C1 with ds1 (spectra not shown), and V1 with ds1 (discussed earlier) are summarized 
by the graphs in Figure 3.4, which reflect the relative ion abundance of the unbound 
duplex ions (black bars), 1:1 complexes (grey bars), and 2:1 complexes (light bars), 
grouped by ligand/DNA ratio. The results for cis-C1 with ds1 are significantly different 
from those of trans-D1 with ds5. As the ligand molar ratio is increased, the relative ion 
abundance of the free DNA duplex decreases and the abundances of the 1:1 complexes 
increase. However, when there is excess cis-C1 in solution, the 1:1 binding stoichiometry 
is dominant and only very low abundance 2:1 complexes are observed. The results of cis-
C1 with ds1 are similar to V1 with ds1, which are also summarized in Figure 3.4C and 
suggest that like V1, cis-C1 is binding specifically to the DNA duplex that contains a 
target site. 
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3.3.6 ESI-MS/MS Studies of Complexes Containing V1, trans-D1 and cis-C1.  
An additional goal of this study was to determine if a bis-intercalative binding 
mode could be distinguished from a mono-intercalative binding mode using CAD since 
full scan mass spectra provide little insight into binding interactions between ligands and 
DNA. Until now, no MS/MS studies have been done on complexes containing bis-
intercalators. Our group34 and others12, 35 have used collisional activated dissociation 
experiments to examine the fragmentation patterns of intercalator/DNA complexes, 
including complexes of actinomycin-D,12,35 daunomycin,34 and nogalamycin.34 For 
complexes containing actinomycin-D, the predominant dissociation route is loss of the 
drug, but some strand separation (with retention of actinomycin D by one strand) and 
some nucleobase loss are also observed to a lesser extent.12, 35 Our own CAD results for 
duplex/actinomycin-D complexes confirm that the primary fragmentation route is the 
disruption of the non-covalent interactions between actinomycin-D and the duplex, 
resulting in loss of actinomycin-D.  Our earlier studies of complexes containing 
daunomycin or nogalamycin in a quadrupole ion trap mass spectrometer indicated that 
the drug/DNA complexes followed charge state dependent fragmentation patterns.34 At 
lower charge states, the dominant fragmentation pathway was ejection of the drug leaving 
the intact duplex, while at higher charge states, separation of the individual single strand 
components of the duplex occurred, leaving the drug bound to one of the single strands.  
Dissociation by cleavage of a nucleobase was insignificant or not observed for complexes 
containing daunomycin or nogalamycin.34 CAD of complexes containing reference ligand 
NDI1,27 a monointercalator, resulted in fragmentation patterns consistent with those 
obtained for the daunomycin and nogalamycin complexes described above (spectra not 
shown).  Complexes in the 5- charge state dissociated via loss of a neutral NDI1 ligand, 
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while complexes in the 6- charge state produced fragment ions resulting from ligand 
ejection and predominant strand scission (spectra not shown). 
CAD experiments were undertaken in the present study to examine what, if any, 
differences exist in the fragmentation pathways of complexes containing V1, trans-D1, 
and cis-C1 compared to the monointercalators. The low charge state [ds + L]5- 
complexes, where L represents either V1, cis-C1, or trans-D1, produced the same 
fragmentation pattern, characterized by the guanine nucleobase loss (Figure 3.5A). This 
fragmentation pattern is different from what is commonly observed for the complexes 
containing commercial monointercalators, which predominantly dissociate via ejection of 
the ligand.12, 35 For V1, trans-D1 and cis-C1, all 1:1 complexes in the 6- charge state 
dissociated via dominant guanine nucleobase loss in addition to strand scission, with the 
ligand remaining bound to a single strand as demonstrated by the CAD spectrum of [ds1 
+ C1]6- shown in Figure 3.5B. There were also very low abundance ions resulting from 
ejection of the negatively charged ligand, leaving the intact duplex. The predominance of 
nucleobase loss rather than ligand ejection of the 1:1 complexes in the 5- and 6- charge 
states is indicative of stronger binding interactions between the bis-intercalators and 
duplex DNA compared to traditional monointercalators, resulting from two intercalation 
sites and specific hydrogen bonding interactions between the scaffold and the DNA 
grooves.  It is interesting that the strand scission pathway occurs in such a way that the 
ligand remains bound exclusively to only one of the ODNs (i.e. ss1a in Figure 3.5B, but 
not to ss1b).  Although ss1a is more G-rich than ss1b, the underlying reason for this ODN 
selectivity is not clear.   
The 2:1 complexes in the 6- charge state produced a different CAD pattern than 
those described above for the 1:1 complexes. Trans-D1 was the only compound to form 
2:1 complexes with sufficient abundance for CAD experiments, and the resulting CAD 
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mass spectrum of [ds5 + 2 x D1]6- is shown in Figure 3.5C. The most abundant product 
ion results from ejection of the negatively charged ligand, leaving the [ds5 + D1]5- 
complex. Ions resulting from strand scission and guanine base loss ions from the 
precursor complex are present but with significantly lower abundances.  This result 
suggests that the second molecule is bound differently (and likely more weakly) than the 
first ligand in the 2:1 complexes which is similar to what has been previously observed 
with complexes containing nogalamycin [34]. Furthermore, the duplex DNA used in 
these experiments contain only one specific binding site for the ligands, so the presence 
of the 2:1 complexes indicates some non-specific binding by the second ligand, which is 
expected to be a weaker binding interaction. 
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Figure 3.5:  CAD mass spectra of (A) [ds1 + cis-C1]5-, (B) [ds1 + cis-C1]6- and (C) [ds5 
+ 2 x trans-D1]6-. The precursor ion is indicated by the asterisk. Solutions 
contained equimolar concentrations (10 µM) of the ligand and DNA duplex. 
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All complexes in the 7- charge state, regardless of binding stoichiometry, 
dissociated by strand scission leaving the ligands bound to a single strand (spectra not 
shown). This fragmentation pattern is consistent with past CAD studies involving 
intercalators34 and is believed to result from coulombic repulsion of the more highly 
charged phosphate backbones.  
The CAD fragmentation patterns of complexes containing echinomycin (Scheme 
3.1) with duplex DNA were also evaluated in this study to serve as a comparison to the 
results of the new bis-intercalators. Echinomycin has been found to bind to duplex DNA 
via bis-intercalation, with the two quinoxaline rings preferably intercalating at CpG sites, 
and the bicyclic peptide scaffold oriented toward the DNA minor groove where hydrogen 
bonds are formed between the peptide and the nucleobases. In general, little ligand 
ejection was observed in the CAD spectra. Complexes in the 5- charge state undergo 
guanine base loss upon collisional activation.  Guanine nucleobase loss is also observed 
in the CAD spectra of all complexes in the 6- charge state, in addition to ions resulting 
from strand scission. Complexes in the 7- charge state dissociated by strand separation. 
The CAD spectra of complexes containing enchinomycin are similar to those containing 
V1, trans-D1, or cis-C1, and are markedly different than those of the complexes 
containing monointercalators.   
3.3.7 Single Strand Binding of V1, trans-D1 and cis-C1  
The bis-intercalators evaluated in this study were designed to engage in two 
primary types of binding interactions with duplex DNA: intercalation interactions 
between the NDI units and the nucleobases, and hydrogen bonding interactions between 
the peptide scaffold and the minor or major groove of the DNA duplex. To determine if 
the ligands bind selectively to duplex DNA via these interactions over other DNA 
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structures, ESI-MS was used to analyze solutions of trans-D1 or cis-C1 with single 
strand DNA. The single strand ODNs used for these experiments, 
d(GGGCGGTACCGCGG) (ss1) and d(GGGACAGTGAGGGG) (ss5), were one of the 
two complementary single strand ODNs used to anneal duplexes ds1 and ds5, 
respectively. Based on the results of the duplex DNA binding studies of the ligands 
discussed above, cis-C1 formed the most abundant complexes with ds1 so the binding of 
cis-C1 to ss1 was evaluated, while trans-D1 formed more abundant complexes with ds5, 
so ss5 was used. Using these single strand ODNs ensures that the same target binding 
sequences present in the duplexes are also found in the single strand sequences. 
Solutions containing one single strand ODN and either V1, trans-D1 or cis-C1 at 
equimolar 10 µM concentration in ammonium acetate/methanol buffer were prepared and 
analyzed using the same instrument conditions used in experiments involving the duplex 
DNA discussed above. While cis-C1 and V1 did not form any complexes with ss1, trans-
D1 formed low abundance ligand/DNA complexes with ss5 (spectra not shown). The 
results of the single strand binding study are summarized by the fraction of bound DNA 
values shown in Table 3.2. In general, the complexes that formed between the trans-D1 
and the single strand DNA were relatively low in abundance compared to ligand/duplex 
DNA complexes (Table 3.2), suggesting that the ligand prefers binding to duplex DNA. It 
is also interesting to note that trans-D1 is less selective for duplex DNA compared to cis-
C1, which echoes the earlier observation that trans-D1 exhibited considerable 
concentration dependent binding behavior with the duplex DNA and formed non-specific 
2:1 complexes.  
3.4 CONCLUSIONS 
The utility of ESI-MS as a tool for screening non-covalent complexes formed 
between threading bis-intercalators and DNA is demonstrated in this study. Binding 
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stoichiometries and ligand sequence selectivity can be quickly assessed and qualitatively 
compared using the ESI-mass spectra, while CAD experiments provide information about 
ligand binding interactions. Our results demonstrated that V1 forms abundant 1:1 
complexes with ds1, the duplex containing its specific binding sequence 5’-GGTACC-3’, 
and forms more abundant complexes with ds1 over ds5, which does not contain the 
specific binding sequence of the ligand. These results correlate well with previous 
DNAse I footprinting and NMR studies. Experiments involving trans-D1 indicate the 
ligand extensively binds to duplex ds5 containing the target sequence 5’-CAGTGA-3’ 
and forms significantly less abundant complexes with ds1, which does not contain a 
specific binding site identified by footprinting experiments. However, at higher 
ligand/DNA molar ratios, trans-D1 forms 2:1 complexes which is indicative of non-
specific binding by the ligand. Cis-C1 exhibited the most promising specific binding 
behavior to ds1 containing the 5’-GGTACC-3’ target sequence as evidenced by the 
formation of significantly more abundant complexes with this duplex over ds5 which did 
not contain a specific binding site. Unlike trans-D1, cis-C1 did not form extensive 2:1 
complexes at ligand/DNA molar ratios greater than one, conveying that the cis structure 
of C1 is favorable for more specific binding. 
In general the CAD spectra of the bis-intercalators are characterized by dominant 
guanine base loss in the 5- and 6- charge states, with increasing degrees of strand scission 
as the charge state increases. The different CAD fragmentation patterns exhibited by the 
bis-intercalator/duplex complexes compared to complexes containing known 
monointercalators mirror the shift in binding interaction of the ligands, characterized by 
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Chapter 4: The Metal-Mediated Binding by Benzoxazoles to Duplex 
DNA Evaluated by ESI-MS 
4.1 INTRODUCTION 
The discovery of the selective cytotoxic activity of UK-1,1-3 a bis(benzoxazole) 
isolated as a secondary metabolite from Streptomyces, has stimulated the development of 
other benzoxazole and benzimidazole compounds with similar anticancer activities.4-6 As 
a topoisomerase II inhibitor, one of the unique properties of UK-1 is its ability to bind 
biologically important divalent metal cations3 and its metal-mediated DNA binding.3,7 
While UK-1 has demonstrated cytotoxicty against a number of cell lines, it does not 
inhibit the growth of bacteria, yeast or fungi,1,8 making the mechanism of this selective 
cytotoxic activity and the metal binding properties of UK-1 and new analogs of great 
interest.  
In a recent study, we used electrospray ionization mass spectrometry (ESI-MS) in 
conjunction with cytotoxicity assays to examine several simple analogs of UK-1 to 
explore the metal ion binding requirements of these compounds, assess metal-mediated 
DNA binding and evaluate anticancer and antibacterial activity.6 Interestingly, the only 
ligand that exhibited anticancer activity, 2 (Figure 4.1), was also the only metal-mediated 
DNA binder with a preference for Ni2+ as determined by ESI-MS experiments. Two other 
compounds, 4 and 5, formed complexes with DNA in a non-specific, non-metal mediated 
manner and showed antibacterial but not cytotoxic behavior. These results suggested a 
correlation between metal-mediated binding and anticancer activity of the compounds.  
To improve upon the solubility of the benzoxazoles in aqueous solutions and to 
allow further examination of the metal-mediated DNA binding and anticancer activity, a 
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series of analogs of 2 have been synthesized with different ester and amide-linked side-









































































Figure 4.1:  Structures of the benzoxazole and benzimidazole ligands. Molecular weights 
are given (in Da) in the parentheses. UK-1, 2, 4, and 5 were examined in a 
previous study.6 
 
In the present study, ESI-MS was used to screen the binding of the new ligands to 
a series of divalent metals including Mg2+, Ni2+, Cu2+, and Zn2+. Ligand binding to duplex 
DNA in the presence and absence of metal ions was also assessed. ESI-MS has been 
shown to be a useful tool for the analysis of non-covalent ligand/DNA complexes due to 
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its sensitivity, low sample consumption, and fast analysis time that make it amenable to 
high throughput screening.10-12 Early studies focused on examining well-studied, 
commercially available duplex DNA-binding compounds including both minor groove 
binders13-16 and intercalators17-19 to establish that the binding stoichiometries, selectivities, 
and specificities observed by ESI-MS correlate with known solution behavior. More 
recent studies have extended the use of the technique to novel compounds, including 
studies by our group examining the metal-dependent binding of UK-1 and related 
benzoxazoles and benzimidazole analogs.6,7 Our previous studies have demonstrated that 
one of the main advantages of a mass spectrometry-based analysis technique for metal-
mediated DNA binding ligands over traditional spectroscopic techniques is that 
information about ligand/metal and ligand/metal/DNA binding stoichiometries is 
obtained.  
For the present study, anticancer cytotoxicity assays were also done so that the 
activity of these analogs could be correlated to the metal binding behavior elucidated in 
the mass spectrometry studies and compared to other previously reported UK-1 analogs.  
Previous studies had identified 2 as a simplified analog of UK-1 that retains the selective 
cytotoxicity of the natural product.4  The analogs of 2 examined here were designed to 
increase the potential for metal ion complexation and metal mediated DNA binding by 
modifying the ester side chain of 2, especially through the addition of addition sites for 
metal ion coordination.     
4.2 EXPERIMENTAL 
4.2.1 Chemicals 
The synthesis of 2 and 12 has been previously reported.4,20 The synthesis of the 
benzoxazole analogs 6, 7, 8, 9, 10, and 11 will be reported separately.9 The 
oligodeoxynucleotides (ODNs) using in this study, d(GCGGGGATGGGGCG), 
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d(CGCCCCATCCCCGC), d(GCGGGAATTGGGCG), d(CGCCCAATTCCCGC), 
d(GCGGAAATTTGGCG), and d(CGCCAAATTTCCGC) were purchased from IDT 
Technologies (Coralville, IA) as ammonium salts. Duplex DNA was annealed by 
preparing equimolar (1 mM) concentrations of the non-self-complementary ODNs in 250 
mM ammonium acetate. Concentrations were verified spectroscopically using Beer’s law 
and the extinction coefficients for the DNA strands provided by the manufacturer. The 
solutions were heated to 90 °C and allowed to cool to room temperature over 7 hours. 
4.2.2 Mass Spectrometry 
Analytical solutions containing a ligand and metal salt, a ligand and DNA duplex, 
or a ligand, metal salt and DNA duplex were prepared at equimolar (10 µM) 
concentrations unless noted otherwise, in 50 mM ammonium acetate solutions with 50% 
methanol. The samples were directly infused at 3 µL/min into a Thermo Electron (San 
Jose, CA) LCQ mass spectrometer. For the DNA binding experiments, the instrument 
was operated in the negative ion mode with an electrospray voltage of 3.5 kV and a 
heated capillary temperature of 90 - 110 °C with sheath and auxiliary gas flows of 40 and 
10 arbitrary units, respectively. Ligand/metal ion solutions were examined in the positive 
ion mode using an electrospray voltage of 4.5 kV and the same heated capillary and gas 
flow rates used for the solutions containing DNA. 
4.3.3 Cytotoxicity Assays 
Cytotoxicity was determined using the AlamarBlue cell viability assay as 
described previously.4   Briefly, aliquots of 100 µl cell suspension (1-3 x 103 cells) were 
placed in microtiter plates in an atmosphere of 5% CO2 at 37 °C. After 24 h, 100 µL of 
culture media and 2 µl of the compound in DMSO were added to each well in duplicate, 
and the plates incubated an additional 72 h at 37 °C.  Compounds, along with Mitomycin-
C as a positive control were evaluated at final concentrations ranging from 0.001 to 50 
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µM.  Cell viability was determined by removing the culture media from each well, and 
adding 200 µL of fresh media and 20 µL of AlamarBlue reagent (Biosource) , followed 
by an additional 6 h incubation and fluorescence measurement Beckman Coulter 
DTX880 plate reader with excitation at 530 nm and emission at 590 nm.  The precent 
growth was calcualted from the fluorescence data using the equation: 
% Growth = 100*(Ft – Fo)/ (Fc – Fo)  
Where: 
Fo = the averaged measured fluorescent intensities of AlamarBlue reagent at the time just 
before the exposure of the cells to the test substance. 
Ft  = the averaged measured fluorescent intensities of AlamarBlue reagent after 72 h 
exposure of the cells to the test substance at a particular concentration.   
Fc  = the averaged measured fluorescent intensities of AlamarBlue reagent after 72 h 
exposure of the cells to the vehicle without the test substance.   
The concentration of compound required to inhibit growth by 50% (IC50) was 
determined by nonlinear regression fitting the %Growth data to the equation: 
y = Min + (Max–Min)/(1+10^[(x-logIC50)*H)]  
Where: 
x = compound concentration. 
y = % Growth. 
Min= the minimum response plateau (0%Growth). 
Max= the maximum response plateau (100% Growth). 
H = the Hill slope co-efficient. 
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4.3 RESULTS AND DISCUSSION 
4.3.1 Ligand Binding to Metals 
The binding of the benzoxazole ligands with metals including Mg2+, Ca2+, Ni2+, 
Cu2+, and Zn2+ was screened by ESI-MS to determine the binding preferences of the 
analogs and identify the metal ions that are most promising for enhancing ligand binding. 
Solutions containing a metal ion and a ligand were prepared at equimolar concentrations 
in the same ammonium acetate buffer used for subsequent DNA binding experiments and 
analyzed in the positive ion mode (Figure 4.2). No complexes were formed between any 
of the ligands and either Mg2+ and Ca2+. Figure 4.2 show mass spectra for solutions 
containing Mg2+ with 11 (Figure 4.2a) and 9 (Figure 4.2b), demonstrating the absence of 
ligand/metal complexes. To ensure that the binding between the ligands and these metals 
was not concentration dependant, the metal ion concentration was increased 10 fold to 




Figure 4.2:  ESI-mass spectra for solutions containing benzoxazole ligands and metal 
ions: (a) 11 and Cu2+, (b) 9 and Cu2+, (c) 11 and Mg2+, and (d) 9 and Mg2+. 
 
These results appear at first to contradict the results of previous studies in which 
the analogs of UK-1, including 2, were found to form complexes with Mg2+.4 However 
the prior binding studies were undertaken in a methanol solvent due to the low solubility 
of the early analogs in aqueous buffers.4 When methanol was used as a solvent in the 
current ESI-MS experiments, 6, 7, 8, 9, 10, 11 and 2  formed abundant complexes with 
Mg2+ (spectra not shown). These results demonstrate the importance of the solvent in the 
metal ion binding of the benzoxazoles, presumably due to the differences in metal ion 
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DNA binding experiments, the ammonium acetate buffer was used for the remaining 
metal ion binding experiments. 
6, 7, 8, 9, 10, 11 and 2 formed complexes with the divalent transition metals Ni2+, 
Cu2+, and to a lesser degree, Zn2+. Typical ligand/metal ion binding stoichiometries ranged 
from 1:1 to 2:2, with the 2:2 complexes most likely being dimers of the 1:1 complexes. 
Ligands with the shorter side chains, 6, 8, and 11 formed abundant 2:1 complexes, as 
shown in Figure 4.2c for a solution containing 11 with Cu2+. The short side-chain ligands 
were also capable of forming 1:1 complexes, however a water adduct was always bound 
to the complex, conceivably to fill the coordination shell of the metal. 7, 9, and 10, the 
long side-chain compounds, were able to form abundant 1:1 complexes without a solvent 
adduct as demonstrated by the spectrum of 9 with Cu2+ shown in Figure 4.2d. It is likely 
that the long side chain is able to wrap partially around the metal ion upon binding, 
thereby filling the coordination shell without addition of solvent molecules.  
The only benzoxazole ligand that did not form complexes with Ni2+, Cu2+, and Zn2+ 
was 12 (spectra not shown). This compound is the only analog examined in this study 
that contains a methyl ester group rather than a hydroxyl group on the phenyl moiety of 
the compound. The 2-(2’-hydroxylphenyl)benzoxazole moiety is also present in synthetic 
metal ion chelators,21, 22 and is believed to play a key role in the metal ion chelation of the 
compounds.3 The lack of metal ion binding observed by 12 in the ESI-MS experiments 
further implicates the role of the hydroxyl phenyl group in the metal ion binding of the 
benzoxazoles and makes 12 a good negative control compound for ligand/metal binding 
examined by ESI-MS. 
The collisionally activated dissociation (CAD) mass spectra of the ligand/metal 
complexes were also examined by ESI-MS. Upon collisional activation, the 2:1 
complexes containing 6, 8 and 11 dissociate via the ejection of a neutral ligand with the 
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rapid adduction of a water molecule (always present in the trap in trace amounts) to the 
resulting 1:1 complex (spectra not shown). This is the same fragmentation pattern 
reported for complexes containing the anti-cancer analog 2 with Cu2+ and Ni2+.6 When the 
resulting 1:1 complexes were subjected to a second stage of CAD (MS3), the complexes 
did not undergo further observable fragmentation. It is likely that the attached water 
molecule is dislodged during collisional activation, but then rapidly re-attaches prior to 
ion detection.  This type of solvent adduction process has been commonly observed for 
transition metal complexes in a quadrupole ion trap.23-27 This was the same fragmentation 
pattern observed for the dissociation of the water-solvated 1:1 complexes containing 6, 8 
and 11 and a transition metal. 
Collisional activation of the 2:1 benzoxazole:metal complexes that contained the 
ligands with longer side-chains, 7, 9, and 10, showed dissociation via the loss of one 
ligand, leaving 1:1 complexes (spectra not shown). Upon MS3, these 1:1 complexes 
produced different fragmentation pathways that were dependent on the ligand. 
Complexes containing 7 and 9, the ligands with a polyethylene glycol side chain, 
dissociated via the loss of small portions of the side chain, such as C2H4O, while the metal 
ion remained bound to the remainder of the ligand. These losses are not observed for 10, 
which contains a six carbon alkyl chain with a terminal hydroxyl group. Instead, the 1:1 
complexes containing 10 dissociate via the loss of the metal ion with the spontaneous 
adduction of methanol or water. In general, these initial ESI-MS experiments not only 
revealed that Ni2+, Cu2+, and Zn2+ are apparently the favored metals for ligand binding, but 
also showed differences in the preferred binding stoichiometries and fragmentation 
patterns for complexes containing ligands with long versus short side-chains. 
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4.3.2 DNA Binding of the Ligands Without Metals 
In previous ESI-MS studies, benzoxazole and benzimidazole ligands that 
exhibited antibacterial activity were found to bind to DNA in the absence of metal 
cations, while compounds exhibiting anticancer activity, notably UK-1 and 2, only 
formed complexes with duplex DNA in a metal-mediated manner. Therefore, the DNA 
binding of the new analogs of 2 (Figure 4.1) in the absence of metal cations was of great 
interest and was examined by ESI-MS in the present study. Three non-self-
complementary DNA duplexes, d(GCGGGGATGGGGCG/CGCCCCATCCCCGC), 
d(GCGGGAATTGGGCG/CGCCCAATTCCCGC), and 
d(GCGGAAATTTGGCG/CGCCAAATTTCCGC), were used for the initial screening 
study. The duplex sequences were selected to have different degrees of G/C and A/T base 
pair composition to account for possible sequence selectivities of the ligands. Solutions 
containing one ligand and one duplex at equimolar (10 µM) concentration were prepared 
in 50 mM ammonium acetate with 50% methanol. The high methanol composition was 
necessary to ensure the ligands remained soluble in the analytical solutions.  To allow for 
comparison of the DNA binding of the new analogs with 2, experiments involving 2 were 
included in the present study to maintain consistency with the earlier study.6 
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Figure 4.3:  ESI-mass spectra of solutions containing duplex 3/4 and (a) 6, (b) 8, (c) 11, 
(d) 7, (e) 9, and (f) 10.  
As demonstrated by the series of spectra shown in Figure 4.3 for solutions 
containing one of six ligands with d(GCGGGAATTGGGCG/CGCCCAATTCCCGC), 
three of the ligands, 7 (Figure 4.3d), 9 (Figure 4.3e), and 10 (Figure 4.3f), were found to 
form low abundance complexes with 1:1 ligand/DNA binding stoichiometries, while 6 
(Figure 4.3a), 8 (Figure 4.3b) and 11 (Figure 4.3c) did not form any complexes detectable 
by ESI-MS. As expected, 2 likewise did not bind to DNA in the absence of metal ions 
(spectra not shown).  The binding results of the ligands with the other two duplexes, 
d(GCGGGGATGGGGCG/CGCCCCATCCCCGC) and 
d(GCGGAAATTTGGCG/CGCCAAATTTCCGC), were similar to those shown in 
Figure 4.3, suggesting that these ligands do not have significant sequence selectivities.  
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The ligands that do bind to the duplex all contain ester- or amide-linked side chains that 
are longer than those compounds that did not bind to duplex DNA, suggesting the side 
chains could play a role in promoting non-metal mediated DNA binding of the 
benzoxazoles.  
The non-metal mediated binding of 7, 9, and 10 differs from that of the 
antibacterial ligands 4 and 5 examined in our previous study. The complexes formed by 4 
and 5 had greater relative abundances, and the binding stoichiometries ranged from 1:1 to 
3:1 and were highly dependent on ligand concentration.6 The binding behavior of ligands 
4 and 5 was similar to  that of commercial intercalators examined in previous ESI-MS 
studies.17, 8 While 7, 9, and 10 formed complexes with duplexes without metals, the 
binding stoichiometries never exceed 1:1, and their relative abundances are low. 
4.3.3 DNA binding of the Ligands with Metals 
Metal cations are documented to play a key role in the DNA binding of UK-1 and 
2, and this metal-mediated binding behavior is thought to be related to the anti-cancer 
activity of these ligands over other non-metal-mediated benzoxazole and benzimidazole 
compounds. Previous studies of the solution metal ion binding ability of UK-1 and 
analogs had indicated that Mg2+ and Zn2+ were implicated in the metal-mediated DNA 
binding by these compounds,4 while in ESI-MS studies Ni2+, Co2+, and Zn2+ promoted the 
greatest duplex binding for UK-1,7 and the duplex binding of 2 was found to be mediated 
by Ni2+.6  
To determine if the binding of the new benzoxazole ligands are also metal-
mediated, ESI-MS experiments were undertaken for solutions containing equimolar (10 
µM) concentrations of a benzoxazole ligand, duplex 
d(GCGGGAATTGGGCG/CGCCCAATTCCCGC), and a metal salt. Based on the first 
section of results described above, only the metals that were found to form complexes 
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with the ligands, Ni2+, Cu2+, and Zn2+, were used in this phase of the study. The most 
significant enhancement in duplex/ligand binding was observed with Cu2+ as 
demonstrated by the spectra shown in Figure 4.4, which correspond to solutions 
containing Cu2+, the duplex and either 6 (Figure 4.4a), 8 (Figure 4.4b), and 11 (Figure 
4.4c). While none of these three ligands bound DNA in the absence of metal ions, 
complexation is observed for all three in the presence of copper, with the most significant 
degree of binding observed for 8 and 11. Complexes containing ligand/metal/DNA 
binding stoichiometries of 1:1:1 and 2:2:1 were observed for 8 and 11, while only low 
abundance 1:1:1 were formed with 6. Similar results were obtained for 2 (spectra not 
shown). The ions that are not labeled in Figure 4.4 correspond to sodium adducts of the 
DNA and ligand/Cu2+/DNA complexes, with the source of sodium contamination likely 





Figure 4.4: ESI-mass spectra of solutions containing duplex 3/4 and Cu2+ with (a) 6, (b) 
8, and (c) 11. 
 
While 7, 9, and 10 were found to bind to duplex DNA in the absence of metal 
cations, their binding was enhanced in the presence of Cu2+, most significantly for 9 and 
10 (spectra not shown). To compare the changes in the degree of ligand binding upon 
addition of the metal salt, the fraction of bound DNA values were calculated by 
expressing the sum of the abundances of all ions attributed to DNA/ligand complexes as a 
fraction of the total abundances of all DNA-containing ions (both free DNA and 
DNA/ligand complexes) as has been previously reported for other ligand/DNA 
complexes.29 The abundances for all of the sodium adducts associated with each complex 
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were included in the calculation, and only ions in the 5- charge state were used since this 
was the dominant charge state in the mass spectra. The increase in the extent of binding 
by 7, 9 and 10 is reflected in the fraction of bound DNA values summarized in Table 4.1.  
The results here and summarized in Table 4.1 demonstrate that Cu2+ has the greatest 
impact on ligand binding, enhancing the binding of 7, 9, and 10, and promoting binding 
by the other ligands with the most dramatic metal-mediated behavior seen for 8 and 11, 
and to a lesser degree, 6. 
In general, Ni2+ had a moderate impact on ligand binding as demonstrated by the 
spectra shown in Figure 4.5.  Extensive binding of Ni2+ to the duplex DNA is observed in 
Figure 4.5, but this does not translate into an enhancement of ligand binding.   11 was the 
only new analog that exhibited binding in the presence of Ni2+ yet did not bind to DNA 
without metal ions, as shown in Figure 4.5c. A low abundance 1:1:1 complex containing 
11 is formed (Figure 4.5c), but with lower abundance relative to the complexes formed 
by 11 in the presence of Cu2+. The duplex binding of 9 was also enhanced in the presence 
of Ni2+ (spectra not shown). For 9, the fraction of bound DNA increased from 0.17 in the 
absence of metal ions to 0.34 in the presence of Ni2+ (Table 4.1). Experiments with 2 
confirmed the results of our previous study that found the binding of the ligand to be Ni2+-
mediated. The fraction of bound DNA values based on the 2/Ni2+/DNA complexes was 




Figure 4.5: ESI-mass spectra of solutions containing duplex 3/4 and Ni2+ with (a) 6, (b) 
8, and (c) 11. 
 
Figures 4.5A and 4.5B show that neither 6 nor 8 bound to the DNA with Ni2+,  nor 
did Ni2+  enhance the binding of 7 or 10 (spectra not shown). As summarized in Table 4.1, 
the fraction of bound DNA values for the 7 and 10 in the absence metal ions were 0.09 
and 0.20, respectively (Figures 4.3d and 4.3f). While both ligands formed 1:1:1 
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ligand/Ni2+/DNA complexes, the relative abundances of these complexes were either the 
same as or lower than the abundances of the complexes formed in the absence of metal 
ions. This is reflected in the fraction of bound DNA values for solutions containing the 
ligands with Ni2+ and DNA which were calculated to be 0.08 for 7 and 0.13 for 10. 
 
Table 4.1:  Fraction of bound DNA valuesa for the benzoxazole ligands and 
d(GCGGGAATTGGGCG/CGCCCAATTCCCGC) with Ni2+, Cu2+, or 
Zn2+, and in the absence of metals. Solutions contained equimolar (10 µM) 
concentration of ligand, DNA, and, where appropriate, metal ion. 
 
aAll values + 0.05. 
 
Zn2+ did not have a significant impact on the benzoxazole ligand binding to DNA. 
Zn2+ did not promote DNA binding by 6, 8, 11, or 2, the ligands that likewise did not bind 
to DNA in the absence of metals (spectra not shown). 10 formed 1:1:1 ligand/Zn2+/DNA 
complexes, however the fraction of bound DNA value for ligand binding in the presence 
of zinc was 0.17 which is not significantly different than it was in the absence of metal, 
0.20 (spectra not shown). The DNA binding of 7 and 9 was enhanced by Zn2+, as 
0 0.270.140 11 
0 0.4000 8 
0 0.1400 6 
0 0.170.180 2 
0.17 0.320.130.2 10 
0.27 0.270.340.17 9 
0.17 0.150.080.09 7 
Zn2+  Cu2+Ni2+No metal Ligand 
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indicated by an increase in their fraction of bond DNA values (spectra not shown). For 7, 
the fraction of bound DNA without metals was 0.08 and in the presence of Zn2+ it 
increased to 0.17, while the values increased from 0.17 to 0.27 for 9. 
Aside from 2, the ligands displaying the most pronounced metal-mediated DNA 
binding based on the ESI-MS results are 8 and 11. The binding of 6 was also mediated by 
Cu2+, however the complexes formed by the ligand are lower in relative abundance than 
those formed by 8 and 11. The structures of 8 and 11 are similar to 2. This result is 
somewhat unsurprising due to the similarities in their structures. The ester linkage of 2 is 
changed to an amide-linkage in 11. While both 11 and 2 exhibited metal mediated 
binding, copper had a more positive impact on 11 binding than it did on 2. Likewise, Ni2+ 
promoted greater binding for 2 than it did for 11. This difference may result from the 
preferential coordination of Cu(II) to nitrogen atoms over those oxygen atoms.30 Similar 
differences can be seen for the binding of 8, which also has an amide-linked side chain 
that is extended by two carbon atoms compared to 11 and 2. Compared to 2, 8 also 
demonstrates greater DNA binding with copper and no binding with Ni2+.  
While the longer side-chains of 7, 9 and 10 enhance non-metal-mediated DNA 
binding, they tend to preclude the dramatic metal-mediated DNA binding behavior 
observed for the ligands with the shorter side-chains. The longer side-chains of the 
ligands are believed to enhance the metal binding of the ligands by wrapping around and 
coordinating to the metals. The ester-linked polyethylene glycol side chain of 9 produced 
the best enhancement of metal mediated binding, as all three metal ions, Ni2+, Cu2+, and 
Zn2+, increased the binding of the ligand to DNA relative to the binding in the absence of 
the metal. The results for 7, with the shorter, amide-linked polyethylene glycol side chain 
were not as favorable. While the binding was enhanced by Cu2+ and Zn2+, the overall 
fraction of bound DNA values were generally lower than the values for the other ligands 
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in the presence of metals. With an amide-linked side chain that did not contain ethylene 
glycol groups, the binding of 10 was only enhanced by Cu2+. The binding results of the 
ligands with the longer side chains suggests that the longer, polyethylene glycol side 
chain of 9 is the most favorable for overall metal-mediated binding.  
4.3.4 CAD Spectra of the DNA Complexes 
The fragmentation pathways of the DNA complexes containing the benzoxazole 
ligands were also evaluated. The ligand/DNA complexes that were formed in the absence 
of metal ions dissociated by the neutral ejection of ligand, leaving the bare duplex ion. 
An example of this fragmentation route is shown in Figure 4.6A for the CAD spectrum of 
[ds + 9]5-. This pathway is similar to what has been observed in past CAD studies of DNA 
complexes containing traditional DNA intercalators.31-33 Complexes with ligand and metal 
bound to DNA dissociated via the ejection of the neutral ligand, with the metal ion being 
retained by the DNA duplex as shown in Figure 4.6B for [ds + 11 + Cu2+]5-. Past ESI-MS 
studies of duplex DNA complexes containing UK-1 with a metal ion reported the same 
fragmentation pathway.7 While it is difficult to draw conclusions about the binding mode 
of the benzoxazole/metal ion/DNA complexes based on CAD results, they do suggest 
that the binding interactions involved in complexes containing the new benzoxazole 
ligands are similar to that of UK-1. 
 68
 
Figure 4.6:  CAD spectra of (A) [ds + 9]5- and (B) [ds + 11 + Cu2+]5-. 
 
4.3.5 Cytotoxicity Assays of Benzoxazole Ligands 
There are some interesting correlations between the degree of metal-mediated 
binding behavior of the benzoxazole ligands determined by ESI-MS and their 
cytotoxicity to two cancer cell lines. As summarized by the IC50 values shown in Table 
4.2, the new ligands with the greatest cytotoxicity against the A549 lung cancer cell line 
were 8, 9, and 11, all having IC50 values that were similar to 2. Both 8 and 11 exhibited 
the most dramatic degree of metal-mediated DNA binding as their fraction of bound 
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respectively, in the presence of Cu2+. 11 was also found to form complexes in the 
presence of Ni2+. While 9 was not a truly metal-mediated DNA binding ligand, it exhibit 
the most consistent and dramatic enhancement in DNA binding in the presence of metal 
ions of the ligands that bound to DNA in the absence of metal ions.  
 
Table 4.2: IC50 values(in µM) for the benzoxazole compounds against the A549 (lung 
cancer) and MCF7 (breast cancer) cell lines. 
 
 
9 and 11 also showed cytotoxicity against the MCF7 breast cancer cell lines with 
IC50 values of 13 + 2 µM and 10 ± 8 µM, respectively. Both of these values are on par 
with the IC50 value of 2, 4 ± 2 µM9 + 7. Interestingly, 8, which showed activity against 
A549 cells comparable to that of 2 was relatively inactive against MCF7 cells (IC50 = 30 
± 10 µM), and 6, which was relatively inactive against A549 cells, retained some activity 
against MCF7 cells (IC50 = 15 ± 5 µM).   At this point the reasons for these differences 
are unclear, but we note that of the two analogs of 2 containing the most conservative 
structural changes, 6 and 11, only 11 demonstrates enhanced metal-mediated DNA 
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binding relative to 2 and this analog also displays the most comparable cytoxicity against 
both cancer cell lines, relative to 2. 9 also demonstrated good cytotoxic activity, and 
while it was not a truly metal-mediated DNA binder, its DNA complexation was 
consistently enhanced by the presence of Cu2+, Ni2+, and Zn2+. In contrast, compound 12, 
which does not bind metal ions, was the only compound in this series that did not display 
cytotoxicity towards either cell line.  
4.4 CONCLUSIONS 
The correlation between significant metal-mediated or metal-enhanced binding 
determined by ESI-MS and anticancer activity of the benzoxazoles ligands assessed by 
cytotoxicity assays is demonstrated in this study. ESI-MS experiments reveal that Cu2+ 
and Ni2+ form the most abundant complexes with 6, 7, 8, 9, 10, and 11, while less 
abundant complexes are formed with Zn2+. For the complexes containing short side-
chains, 6, 8, and 11, 2:1 ligand/metal ion binding stoichiometries were predominant, 
which the compounds with longer side-chains, 8, 9, and 10, formed abundant 1:1 
complexes. DNA binding experiments reveal that the analogs with longer side-chains 
formed complexes with duplex DNA in the absence of metal ions, while those with 
shorter side-chains did not.  
Of the ligands that did not bind to duplex DNA in the absence of metal ions, the 
DNA binding by 8 and 11 was enhanced most dramatically by Cu2+. Ni2+ influenced 
duplex binding for 11 and 2, and enhanced the binding by 9. The metal ion with the least 
substantial effect was Zn2+ which only enhanced the binding of 7 and 9, two ligands that 
formed complexes with DNA regardless of the presence of metals.  
Of the compounds examined in this study, both 8 and 11 were also found to be the 
most cytotoxic against the A549 lung cancer cell line and 11 demonstrated moderate 
cytotoxicity against  MCF7 breast cancer cells. Metal ions also enhanced the DNA 
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binding of the ligands with the long side-chains, most notably for 9, which also exhibited 
the highest level of cytotoxicity of the long side-chain compounds. 
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Chapter 5: Evaluation of Binding of Perylene Diimide and 
Benzannulated Perylene Diimide Ligands to DNA by Electrospray 
Ionization Mass Spectrometry 
5.1 INTRODUCTION 
Small molecules that interact non-covalently with nucleic acid structures 
comprise an important class of anticancer, antitumor, and antibacterial therapies.1, 2 
Increased interest in the development and evaluation of DNA-interactive agents has 
stimulated the need for sensitive analytical techniques that can not only characterize 
drug/DNA interactions but are also compatible with library-based screening. Electrospray 
ionization-mass spectrometry (ESI-MS) has emerged as a useful tool for examining non-
covalent drug/DNA complexes because its low sample consumption and fast analysis 
time makes it well-suited for high throughput screening techniques.3, 4 The full-scan mass 
spectra can be used to evaluate binding stoichiometries and selectivity, while binding 
mode and structural information can be examined via tandem mass spectrometry 
techniques such as collisional activated dissociation (CAD).5-7 
Much of the past work done in this area has focused on analyzing well-
characterized drug/duplex DNA complexes, with promising results that indicate behavior 
in the gas-phase can be correlated to solution.5-25 For example, Gabelica and co-workers 
demonstrated that binding stoichiometries and relative ion abundances observed in the 
mass spectra reflect known solution binding behavior.6 Minor groove and intercalation 
binding modes of well-studied duplex-interactive drugs were distinguished by Wan and 
co-workers using collisional activated dissociation (CAD) experiments.7  
Recent work by our group and others has extended the use of ESI-MS to evaluate 
non-covalent interactions of small molecules with G-quadruplex DNA,18, 20, 23, 24, 26-28 a 
higher order nucleic acid structure being investigated as an anticancer drug target.29, 30 G-
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quadruplex DNA is formed from hydrogen bonding between a planar arrangement of four 
guanine nucleobases with the central cavity serving as a binding site for monovalent 
metal ions, the presence of which is generally required for the formation of the 
quadruplex. A variety of G-quadruplex structures can be formed from hydrogen bonding 
between guanines on up to four separate strands of oligodeoxynucleotides (ODNs).29  
There is interest in studying G-quadruplex DNA as an anticancer target because 
of its role in telomere maintenance in cancer cells.31, 32 Telomeres are the extremities of 
linear chromosomes that play an important role in protecting the chromosome ends from 
fusion and degradation and ensuring the complete replication of chromosomal DNA. 
Composed of G-rich sequences (TTAGGG is the human telomeric sequence), the single 
strand 3’ overhangs of telomeres have the ability to form G-quadruplex structures. 
Ligands that selectively bind and stabilize the quadruplex structure of telomeric DNA 
may lead to the inhibition of telomerase, the enzyme responsible for the synthesis of 
telomeric DNA.33 While telomerase is not active in most somatic cells, high levels of 
telomerase activity have been associated with most cancer cells.34 Developing a drug that 
exhibits binding selectivity for G-quadruplex DNA over other DNA structures is also a 
primary focus of G-quadruplex-interactive drug design given the implications for 
reducing cytotoxic side-effects of anticancer agents. 
  One promising class of quadruplex selective-ligands are perylene diimides 
(PDIs).35-43 Recent solution studies of N,N’-bis[2-(1-piperidino)-ethyl]-3,4,9,10-
perylenetetracarboxylic acid diimide (PIPER)35 and N,N’-bis(4-morpholinylpropyl)-
3,4,9,10-perylenetetracarboxylic acid diimide (Tel01)38 indicate that these molecules 
exhibit G-quadruplex affinity by stacking on the faces of the terminal G-tetrads, thereby 
stabilizing the G-quadruplex structure. We previously demonstrated the selectivity of 
Tel01 for quadruplex over duplex DNA based on ESI-MS studies in a quadrupole ion 
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trap mass spectrometer.26 A more comprehensive series of PDI ligands, including those in 
which the perylene diimide chromophore is modified through substitution or 
benzannulation, (Figure 5.1) have been designed to further investigate the structural 
features most important for G-quadruplex DNA binding. In this study we demonstrate the 
utility of ESI-MS as a screening tool to characterize binding stoichiometry, distinguish 
between selective and non-selective binding, and determine the binding mode of these 
novel perylene diimide ligands. 
 
 
Figure 5.1:  Structures of perylene diimide analogs. Molecular weights of compounds 
(Tel01, PIPER, Tel32) or organic ions (Tel11, Tel12, Tel18, Tel34) in Da 




PIPER, Tel01, Tel11, Tel12, were prepared as described previously.35, 37, 38 The 
manuscript detailing the synthesis of Tel18, Tel32 and Tel34 is in preparation.  
Ammonium salts of oligodeoxynucleotides (ODNs) custom synthesized on the 1.0 µmole 
scale with purification by RP-HPLC were obtained from TriLink Biotechnologies Inc. 
(San Diego, CA) and Integrated DNA Technologies (Coralville, IA) and used without 
further purification. The oligonucleotide d(TTTTTTTT) was synthesized on a 10 µM 
scale using a DNA synthesizer and purified by RP-HPLC. Collected fractions were 
combined and extensively dialyzed against deionized water before being lyophilized 
completely.  A 2 mM stock solution of the G-quadruplex-forming ODN 
(d(TTGGGGGT)) was prepared in deionized water. A portion of the initial stock solution 
was diluted to 500 µM in deionized water and set aside for single strand experiments. 
The remaining solution was annealed by diluting in 150 mM ammonium acetate, heating 
to 90° C and slowly cooling to room temperature over a period of 7 hours. The self-
complementary duplex-forming ODNs 
(d(GCGGGGATGGGGCG/CGCCCCATCCCCGC), 
d(GCGGGAATTGGGCG/CGCCCAATTCCCGC), and 
d(GCGGAAATTTGGCG/CGCCAAATTTCCGC)) were annealed in 250 mM 
ammonium acetate by heating to 90° C and slowly cooling to room temperature over a 
period of 2-3 hours. 
5.2.2 Absorption Spectroscopy 
Spectra were recorded on a UNICO model 2102 UV-spectrophotometer.  
Experiments were carried out in polystyrene cuvettes to minimize nonspecific binding of 
the ligands to the surface of the cuvettes.  For DNA binding experiments, the absorption 
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spectra were obtained under high and low salt conditions.  For the high salt conditions, 
the compound (20 µM) in 70 mM potassium phosphate, 100 mM potassium chloride, 1 
mM EDTA buffer (pH 7) was analyzed alone or in the presence 20 µM structure of G4-
DNA [d(TAGGGTTA)]4, G4’-DNA [d(TTAGGG)4] double-strand DNA 
[d(CGCGCGATATCGCGCG)]2, or single-stranded DNA d(TTTTTTTT).  For the low 
salt conditions, the compound (10 µM) in 3:1 25 mM ammonium acetate/methanol was 
analyzed alone or in the presence of 10 µM structure of G4-DNA [d(TTGGGGGT)]4, 
double-stranded DNA [d(GCAAATTTCG)]2 or single-stranded DNA d(TTTTTTTT).  
Samples were monitored until equilibrium was achieved, as evidenced by constant 
absorbance readings.  
5.2.3 Fluorescence Spectroscopy and Resonance Light Scattering 
Spectra were recorded on a Hitachi model F-2000 spectrofluorometer. Quartz 
cuvettes were treated with SigmaCote for 1 hour followed by extensive washing with 
water to minimize nonspecific binding of the ligands to the surface of the cuvette.  
Fluorescence and resonance light scattering (RLS) measurements were carried out on the 
ligands under both high- and low-salt conditions.  The high salt conditions employed 
solutions of compound in 70 mM potassium phosphate, 100 mM potassium chloride, 1 
mM EDTA buffer at the indicated pH.  Low-salt conditions employed solutions of 
compound in 3:1 25 mM ammonium acetate/methanol at the indicated pH.   Solutions 
were allowed to equilibrate for the specified time before scans were performed at 25 °C 
using the noted excitation and emission wavelengths.   
5.2.4 Mass Spectrometry 
Stock solutions of the ligands were prepared in either 0.1% aqueous 
trifluoroacetic acid (PIPER and Tel01), deionized water (Tel11, Tel12, and Tel18), 
acetonitrile (Tel32) or dimethylsulfoxide (Tel34) and stored at room temperature. 
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Analytical solutions were prepared containing G-quadruplex, duplex, or single strand 
DNA and one ligand each at equimolar 10 µM concentrations in 3:1 25 mM ammonium 
acetate/methanol solvent. A Harvard syringe pump (Holliston, MA) set at a flow rate of 3 
µL/min was used to directly infuse the sample solutions into a ThermoFinnigan LCQ 
Duo mass spectrometer (San Jose, CA). The ESI source was operated in the negative ion 
mode with an electrospray voltage of 3.5 kV and a heated capillary temperature of 90 to 
120° C. To aid in desolvation, nitrogen sheath and auxiliary gas were set at 40 and 10 
arbitrary units, respectively. The base pressure of the trap was ~1 x 10-5 Torr. Spectra 
were acquired by summing 300 scans, with an ionization time ranging from 100 to 250 
ms.  
Collisional activated dissociation (CAD) experiments were performed on selected 
complexes by isolating the desired precursor ion in the ion trap using resonance ejection, 
followed by fragmentation promoted by increasing the collisional energy applied to the 
trap (reported as a percentage of 5 V0-p) until the intensity of the precursor ion was 
reduced to approximated 10 % of its original intensity. An activation time of 30 ms was 
used in all CAD experiments. 
5.3 RESULTS AND DISCUSSION 
5.3.1 Fluorescence and Resonance Light Scattering Studies of PDI Aggregation 
PDIs like Tel01 and PIPER are known to undergo pH-dependent self-association 
to form aggregates in solution.37-39 The selectivity of PDIs towards G-quadruplex DNA 
depends on the aggregation state of these ligands, which, in addition to pH, may also be 
affected by ligand concentration, buffer ionic strength, and the presence of non-aqueous 
co-solvents.36, 38  Previous solution studies of the aggregation state and G-quadruplex 
DNA binding selectivity of PIPER,36,38 Tel01,36,38 Tel11,37 and Tel1237 were carried out 
under relatively high-salt (170 mM KCl) phosphate buffer.  In order to determine the 
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aggregation state of these and the other PDI ligands under the conditions of the ESI-MS 
analysis discussed later, the fluorescence and resonance light scattering spectra were 
determined in 3:1 25 mM ammonium acetate/methanol.   
As reported previously, the intense fluorescence of the monomeric PDIs is 
quenched upon ligand self-association in solution.36-38 Solutions of PIPER (1 µM) in 
methanolic ammonium acetate buffer display a pronounced fluorescence emission at 550 
nm whereas solutions of Tel01 do not (spectra not shown).  For aggregates in which there 
is good overlap between adjacent monomer chromophores, a large increase in the 
intensity of scattered light is observed when the incident light is the same wavelength as 
the aggregate absorbance.44 This resonance light scattering (RLS) signal has been used as 
a qualitative measure of the presence of PDI aggregates in solution.36-38 Solutions of Tel01 
display a large RLS signal; however, the RLS signal for PIPER is absent (data not 
shown).  The absence of strong fluorescence and the presence of a strong RLS signal for 
solutions of Tel01 indicate that this PDI is aggregated under these conditions.  In 
contrast, the lack of an RLS signal and the presence of strong fluorescence for solutions 
of PIPER indicate that this PDI exists in the monomeric state.  Similar observations were 
made for solution of Tel01 and PIPER in high-salt buffer conditions, indicating that the 
aggregation state of these two PDIs is largely unaffected by the methanolic buffer 
conditions employed in the ESI-MS analysis. 
The fluorescence and RLS spectra of the other PDIs were also examined under 
the methanolic buffer conditions.  As shown in Table 5.1, PIPER, Tel11, and Tel18 are 
not aggregated in solution, as judged by the strong fluorescence and lack of RLS signals 
of these solutions.  The PDI Tel12 displays only weak fluorescence and no RLS spectra.  
The weak fluorescence of Tel12 may be due to ligand dimerization, as has been noted for 
this PDI in 150 mM KCl phosphate buffer;37 however, the fluorescence intensity of Tel12 
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in methanolic buffer is higher than that in the high-salt buffer (data not shown), 
indicating that dimerization is less extensive in the methanolic buffer. Because Tel12 has 
been found to dimerize, but does not produce a RLS spectrum, this ligand self-associates. 
Self-association refers to the formation of dimers, as is the case for Tel12, as well as 
high-order species and aggregates, which we functionally define as PDI species that can 
be observed by resonance-light scattering.  
 
Table 5.1: Resonance light scattering and fluorescence data for PDIs.  
 




TEL01 0.649 36 
PIPER 25.31 nsc 
TEL11 25.83 nsc 
TEL12 12.74 nsc 
TEL18 41.82 nsc 
TEL32 0.189 6 
TEL34 0.524 5 
 
a Relative intensity of fluorescence emission (550 nm) from a 1 µM solution of PDI in 3:1 25 mM 
ammonium acetate /methanol buffer, pH 7.  Excitation was at 520 nm for all ligands except Tel32 and 
Tel24, which were excited at 495 nm.  b Relative intensity of the resonance light scattering peak at 470 nm 
for solutions of PDI (1 µM) in 3:1 25 mM ammonium acetate /methanol buffer, pH 7.  c No significant RLS 
signal observed. 
 
Like Tel01, solutions of the benzannulated PDI Tel34 in methanolic buffer do not 
fluoresce; however, unlike Tel01, Tel34 solutions do not display a strong RLS signal, 
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indicating that if Tel34 is aggregated in solution, the aggregates are RLS-silent.  Attempts 
to compare the aggregation state of Tel34 in methanolic ammonium acetate and 150 mM 
KCl phosphate buffer were unsuccessful due to the very low solubility of this PDI in the 
high-salt buffer.  Similarly, the low solubility of Tel32, even in methanolic ammonium 
acetate, made characterization of this PDI difficult.  Immediately prepared solutions of 
Tel32 showed very low fluorescence and RLS signals; however, over a period of minutes 
the ligand began to precipitate from these solutions. 
5.3.2 DNA Binding Studies by UV-Vis Absorption Spectroscopy 
The UV-Vis absorption spectra of the PDIs (10 µM in 3:1 25 mM ammonium 
acetate/methanol) were determined in the absence and presence of 10 µM of G-
quadruplex DNA, duplex DNA, or single-stranded DNA.  The parallel stranded G-
quadruplex [d(T2G5T)]4 (G5), which is similar to the well-characterized [d(T2G4T)]4, was 
employed for both these solution binding studies as well as the ESI-MS analysis.  An 
advantage of this parallel-stranded G-quadruplex over intramolecular G-quadruplexes is 
the ease with which the G-quadruplex form can be distinguished from single-stranded 
DNA in the ESI-MS spectra (see below).  The duplex DNA formed by the self-
complementary ODN d(GCAAATTTCG) and single-stranded d(T8) were also used in 
these solution binding studies. 
 83
Figure 5.2:   UV-Vis absorbance spectra of 10 µM Tel01(A),  PIPER (B), Tel18 (C), and 
Tel34 (D) alone and in the presence of 10 µM G5-DNA [d(T2GT)]4, ds-DNA 
[d(GCAAATTTCG)]2, or ss-DNA [d(T8)] in 3:1 25 mM ammonium 
acetate/methanol, pH 7. 
As shown in Figure 5.2A, the UV-Vis spectrum of Tel01 shows an absorbance 
peak at 470 nm.  Similar absorbance spectra are recorded for solutions of Tel01 in the 
presence of equimolar duplex or single-stranded DNA; however, in the presence of 
equimolar G-quadruplex DNA, the absorbance spectrum of Tel01 is remarkably different, 
consisting of two large peaks at 550 and 510 nm.   The UV-Vis spectrum of PIPER 
displays an absorbance peak at 500 nm, which shifts to 510 nm in the presence of 
equimolar single-stranded, double-stranded, or G-quadruplex DNA (Figure 5.2B).  
Additionally, in the presence of each of these DNA structures, there is a new absorbance 
from the PIPER chromophore at 550 nm.  The intensity of this long-wavelength band 
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increases in the order single-stranded DNA < double-stranded DNA < G-quadruplex 
DNA. 
These UV-Vis spectral changes for Tel01 and PIPER indicate a difference in the 
G-quadruplex DNA binding selectivity of these two ligands.37,38  Tel01, whose absorbance 
spectrum in the absence of DNA is blue-shifted due to ligand aggregation, forms a 
complex with G-quadruplex DNA that absorbs in the 550 nm region.  PIPER, whose 
spectrum in the absence of DNA does not indicate ligand aggregation, forms similar 
long-wavelength absorbing complexes with G-quadruplex, duplex, and even single-
stranded DNA (Figure 5.2B).   
Other PDIs shown in Figure 5.1 also undergo UV-Vis spectral changes in the 
presence of G-quadruplex DNA.  Tel11 and Tel12, whose absorbance spectra in the 
absence of DNA is similar to that of PIPER, also form complexes with G-quadruplex 
DNA characterized by absorbance peaks at 550 nm (data not shown).  Tel11, but not 
Tel12, also gives rise to a peak at 550 nm in the presence of double-stranded DNA.  As 
expected, the UV-Vis absorbance spectrum of the chromophore-modified PDI Tel18 is 
different from that of PIPER and the other PDIs. The Tel18 spectrum, consisting of a 
peak at 525 nm with a shoulder at 492 nm, undergoes hypochromic and bathochromic 
shifts in the presence of G-quadruplex DNA (Figure 5.2C).  Similar changes are also 
observed in the presence of duplex DNA, and to a lesser extent, single-stranded DNA.   
The absorbance spectrum of Tel34 includes a long wavelength peak at 450 nm with a 
shoulder at 490 nm (Figure 5.2D).  In the presence of G-quadruplex DNA, there is a shift 
of the 490 nm absorbance to 480 nm, accompanied by slight hyperchromism.  
Immediately after the addition of double-stranded or single-stranded DNA, there is a 
slight hypochromism in the Tel34 absorbance spectrum, but no appreciable changes in 
the position of the absorbance peaks (Figure 5.2D).  Over a period of an hour, solutions 
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of Tel34 containing duplex or single-stranded DNA exhibit a pronounced decrease in 
UV-Vis absorbance that is accompanied by the formation of insoluble material.  This 
behavior is not observed in the presence of G5 DNA, presumably because the complex 
formed between this benzannulated PDI and the G-quadruplex DNA is more soluble in 
the buffer than the ligand itself.  The benzannulated and uncharged PDI Tel32 is also 
relatively insoluble, and at the concentration employed for these absorbance studies (10 
µM), the ligand precipitated from solution over the course of a few minutes.  
5.3.3 Fluorescence Quenching Studies 
It has previously been shown that PDI fluorescence is quenched upon ligand 
binding to DNA structures.36-38  Fluorescence quenching experiments of the PDIs with 
quadruplex, duplex, and single-stranded DNA allow better quantification and insight into 
the affinity and selectivity differences of these ligands for G-quadruplex DNA.  Solutions 
of 1 µM PDI in 3:1 25 mM ammonium acetate/methanol buffer, pH 7 were titrated with 
stock solutions of each DNA structure in the same buffer.  Fluorescence spectra were 
recorded at appropriate emission and excitation wavelengths for each class of 
chromophore:  unmodified PDIs Tel01, Tel12, Tel12, Tel34, and PIPER (emission at 545 
nm, excitation at 495 nm); chlorinated PDI Tel18 (emission at 555 nm, excitation at 495 
nm); and benzannulated PDI Tel32 (emission at 565 nm, excitation at 469 nm (data not 
shown). While all three DNA samples quench the fluorescence of Tel18, there is clearly a 
difference between the efficiency of fluorescence quenching, with G5-DNA causing the 
most extensive quenching at low concentrations, single-stranded DNA producing the 
least quenching, and duplex DNA leading to intermediate quenching.   In the case of G-
quadruplex DNA, there is nearly 80% fluorescence quenching after the addition of just 
one-half equivalent of DNA, indicating that multiple Tel18 ligands are binding to the 
DNA. 
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The results of the fluorescence quenching studies of the PDIs are summarized in 
Table 5.2, which shows the percent PDI fluorescence quenching after the addition of one 
equivalent of the different DNA structures.  In accord with the UV-Vis absorbance 
studies (Figure 5.2A), Tel01 displays a high degree of selectivity for G-quadruplex DNA 
binding, as shown by the minimal fluorescence quenching in the presence of either 
duplex or single-stranded DNA compared to G-quadruplex DNA.  
 Other PDIs, such as PIPER and Tel11, appear to interact more strongly with G-
quadruplex DNA when compared to Tel01, but show very little selectivity for G-
quadruplex DNA versus duplex DNA. Both PIPER and Tel18 also show significant 
interactions with single-stranded DNA; the addition of one equivalent of single-stranded 
DNA to these PDIs quenches their fluorescence by more than 50%.  Tel18 and Tel34 
appear to be of intermediate selectivity for G-quadruplex DNA versus duplex DNA and 
have moderate affinity for single-stranded DNA.  Tel12 does not interact strongly with 
G-quadruplex DNA, as evidenced by only 29% fluorescence quenching in the presence 
of one equivalent of G5-DNA; however, this PDI is relatively selective for G-quadruplex 
DNA and does not bind to single-stranded DNA.  There was insignificant fluorescence 








Table 5.2:   Fluorescence quenching of PDIs by quadruplex, duplex, and single-stranded 
DNA. 
 
 Percent Fluorescence Quenching in the presence of 
equimolar DNAa 
Ligand G5-DNAb ds-DNAc ss-DNAd 
TEL01e 64 ± 4% 6 ± 2 % 2 ± 1% 
PIPERe 100 ± 1 % 94 ± 2 % 57 ± 4 % 
TEL11e 99.8 ± 0.1 % 96 ± 1 % 67 ± 5 % 
TEL12e 29 ± 6 % 16 ± 8% 13 ± 6 % 
TEL18f 92.9 ± 0.1 % 66 ± 3% 12 ± 9 % 
TEL32e 4 ± 2 % 1 ± 2% 7 ± 2 % 
TEL34g 90 ± 2 % 62 ± 4% 40 ± 6 % 
 
 
aFluorescence emission intensity of solutions of 1 µM PDI and 1µM DNA in 3:1 25mM ammonium acetate 




e Excitation = 495 nm, emission = 545 nm. f Excitation = 495 
nm, emission = 555 nm. g Excitation = 469 nm, emission = 565 nm. 
 
5.3.4 Binding Stoichiometry of Perylene Diimides by Electrospray Ionization Mass 
Spectrometry 
To begin an ESI-MS investigation of the binding selectivity of the perylene 
diimide ligands, the complexation of each ligand with G-quadruplex DNA was evaluated. 
The intermolecular, parallel stranded G-quadruplex [d(T2G5T)]4 (G5) was used in this 
study.  Rosu et al. were the first to demonstrate that G-quadruplex DNA can be annealed 
in an ammonium acetate buffer and analyzed by ESI-MS.27 When ammonium acetate is 
used, the G-quadruplex structure is stabilized by NH4
+ counterions, rather than by Na+ or 
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K+, resulting in cleaner spectra as a result of the greater lability of the associated 
counterions during the ESI process.  The ESI mass spectrum of the G-quadruplex without 
any added ligands (Figure 5.3A) demonstrates that the G-quadruplex species can readily 
be detected in the -6 charge state, and to a lesser degree in the -7 charge state with two to 
four ammonium adducts associated with each quadruplex. It is likely that the ammonium 
ions are bound in the central cavity of the G-tetrad, stabilizing the quadruplex. For visual 
simplicity, the NH4
+ ions are not labeled in the remaining figures. 
Solutions containing the G-quadruplex and one of each of the five non-
benzannulated ligands (Tel01, Tel11, Tel12, Tel18, and PIPER) at equimolar 
concentrations of 10 µM in a 3:1 25 mM ammonium acetate/methanol solution exhibited 
a variety of binding stoichiometries as demonstrated by the mass spectra shown in Figure 
5.3.  For the solution containing Tel18 (Figure 5.3B), complexes with Tel18/G5 binding 
stoichiometries of 1:1 and 2:1 are present with greater abundances than the free G-
quadruplex ions. Other ligands formed less abundant complexes with the G-quadruplex. 
This is apparent in the spectrum of G5 with Tel12 (Figure 5.3C) in which only 1:1 
complexes are present at lower abundances than the unbound G-quadruplex ions. 
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Figure 5.3:  ESI mass spectra for complexes containing [d(T2G5T)]4 (G5) (A) alone, and 
with (B) Tel18, and (C) Tel12. Complexes containing one or more ligands 
are labeled with a “L”. 
With the exception of Tel01 and Tel12, 1:1 and 2:1 binding stoichiometries were 
consistently observed. This result is in agreement with a previous NMR-based study of 
the perylene diimide analog PIPER that found 1:1 and 2:1 complexes were typically 
formed in solution by end-stacking on the faces of the terminal G-tetrads.35 The 3:1 
complexes present in the ESI mass spectrum of Tel01 with G5 may be the result of ligand 
aggregation, as discussed above.  Recent x-ray crystallographic studies of an 
anthraquinone bound to a parallel-stranded G-quadruplex DNA show three ligands bound 
to a single G-tetrad face.45   Presumably, a similar sort of self-association of multiple PDI 
ligands on G-tetrad faces could occur for Tel01, which undergoes aggregation in solution 
even in the absence of G-quadruplex DNA.  Ligand aggregation is not observed in 
 90
solution for the analogs with charged side chains (Tel11, Tel12, and Tel18). Aggregation 
is less expected for these ligands due to charge repulsion, which is especially true in the 
gas-phase, thus explaining why aggregation was not observed with those ligands. Charge 
repulsion may also explain why only 1:1 complexes were observed for Tel12. As the only 
ligand with negatively charged side chains, Tel12 may experience coulombic repulsion 
with the anionic backbone of the DNA in solution and the gas-phase, preventing the 
binding of multiple ligands. In general, the predominant 1:1 and 2:1 binding 
stoichiometries observed for the ligands with G5 DNA is expected based on an end-
stacking binding mode.  
5.3.5 Binding Stoichiometry of Benzannulated Ligands by ESI-MS 
The interactions of G-quadruplex DNA with a series of benzannulated perylene 
diimides (Figure 5.1) with an extended chromophore, Tel32 and Tel34, were also 
examined by ESI-MS. The benzannulated analogs may engage in increased end-stacking 
interactions with the G-tetrad as a result of the larger conjugated ring system. The ESI-
MS results for this set of analogs (spectra not shown) indicate that Tel34 forms 
complexes with the quadruplex DNA, but only with binding stoichiometries of 1:1. 
Interestingly, Tel11 and Tel18 have the same side chain as Tel34, but both formed 
complexes with higher binding stoichiometries than Tel34, indicating that the 
benzannulated analogs may interact differently with the G-quadruplex. The larger 
chromophore of the benzannulated analogs may prevent multiple ligands from binding to 
the G5 structure due to steric hindrance. While Tel34 formed complexes with G-
quadruplex DNA, the other benzannulated analog, Tel32, was the only perylene diimide 
ligand that did not form any complexes with G5 DNA. 
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5.3.6 Concentration Effects 
To examine how changes in the solution conditions affect the binding 
stoichiometries of  the ligand/G5 DNA complexes, solutions containing 10 µM of G5 
DNA and either 2.5, 5.0, 10, and 20 µM of each PDI ligand were analyzed by ESI-MS 
(spectra not shown). The binding stoichiometries of the analogs containing charged side 
chains (Tel11, Tel12, Tel18, and Tel34), did not change from those observed at a 1:1 
ligand/G5 ratio with either higher or lower ligand/G5 molar ratios. For example, when 
the Tel12/G5 molar ratio was 1:4, only complexes with a 1:1 binding stoichiometry were 
present in the ESI mass spectra. When the Tel12/G5 molar ratio was increased from 1:4 
to 2:1, the relative abundances of the 1:1 peaks remained the same and no 2:1 complexes 
appeared. 
Ligands containing basic side chains (Tel01 and PIPER) do show concentration 
dependent binding. At ligand/DNA molar ratios of 1:4 to 1:1, the complexes with binding 
stoichiometries of 1:1 are the most abundant, with 2:1 complexes present at relative 
abundances that are approximately three times less than that observed for the 1:1 
complexes. When the ligand/DNA ratio is increased above 1:1, the 2:1 complexes 
become nearly twice as abundant as the 1:1 complexes, and very low abundance 3:1 
complexes emerge that were not present at lower ligand/DNA ratios. The concentration 
dependent binding of Tel01 was demonstrated in a past study by David et al.26 and is 
confirmed by experiments in this study.  These results indicate that while all of the 
perylene diimides bind G-quadruplex DNA at primarily 1:1 and 2:1 binding 
stoichiometries, ligands with side chains that are basic, Tel01 and PIPER, demonstrate 
the ability to bind with higher stoichiometries at increased ligand/G5 molar ratios.   Both 
Tel01 and PIPER can undergo aggregation in solution in a pH-dependent fashion.37, 38 The 
observation of higher binding stoichiometries for these two ligands may be due to ligand 
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self-association during ESI, as supported by the RLS and fluorescence data discussed 
above and summarized in Table 5.1.   
5.3.7 ESI-MS/MS Studies of G5 DNA/Perylene Diimide Complexes 
ESI-MS/MS experiments were undertaken to examine the fragmentation patterns 
of ligand/G-quadruplex complexes via collisional activated dissociation. While full-scan 
ESI mass spectra are useful for comparing the binding stoichiometries of the various 
ligands with DNA, ligand binding modes are generally not distinguishable. Past ESI-
MS/MS studies of drug/DNA complexes suggest that  complexes with different binding 
modes produce distinct fragmentation patterns upon collisional activation.6, 7, 26  In this 
study, all complexes, including [G5 + L]-6, [G5 + 2 x L]-6, [G5 + 3 x L]-6, [G5 + L]-7, and 
[G5 + 2 x L]-7, where L represents a perylene diimide ligand, were subjected to CAD 
experiments. All complexes, regardless of the charge of the ligand, the charge state of the 
complex, or the binding stoichiometry, dissociated via guanine base losses from the 
precursor ions in addition to the ejection of one anionic or neutral ligand, leaving the 
intact quadruplex. Triplex and single strand oligonucleotide ions without bound ligand 
are also present in the spectra as a result of further dissociation of the quadruplex. 
Ligands Tel12, Tel01, and PIPER were ejected as anions, while Tel11, Tel18, and Tel34 
were ejected as neutral species. An example of this fragmentation pattern is shown in 
Figure 5.4 for the CAD spectrum of the [G5 + Tel012]-6 complex. In addition to ions 
resulting from guanine base loss, the -5 charge state of the intact quadruplex and the -2 
charge state of the single strand species are present. Presumably the -3 charge state of the 
triplex is also formed, however the m/z of this ion lies outside the detectable mass range 
of our instrument.   
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Figure 5.4:  CAD product ion spectrum [G5 + Tel12]-6. An activation energy of 1.98 V 
was used. Complexes containing one or more ligands are labeled with a “L”. 
Parent ions are labeled with an astrisk.  
 
The facile loss of ligand observed in the CAD spectra of the DNA/perylene 
diimide complexes is consistent with past studies of ligands that bind to G-quadruplex 
DNA by end-stacking26,27 suggesting the perylene diimides bind to quadruplex DNA in a 
similar manner. Previously published results by our group demonstrated that complexes 
containing distamycin A and diethyloxadicarbocyanine (DTC), ligands that presumably 
bind to G-quadruplex DNA via groove binding,46,47 produce single stranded, double 
stranded, and triplex ODNs with and without bound ligand upon CAD.26  It is important 
to note that both distamycin A and DTC are cationic, while the postulated quadruplex 
end-stacking ligands involved in a past ESI-MS/MS study26 were neutral. It has been 
difficult to determine whether the differences between the fragmentation patterns of the 
end-stacking and the groove-binding quadruplex-interactive ligands were the result of 
different binding modes and/or ligand charge. However, in this study, all analogs, 
including the cationic Tel11, Tel18, and Tel34 ligands dissociated via the ejection of 
ligand from the intact G-quadruplex, suggesting that the charge of the ligand has less of 
an impact on the dissociation pathway than binding mode.  
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5.3.8 Duplex and single strand DNA binding of ligands by ESI-MS 
The evaluation of duplex versus quadruplex binding selectivity is a critical issue 
in the design of new anti-cancer drugs. To evaluate selectivity, ESI mass spectra of 
solutions containing the perylene diimide ligands with duplex DNA (abbreviated as ds) 
have also been obtained to allow comparison of the selectivity of the ligands for 
quadruplex versus duplex versus single strand ODNs. To account for potential sequence 
selectivity, a series of three non-self-complementary duplex ODNs with varying G-C and 
A-T base pair composition were used 
(d(GCGGGGATGGGGCG/CGCCCCATCCCCGC), 
d(GCGGGAATTGGGCG/CGCCCAATTCCCGC), and 
d(GCGGAAATTTGGCG/CGCCAAATTTCCGC)). As shown in Figure 5.5, there is 
considerable variation in duplex versus quadruplex selectivity. Some ligands, such as 
Tel18, formed numerous complexes with the duplex DNA (Figure 5.5B), while others 
formed no complexes, as demonstrated by the spectrum containing Tel34 (Figure 5.5C). 
The increased number of adducts, especially for the single strand ions, present in Figure 
5.5C are due to higher levels of salts present in the Tel034 ligand sample.  The ligands 
that did bind to the duplex DNA, namely PIPER, Tel11, and Tel18, formed complexes 
with binding stoichiometries of 4:1, 3:1, 2:1, and 1:1, and did not demonstrate any 
notable base-pair selectivity.  
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Figure 5.5:  ESI mass spectra for complexes containing 
d(GCGGGAATTGGGCG/CGCCCAATTCCCGC): (A) alone, and with (B) 
Tel18 (extensive binding) and (C) Tel34 (no binding). The 
d(GCGGAATTGGGCG) single strand is labeled “ss1” and 
d(CGCCCAATTCCCGC) is labeled “ss2.”  
 
To further examine the interaction between the ligands and duplex DNA, CAD 
experiments were performed on all ligand/DNA complexes present in the mass spectra. 
The complexes subjected to CAD included  [ds + L]-5, [ds + L]-6, [ds + 2 x L]-6, [ds + 3 x 
L]-6, [ds + 4 x L]-6, where “L” represents either PIPER, Tel11, or Tel18. All complexes 
produced the same charge-state dependent CAD pattern, regardless of the ligand or 
binding stoichiometry. At lower charge states, such as -5, the complexes dissociated by 
loss of nucleobases (specifically A, G, and C) from the intact complex, while at higher 
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charge states, strand scission was observed, with one or more ligands remaining bound to 
the single strand ODN.   
The complexes containing PIPER, the only analog without cationic side chains 
that bound to duplex DNA, exhibited an additional fragmentation route. At low charge 
states, neutral ligand ejection was observed (a new route), leaving the duplex ion, in 
addition to base losses from the complex. These two processes are competitive since both 
types of fragments are formed from the same parent ion. The fragmentation pattern 
produced by the PDI/duplex DNA complexes, characterized by both non-covalent strand 
scission and ligand ejection,  in addition to covalent cleavages of high proton affinity 
nucleobases from the complex, is similar to the results of past MS/MS studies of 
intercalator/duplex DNA complexes.5,7  In quadrupole ion trap instruments, complexes 
containing minor groove binding ligands also undergo strand scission and cleavage of 
nucleobases, and covalent cleavages of the terminal portions of the duplex resulting in 
losses of an and (dn + B) ions are also observed upon CAD.
7   The loss of these small 
sequence ions is never observed in the CAD spectra of the PDI/duplex complexes. 
Intercalation has been suggested for perylene diimide molecules that bind to duplex 
DNA,37, 38 and would be expected with a duplex DNA-interactive molecule containing a 
planar chromophore. Future work is necessary to examine the correlation between the 
fragmentation patterns of the perylene diimide/duplex complexes and ligand binding 
mode. 
ESI mass spectra of solutions containing one ligand and a single strand ODN 
were also acquired. The single strand sequence used to anneal quadruplex DNA, 
d(T2G5T), was used for these experiments to determine whether the analogs that 
selectively bound to the G-quadruplex DNA were selective for the G-quadruplex 
structure or for the sequence of DNA. To ensure that there were no Hoogsteen base pair 
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interactions between the guanine residues of the single strand ODN, ESI mass spectra 
were first obtained for the ODN alone (spectra not shown). The mass spectrum shows 
that the most abundant ions are found at m/z 831 and 1247, corresponding to the [ss]-3 and 
[ss]-2 species respectively. The appearance of this mass spectrum is significantly different 
than the one obtained for the annealed G-quadruplex (Figure 5.3A). 
Solutions containing the single strand ODN and each ligand were prepared at 
equimolar 10 µM concentration in 3:1 water/methanol. The ESI mass spectra show that 
the two ligands with cationic side chains that formed complexes with duplex DNA and 
quadruplex DNA, Tel11 and Tel18, also formed complexes with the single strand ODN, 
while the remaining ligands exhibited no single strand binding (spectra not shown). 
These results suggest that Tel11 and Tel18 indiscriminately bind to DNA, regardless of 
the higher order structure. This lack of selectivity may be the result of electrostatic 
interactions between the cationic side chains of the analogs and the phosphate backbone 
of DNA. However, Tel34 also has a cationic side chain but was only found to bind to G-
quadruplex DNA, suggesting that the ligand/DNA complexes observed in the ESI mass 
spectra are not merely the result of non-specific electrostatic interactions in the gas phase.  
5.3.9 ESI-MS evaluation of binding selectivity of ligands 
After evaluating the binding of the ligands to G-quadruplex, duplex, and single 
strand DNA by ESI-MS/MS, the overall selectivity of the analogs is summarized in Table 
5.3. The values in the table represent the fraction of bound DNA calculated using the 
following equation: 
 
Fraction of bound DNA = I(1:1) + I(2:1) + I(3:1) + I(4:1) 
                                              I(DNA) + I(1:1) + I(2:1) + I(3:1) + I(4:1) 
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where IDNA is the relative abundance of the free (unbound DNA) and I(n:1) are the 
relative abundances of the ligand/DNA complexes. This equation is a modified version of 
an equation developed by Rosu et. al.17 that was used to estimate the concentration of all 
individual species at equilibrium based on the relative abundances of DNA ions in the 
mass spectrum, with the assumption that the abundances of the free and bound DNA ions 
are proportional to their relative concentrations in solution. We are not convinced that the 
ESI response factors of the unbound DNA ions and the DNA/perylene diimide complexes 
are identical, so instead we calculate the fraction of bound DNA to obtain a relative 
comparison of the extent of ligand binding to the different DNA structures. 








a Values in the chart represent the fraction of bound DNA. “--” indicates no complexes were observed. All 
values +/-0.05. 
 
While PIPER, Tel11, and Tel18 readily formed complexes with the quadruplex 
DNA, these three analogs also bound to duplex DNA which is undesirable for target 
selectivity. Both Tel11 and Tel18 were also found to bind to single strand DNA, 
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suggesting that the cationic side chains of the ligands may promote indiscriminant 
binding to DNA due to electrostatic interactions with the anionic phosphate backbone. 
Interestingly, Tel34 has a cationic side chain but did not bind to duplex or single strand 
DNA, thus exhibiting significant selectivity.  This suggests the side-chains of the 
benzannulated analogs have a different role in DNA binding, which may be a key issue 
for G-quadruplex selectivity. 
The only analog with anionic side chains, Tel12, formed 1:1 complexes with the 
G5 DNA, but did not bind to duplex or single strand DNA. Whether the anionic side 
chains play a role in the selectivity of the analog is still unclear, but the binding of the 
ligand to the G-quadruplex suggests that the complexes observed in the ESI mass spectra 
are not solely the result of electrostatic interactions. Finally, PIPER was found to bind to 
G-quadruplex and duplex DNA, while the structurally-similar ligand, Tel01, 
demonstrated selectivity for the G-quadruplex.  
There is good correlation between these ESI-MS results and the spectroscopic 
studies of G-quadruplex DNA binding by these PDIs (see above).  Both the UV-Vis 
spectroscopic studies and ESI-MS analysis demonstrate that all of the PDIs examined 
here, with the exception of Tel32, bind to parallel-stranded G-quadruplex DNA.  
Spectroscopic and ESI-MS studies also both reveal the selectivity of certain PDIs (e.g., 
Tel01) for G-quadruplex versus duplex DNA and the lack of selectivity of other PDIs 
(e.g., Tel11) for any of the DNA structures studied here.  Additional insights into the 
origin of the G-quadruplex binding selectivity observed for certain PDIs is provided by 
ESI-MS.  Of the PDIs studied, three were found to undergo extensive self-association 
(Tel12, Tel34) or aggregation (Tel01) in solution.  All three of these ligands display 
selectivity for G-quadruplex DNA.  However, ESI-MS reveals that the stoichiometries of 
G-quadruplex DNA binding by these ligands are different.  Tel01 binds to G-quadruplex 
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DNA to form complexes with as many as three ligands associated with a single 
quadruplex.  Tel12 and Tel34 only form 1:1 complexes with G-quadruplex DNA. Non-
selective PDIs such as PIPER and Tel11, which are not aggregated or highly self-
associated in solution, also form 1:1 and 2:1 ligand/DNA complexes with G-quadruplex 
DNA.  Clearly, the selectivity of PDIs for G-quadruplex DNA binding is correlated with 
the self-association state of these ligands in solution and not their self-association on G-
quadruplex DNA.   
5.4 CONCLUSIONS 
The results of this study demonstrate the use of ESI-MS to evaluate non-covalent 
interactions between perylene diimide ligands and G-quadruplex DNA and to screen the 
ligands for selectivity.  There is good correlation between spectroscopic binding studies 
and ESI-MS analysis of G-quadruplex DNA binding.  Qualitative comparisons can be 
made to quickly screen ligands with minimal consumption of analyte, making this 
technique compatible with high throughput screening techniques. Our results found, with 
the exception of Tel32 which exhibited no DNA binding, all ligands evaluated in this 
study formed complexes with G-quadruplex DNA. Binding stoichiometries of 1:1 and 2:1 
were observed for PIPER, Tel11, and Tel18; this is a binding stoichiometry that is 
consistent with telomerase inhibitors that bind to G-quadruplex DNA by stacking on the 
faces of the terminal G-tetrads [35, 40]. Interesting, the three most quadruplex-selective 
ligands formed complexes with quadruplex DNA with a different binding stoichiometry. 
Tel01 formed 3:1 complexes, and Tel12 and Tel18 only formed 1:1 complexes. This 
unusual behavior will be explored in future studies.   CAD experiments also suggested an 
end-stack mode of binding since all complexes dissociated by ejecting the ligand, leaving 
the intact G-quadruplex, triplex, or single strand ODN. Based on binding to G-
quadruplex, duplex, and single stranded DNA, the analogs Tel01, Tel12, and Tel34, are 
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most promising in terms of G-quadruplex selectivity. Our future work will focus on 
obtaining more quantitative information about ligand/G-quadruplex complexes, such as 
binding constants, and identification of specific binding sites. 
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Chapter 6: Gas-Phase Stability of G-quadruplex DNA Determined by 
Electrospray Ionization Tandem Mass Spectrometry and Molecular 
Dynamics Simulations 
6.1 INTRODUCTION 
The basis of many anticancer and antitumor therapies is the interaction between 
small molecule drugs and nucleic acid structures. While most current DNA-interactive 
therapies target duplex DNA, G-quadruplex DNA has attracted recent interest as a 
potential anti-cancer drug target because of its role in telomere maintenance.1-3 Telomeres 
are the regions of non-coding DNA found on the extremities of chromosomes.4 In 
addition to protecting the chromosomes from fusion and degradation, telomeres allow for 
the complete replication of the chromosomal DNA. With each subsequent cell division 
process, the length of the telomeres is shortened until a critical length is reached, leading 
to cell senescence and death.5 Telomerase is a reverse transcriptase enzyme that is 
responsible for maintaining the length of telomeric DNA. While this enzyme is inactive 
in most human somatic cells, high levels of telomerase activity is found in 80-90% of 
human cancer cells. 6, 7  
Telomeric DNA is composed of tandem repeats of G-rich sequences, such as the 
d(T2AG3)n sequence in mammals,
8 d(T2G4)n in Tetrahymena
9 and d(T4G4)n in Oxytricha.
10 
These and other G-rich sequences have been shown to form G-quadruplex structures in 
vitro.  G-quadruplex DNA forms via Hoogsteen hydrogen bonding between a planar 
arrangement of four guanine nucleobases, termed a G-quartet. In the quadruplex 
structure, the G-quartets stack on top of one another and the overall structure is stabilized 
by monovalent cations such as Na+, K+, or NH4
+ coordinated in the central cavity of the 
tetrad 11. Structural polymorphism resulting from different quadruplex sequences and 
strand orientations has been demonstrated in vitro.12 A DNA sequence containing a single 
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G-rich repeat can form a four-stranded parallel G-quadruplex. Strands containing two or 
more G-rich regions can form G-G hairpins and dimerize in different orientations to form 
a two-stranded quadruplex, while a sequence with four G-rich repeats can fold upon itself 
to form a intramolecular quadruplex.12  
The stabilization of the G-quadruplex structure of the 3’ single strand overhang of 
telomeric DNA by ligands and metal cations has been demonstrated to inhibit telomerase 
activity in vivo, thus stimulating interest in the study of telomeric quadruplex formation 
and the development of G-quadruplex selective ligands and anticancer compounds.13-15 
Electrospray ionization mass spectrometry (ESI-MS) has emerged as a useful tool for the 
analysis of quadruplex DNA and its non-covalent complexes with ligands due to its low 
sample consumption and fast analysis time. During the ESI process, non-covalent 
complexes in solution are transferred to the gas-phase with minimal internal energy, 
allowing many of the binding interactions to be maintained. The preservation of these 
non-covalent complexes allows information about binding stoichiometry and selectivity 
to be elucidated from the mass spectra Our group16,17 and others18-23 have focused on 
developing ESI-MS based techniques to assess whether the binding of quadruplex 
interactive ligands observed in the gas-phase can be correlated to known solution 
behavior with the ultimate goal of developing ESI-MS as a screening tool for drug/DNA 
complexes. 
There have been several ESI-MS studies aimed at examining structural features of 
duplex24-26 and hairpin27,28 DNA in solution and the gas-phase, primarily based on 
correlation of relative abundances of ions observed in ESI mass spectra as a function of 
solution conditions or based on collisional activated dissociation (CAD) patterns.  CAD 
is a versatile technique that has been used to characterize gas-phase stabilities and 
fragmentation pathways of DNA duplexes.22,25,26,29,30 For example, the dissociation profiles 
 107
of a series of 6-, 8- and 12-base pair self-complementary duplexes have been shown to 
correspond to the known solution melting behavior of DNA, demonstrating the utility of 
CAD to provide relative comparisons of the gas-phase stabilities of DNA duplexes.29 Few 
studies have been undertaken to elucidate the gas-phase structures or stabilities of 
quadruplex DNA. One recent study focused on using ion mobility mass spectrometry and 
molecular dynamics simulations to examine gas-phase conformations of quadruplexes 
with different lengths of the telomeric repeat d(TTAGGG)n where n = 1, 2, 4, and 6.
31 The 
experimental cross sections of the quadruplex structures determined by ion mobility 
matched those determined by molecular modeling, with the gas-phase structures also 
corresponding to solution structures unveiled by circular dichroism.  Only one study has 
been devoted to the CAD fragmentation of DNA quadruplexes, and it found that 
[d(TGGGT)]4 ions dissociated via the loss of a single strand ion, producing a triplex 
species.32   
Molecular modeling techniques comprise another promising tool for the study of 
nucleic acid structures in a solvent free environment. Molecular dynamics (MD) 
simulations are suitable for the detailed study of the structural, energetic, and dynamic 
properties of macromolecules, including proteins and nucleic acids. Recently, many 
research groups have studied G-quadruplexes with MD simulations in a solvent-free 
environment.18,31,33-35 An interesting conclusion of those studies was that, in the proper 
charge state, G-quadruplex structures could be maintained with some distortion during 
the solvent-free MD simulations. The additional finding that the collision cross sections 
of MD snapshots were in good agreement with those measured by ion mobility 
experiments18, 31 indicates that both are viable techniques for the determination of strand 
orientation patterns for G-quadruplexes. Baker et al. also found this approach to be useful 
for determining the proper binding patterns of ligands with G-quadruplexes.18 However, it 
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should be noted that similar collision cross sections can be associated with extremely 
different conformations; therefore this method may not be used to measure how well a G-
quadruplex maintains its G-quartets in the solvent-free environment of ESI-MS 
experiments.  
In the present study, we use the capabilities of both ESI-MS/MS and molecular 
dynamics simulations to assess the relative stabilities of different quadruplex structures in 
the gas phase. First, tandem mass spectrometry, specifically collisional activation 
dissociation, was used to evaluate the fragmentation patterns of gas-phase quadruplex 
ions and create energy-variable dissociation curves which provide a way to compare the 
relative stabilities of different quadruplex structures.  Second, molecular dynamics 
simulations were performed to examine the structures and trajectories of the 
quadruplexes in a solvent free environment to not only confirm that the quadruplexes are 
maintained, but also to assess their relative stabilities using free energy measurements. To 
the best of our knowledge, this is the first attempt to predict the relative stabilities for a 
set of G-quadruplexes through free energy analysis. 
6.2 EXPERIMENTAL 
6.2.1 Chemicals 
Single strand oligodeoxynucleotides (ODNs), custom synthesized as ammonium 
salts on the 1.0 µmole scale with purification by HPLC, were obtained from Integrated 
DNA Technologies (Coralville, IA) and used without further purification. The sequences 
of the quadruplex-forming ODNs are shown in Table 6.1. Stock solutions of d(G4T4G4) 
(G2), d(T2AG3)2 (G3), d(T2AG3)4 (G4), d(T2G4)4 (G5), and d(G2T4)4 (G6) were prepared at 
0.8 mM concentration in 150 mM ammonium acetate buffer while d(TG4T) (G1) and 
d(T2G3T) (G7) were prepared at 1 mM in 150 mM ammonium acetate buffer. Each 
quadruplex structure was annealed by heating the stock solutions to 90 °C for 10 min. 
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followed by cooling to 25 ° C during a period of 7 h. The ammonium acetate buffer was 
chosen for the annealing solutions since quadruplexes form in the presence of the NH4
+ 
ion, and NH4
+ is more suitable than Na+ or K+ for ESI-MS studies due to its greater 
lability.32 Stock solutions of the duplex forming ODNs, d(GCG3A2T2G3CG) and 
d(CGC3A2T2C3GC) were prepared at 2 mM in 250 mM ammonium acetate. Equal 
volumes of each single strand were combined and the duplex was annealed using the 
same procedure described above for the quadruplex DNA. A 500 µM stock solution of 
the single strand ODN d(TTGGGGGT) was prepared in deionized water. N,N’-bis(2-
morpholinylpropyl)-3,4,9,10-perylenetetracarobxylic acid diimide (Tel01) was prepared 
as previously reported.36 A 1 mM stock solution of the ligand was prepared in 0.1% 
aqueous trifluoroacetic acid. 
 














































6.2.2 Mass Spectrometry 
ESI-MS experiments were undertaken on a ThermoFinnigan LCQ Duo mass 
spectrometer (San Jose, CA). Analytical solutions of the quadruplex were prepared at 10 
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µM concentration in 50 mM ammonium acetate buffer with 25% (v/v) methanol to aid in 
the desolvation of the DNA. Equimolar (10 µM) concentrations of Tel01 with each 
quadruplex, duplex or single strand ODN were prepared in the ammonium acetate buffer 
for the ligand binding study, The samples were directly infused into the mass 
spectrometer at 3 µL/min using a Harvard Syringe Pump (Holliston, MA). Ions were 
generated in the negative ion mode using a needle voltage of 3.5 kV, a heated capillary 
temperature of 110 °C and sheath and auxiliary gas flows of 40 and 10 arbitrary units, 
respectively. An ion accumulation time of 100 ms was used and spectra were acquired by 
summing 300 scans. 
For collisional activated dissociation (CAD) experiments, the desired precursor 
ion was isolated in the trap using resonance ejection, followed by fragmentation induced 
by increasing the resonance voltage applied to the trap. An activation time of 30 ms was 
used for all experiments. To obtain the energy-variable dissociation curves, the applied 
CAD voltage, a parameter which influences the collision energy, was increased from 0.70 
to 1.70 V in increments of 0.11 V. The data presented represent an average of three 
experiments done on three different days to account for possible instrument instability. 
Aside from the energy variable experiments, CAD was performed by increasing the 
collision voltage to the amplitude that resulted in dissociation of the precursor ion to 10% 
of its initial abundance. 
6.2.3 Molecular Modeling 
Gas phase MD simulations were performed for quadruplexes G1-G6. The initial 
structure of G1 was taken from a parallel-stranded crystal structure resolved at 0.95 Å 
(PDB: 1S45)37 and the starting structure of G2 was taken from an antiparallel-stranded 
crystal structure resolved at 1.86 Å (PDB: 1JB7).38 For G3-G6, a parallel-stranded crystal 
structure resolved at 2.1 Å (PDB 1KFI)39 and an antiparallel-stranded NMR structure 
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(PDB 143D)40 were applied as templates to construct the initial structures of both strand 
orientations for each G-quadruplex. An additional starting structure for G6 was modeled 
by mutating G to T and T to G on the model structure of antiparallel G5. It should be 
noted that for a particular quadruplex our decision on which strand orientations to model 
was based on both experimental and theoretical findings. To investigate the role of 
cations in stabilizing the G-quartet, two models were built for G1, one with and one 
without ammoniums residing in the central channel. In total, twelve model structures, 
namely, G1-ammonium, G1-no-cation, G2-antiparallel, G3-antiparallel, G3-parallel, G4-
antiparallel, G4-parallel, G5-antiparallel, G5-parallel, G6-antiparallel, G6-parallel, G6-T-
tetrad, were used for the MD simulations. 
Although the most abundant charge state observed in ESI-MS experiments can be 
readily identified from the mass spectra, the exact locations of the deprotonation sites are 
not clear. Rueda et al. proposed two neutralization protocols to model the desired charge 
state for a G-quadruplex: a distributed model and a more realistic localized model.33-35 In 
this study, we adopted the a modified version of localized model. Instead of maximizing 
the sum of the distances between the charged phosphates, we calculate electrostatic 
energies of all possible ways of assigning deprotonation sites and the assignment that 
gave the most favorable electrostatic energy was chosen for the subsequent molecular 
mechanical studies. If a G-quadruplex has ammonium adducts, a set of 3-dimensional 
fine grids (0.2 Å) that enclosed the quadruplex was constructed. Grid points that were 
within 2.0 Å of any atom of the quadruplex were dropped off. A +1 charge probe was 
placed at each grid point to calculate the electrostatic energy between the point charge 
and the quadruplex. Finally, an ammonium ion was placed at the grid point that gave the 
optimum electrostatic energy. This procedure was repeated n times to incorporate n 
ammonium molecules.  
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All of the minimizations, MD simulations and subsequent structural and energetic 
analyses were carried out with the AMBER 8 suite of programs41 using the Parm99 force 
field.42 A delicate minimization protocol was designed to minimize the initial structures 
step by step: (1) Only hydrogen atoms were optimized for 1000 steps.  (2) A 1000-step 
minimization was carried out with the G-quartet guanine nucleosides restrained by a 50 
kcal/molÅ2 harmonic potential. (3) The G-quartet guanine bases were restrained by a 50, 
10, 5 and 1 kcal/molÅ2 harmonic potentials in a set of subsequent 1000-step 
minimizations. (4) 1000-step full minimization was carried out for the complete 
molecules.  
The fully minimized structures were then subjected to a set of MD simulations. 
Similar to the restrained minimizations, the G-quartet guanine bases were restrained by a 
10, 5, 1, 0.5, 0.1 kcal/molÅ2 harmonic potential in a set of subsequent 100 picosecond 
restrained MD simulations. In each step, the last snapshot was taken as the starting 
structure for the next simulation run. Finally, a completely unrestrained 50 nanosecond 
MD simulation was performed. All the simulations were carried out at 300 K with a time 
step of 1 femtosecond. No non-bonded cutoff was applied and the SHAKE algorithm was 
applied for all the bonds involving hydrogen atoms.43 
 A large variety of geometrical analyses including root-mean-square 
displacements (RMSD), hydrogen bonding, stacking between two guanines, and free 
energy analysis, were performed for 50 snapshots evenly selected from the last 30 
nanosecond simulations. Hydrogen bonds were formed when the heteroatom-heteroatom 
distance was less than 4.0 Å and the donor-hydrogen/donor-acceptor angle was deviated 
less than 60° from linearity. A stacking interaction was recognized when the distance 
between two base rings was less than 5.5 Å, the angle between the two normals to the 
base planes was less than 30°, and the angle between the normal of any base plane and 
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the vector between the centers of the two bases was less than 50°. The numbers of 
stacking pairs were 4, 8 and 12 for an ideal G-quadruplex with two, three and four 
tetrads, respectively.  
The free energy of a molecule was composed of two parts: the molecular 
mechanical energy (EMM) and the conformational entropy (TS). The EMM energies were 
calculated with the Anal program of AMBER 8 on the minimized structure of each 
snapshot,41 while the conformational entropies were estimated by normal model analysis 
on a thoroughly minimized structure with the Nmode program of AMBER 8.41 The 
principles behind the free energy calculations were the thermodynamics and the widely 
used MM-PBSA free energy theories44-46 (Solvation free energies were omitted because 
all the molecules were studied in the gas phase). As discussed above, free energy analysis 
was essential in interpreting the CAD experimental data. 
6.3 RESULTS AND DISCSUSSION 
6.3.1 Mass Spectra of the G-quadruplexes 
The quadruplex structures selected for this study represent a variety of 
quadruplex-forming sequences and strand orientations. The variation allows one to 
evaluate which structures are most stable in the gas-phase and thus most suitable for 
future ESI-MS studies of quadruplex DNA. Sequences G1 and G7 were selected to form 
four-stranded quadruplex structures with four and three quartets, respectively. Previous 
circular dichroism (CD) studies performed on G1 in an ammonium acetate buffer indicate 
that it forms a parallel, four stranded quadruplex structure.31 Both G2 and G3 contain two 
G-rich regions per strand and form two-stranded quadruplex structures. CD studies have 
found that G2 forms an antiparallel structure32 while the CD spectrum for G3 has 
characteristics of both parallel and antiparallel orientations.31 The intramolecular 
quadruplex-forming sequences selected for this study, G4, G5, and G6, contain four 
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repeats each of G-rich sequences capable of forming three, four, and two quartets, 
respectively. The major species in the CD spectrum of G4 in an ammonium acetate buffer 
is the antiparallel quadruplex, with evidence that the parallel quadruplex is also present to 
a lesser degree.31  All quadruplexes in the present study contain 24 nucleobases to ensure 
that the molecular weights and degrees of freedom of the DNA molecules were 
comparable for the energy-variable dissociation studies.  
Full scan ESI mass spectra of solutions containing each quadruplex were obtained 
to evaluate the annealing efficiencies. Representative spectra are shown in Figure 6.1 for 
the four-stranded quadruplex G1 (Figure 6.1a), the two-stranded structure G2 (Figure 
6.1b), and the intramolecular quadruplex G4 (Figure 6.1c). The 5- charge state proved to 
be the most abundant for all of the quadruplex structures, and thus was used for all 
subsequent CAD and variable-energy dissociation experiments. The 5- ions of 
intermolecular quadruplexes G1 (Figure 6.1a) and G7 (spectra not shown) can also 
unambiguously assigned as four stranded structures, while G2 (Figure 6.1b) and G3 can 
be defined as two-stranded structures for G2 and G3 based on the m/z values which are 
distinctive for species containing one, two, three or four strands.  
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Figure 6.1: ESI mass spectra of solutions containing 10 µM of (a) G1, (b) G2, and (c) 
G4. 
Ammonium adducts are also associated with the four-stranded quadruplexes G1 
and G7. The dominant 5- ion of G1 contained three ammoniums (Figure 6.1a) while the 
corresponding ion of G7 contained two adducted ammoniums (spectra not shown). These 
results are consistent with the previous observation that n-1 ammonium cations are 
incorporated in quadruplex structures containing n tetrads.32  As shown in Figure 6.1b and 
6.1c, no ammoniums are associated with the most abundant ions for the two-stranded G2 
and single stranded G4 quadruplex. Similar results were obtained for other two-stranded 
quadruplex G3 and the single stranded G5 and G6 (spectra not shown). In addition, an 
ion corresponding to the two-stranded G2 structure with two ammoniums is present in the 
mass spectra but it is approximately one third the abundance of the dominant ion without 
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adducted ammonium (Figure 6.1b). These results are consistent with previous studies of 
quadruplexes by ESI-MS that found  adducted ammoniums are only retained by the 
dominant quadruplex species for the four-stranded quadruplex G1, suggesting tighter 
binding of the ammonium ions by this structure.31, 32 
 While Figure 6.1 confirms that ions containing strand stoichiometries consistent 
with quadruplex structures for G1 and G2 are present, it does not verify that the 
quadruplex structures are maintained in the gas-phase nor does it indicate whether G4 is 
in the folded quadruplex conformation or a denatured state. ESI-MS studies of 
quadruplexes have been largely limited to using multiple stranded quadruplexes because 
the m/z of an intramolecular quadruplex is the same as a denatured single strand structure, 
thereby precluding direct confirmation that the quadruplex is maintained in the gas-phase.  
While recent studies have confirmed that quadruplex structures are conserved in the gas-
phase, they did not provide information about the relative stabilities of the structures.31 
Here, molecular dynamics studies were carried out to demonstrate that quadruplex 
structures can be maintained in the gas-phase, while further calculations and CAD 
experiments were used to assess quadruplex stability. 
6.3.2 Ligand Binding of the Quadruplexes 
The binding of the quadruplexes to one quadruplex-selective ligand was used to 
demonstrate that the quadruplexes were present in the annealed solutions. In a previous 
study we demonstrated that that the perylene diimide N,N’-bis(2-morpholinylpropyl)-
3,4,9,10-perylenetetracarobxylic acid diimide (Tel01)36 demonstrated binding selectivity 
for quadruplexes over duplex and single strand DNA by forming significantly lower 
abundance complexes with duplex DNA and exhibited no binding to single strand DNA.17 
Here, we examined the binding of Tel01 to the quadruplexes, one duplex, and one single 
strand oligonucleotide by ESI-MS. Solutions containing equimolar concentrations of the 
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DNA and ligand were prepared and analyzed by ESI-MS. The fraction of bound DNA 
values were determined from the mass spectra as described previously,17 and the results 
are summarized in Table 6.2. Tel01 formed abundant complexes with each quadruplex, 
with fraction of bound DNA values ranging from 0.80 for G5 to 0.95 for G6. These 
values are on par with the results of our previous study.17 The binding of Tel01 to a 
duplex d(GCGGGAATTGGGCG/CGCCCAATTCCCGC) (DS1) was indicated by the 
presence of Tel01/DS1 complexes in the mass spectrum, but they are significantly lower 
in abundance than the complexes formed between the ligand and the quadruplexes. Tel01 
also did not form any complexes with the single strand d(TTGGGGGT) (SS1). This 
sequence was selected since it is G-rich like many of the quadruplexes however it was 
not annealed and ESI-MS experiments were done to confirm that only the single strand 
species was present in solution (spectra not shown). Had the quadruplexes not properly 
annealed and remained in the denatured single strand conformation, little or no Tel01 
binding would be expected.  These results confirm that the quadruplexes are present in 
solution and that the ESI-MS results reflect the anticipated quadruplex selectivity. 
Table 6.2:  Fraction of bound DNA values for equimolar concentrations (10 µM) of 










Bound to Tel01aDNA Sequence
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6.3.3 Molecular Dynamics Trajectories of the Quadruplexes in the Gas-Phase 
Molecular dynamics simulations were undertaken to demonstrate that the 
quadruplex conformations are maintained under conditions used for the ESI-MS/MS 
experiments. A net charge of 5- was assigned to the twelve model quadruplexes since this 
was the most abundant charge state observed in the ESI-MS experiments. Plots of the 
RMSD values of the tetrad forming guanines versus simulations time were constructed 
using the final minimized structure as a reference point. In most cases, the trajectories 
fluctuated vigorously during the first few nanoseconds and then became quite stable after 
20 nanoseconds as demonstrated by the plots for G1 shown in Figure 6.2. The reference 
structures for the comparisons are the last structures of a series of minimizations which 
have their G-quartets well maintained. This behavior is consistent with what Rueda et al. 
found in their simulations of DNA in the gas phase.33-35  
The final snapshots of the G1 simulations with and without the ammonium ions  
are depicted in Figure 6.3. From Figures 6.3a and 6.3b, it is clear that the ammonium 
cations (blue) reside in the centers of two adjacent tetrad planes. Furthermore, a 
comparison of Figures 6.3b and 6.3d shows the impact of the ammonium ions on the G-
tetrad stabilization as the deviations in the tetrad position are more pronounced when the 
ammoniums are absent.   The final snapshots of the structures with the most energetically 
favorable strand orientations of G2-G6 are presented in Figure 6.4. The antiparallel 
structures of G2, G3, G4, and G6 and the parallel structure of G5 were identified as the 
most favorable strand orientations of the quadruplexes in the gas-phase. The results of the 
MD simulations demonstrate that the G-quartets of the quadruplexes are maintained in 




































(a)      (b) 
Figure 6.2:  Root-mean-square displacements (Å) of G-tetrad guanines over 50 
nanosecond MD simulations (compared to minimized reference structures) 
for two G1 models: (a) G1 with three ammoniums residing in the central 
cavity between the stacked tetrads, and (b) G1 in the absence of ammoniums 




(a)       (b) 
  
(c)            (d) 
Figure 6.3:  The final snapshot of a 50 nanosecond MD simulations for G1: (a) an all 
heavy atom model with three ammoniums residing in the central channel, 
(b) G-quartets with three ammonium ions (the green capped sticks of the G-
quartets in the reference structure are presented for comparison purposes) 
(c) an all heavy atom model in the absence of ammonium ions, and (d) G-
quartets in the absence of ammonium ions (the green capped sticks of the G-










             (e) 
Figure 6.4:  The G-quartets of G2-G6 in the final snapshots of 50 nanosecond MD 
simulations. Only the energetically more favorable strand orientations are 
presented: (a) G2-antiparallel, (b) G3-antiparallel, (c) G4-antiparallel, (d) 
G5-parallel, and (e) G6-antiparallel. The green capped sticks of the G-
quartets in the reference structure are presented for comparison purposes.  
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6.3.4 CAD Fragmentation Pathways of the Quadruplexes 
While significant attention has been devoted to examining the fragmentation 
pathways of DNA duplexes of different length, sequence and base pair composition,29, 47 
fewer studies have focused on quadruplexes. Thus, CAD spectra of G1, G2, G3, G4, G5, 
G6, and G7 (5- charge state) were obtained to determine how different quadruplex strand 
stoichiometries and sequences affect the fragmentation patterns. The quadruplex ions 
dissociate via the loss of a nucleobase, strand separation, or a combination of the two 
(Figure 6.5). The primary fragmentation route of the four-stranded quadruplexes G1 and 
G7 was strand separation to produce a triplex ion and single strand species in the 3- and 
2- charge states, respectively. Guanine base loss from the resulting triplex species was 
also observed as demonstrated by the CAD spectrum of [(G1)4]
5- shown in Figure 6.5a.  
In contrast to the four-stranded quadruplexes, the two-stranded quadruplexes 
dissociate primarily through guanine base loss from the precursor ion, although some 
strand separation products are also present. Interestingly, different degrees of strand 
separation are observed in the CAD spectra of G2 (Figure 6.5b) and G3 (Figure 6.5c) 
even though an applied collision voltage of 1.25 V was used for each ion. The relative 
abundances of the single strand ions in the CAD spectrum of G2 are significantly lower 
than those of the single strand ions in the spectrum of G3, suggesting the different 
sequences or orientations of the quadruplexes impact the fragmentation pathways.  G2 
has two repeats of four guanine nucleobases, allowing it to form a quadruplex containing 
four G-tetrads, while the sequence of G3 allows it to form only three tetrads. With a 
greater number of tetrads, there are more Hoogsteen hydrogen bonds holding the single 
strands of G2 together, making covalent cleavage of guanines favored over non-covalent 
strand separation. This result is reminiscent of an increase in nucleobase loss observed in 
the CAD spectra of DNA duplexes that parallels the total number of interstrand hydrogen 
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bonds, either by increasing the GC content of the sequence and/or lengthening the 
duplex.29,30,47,48 
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Figure 6.5:  CAD spectra of the 5- charge state of: (a) [(G1)4], (b) [(G2)2], (c) [(G3)2], 
and (d) [G4]. 
 Guanine nucleobase loss is also the primary fragmentation pathway of the 
intramolecular quadruplexes, as demonstrated by the CAD spectrum of G4 in Figure 
6.5d. Similar spectra were acquired for G5 and G6 (data not shown). This result was 
expected since the quadruplex is single stranded, and thus cannot undergo strand 
separation. The CAD spectra of the intramolecular quadruplexes resemble those of single 
strand ions that have not formed a quadruplex, and thus give no diagnostic information 
about differences in the binding interactions between the quadruplexes.  
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6.3.5 Energy-Variable Dissociation Studies 
While there are some general differences in the CAD spectra of the four, two and 
single stranded quadruplexes, the fragmentation pathways alone do not provide insight 
into the relative stabilities of the quadruplexes, nor can they distinguish the 
intramolecular structures (G4, G5, and G6) or the four-stranded structures (G1 and G7). 
To probe the relative stabilities of the quadruplexes in the gas-phase, energy-variable 
dissociation experiments were undertaken. The quadruplexes that dissociate via the same 
fragmentation pathway may require different amounts of energy to induce their 
dissociation as a result of different strand orientations and/or binding interactions. For 
this part of the study, the quadruplex ions in the 5- charge state were isolated and 
subjected to increasing collision energy based on the applied collisional activation 
voltage. The abundance of the precursor ion relative to the abundance of the product ions 
was monitored as a fraction of 1.0 and plotted as a function of CAD voltage. The reported 
E1/2 values are calculated by determining the CAD voltage at which the relative 
abundance of the precursor ion is reduced to 50%.26,29,49  A greater E1/2 value implies a 
more stable ion, one that requires greater energization to induce dissociation.  A similar 
approach has been used for in-source CAD and thermal denaturation experiments of 
DNA duplexes.30   
The four-stranded quadruplexes G1 and G7 both dissociate via strand separation 
to produce single strand ions in the 2- charge state and triplex species with a 3- charge. 
However, the CAD voltages (E1/2 values) required to produce these ions are significantly 
different as demonstrated by the dissociation profiles shown in Figure 6.6. The E1/2 value 
for G1 was calculated to be 1.33 + 0.05 V, while that of G7 was 1.14 + 0.05 V, indicating 
G1 is substantially more stable in the gas phase than G7. This result is unsurprising since 
the sequence of G1 contains a single repeat of four guanines, allowing it to form four 
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tetrads, while G7 can only form three tetrads. With four tetrads, there are more hydrogen 
bonds between the four strands (16 for G1 versus 12 for G7) and greater stacking 
interactions between the tetrads. The differences in binding interactions between the 
single strands in G1 versus G7 are reflected in the E1/2 values of the quadruplexes. 




























Figure 6.6: Energy-variable dissociation curves for [(G1)4]
5- and [(G7)4]
5-. 
The gas-phase stabilities of the intramolecular quadruplexes G4, G5, and G6 are 
also distinguished based on different E1/2 values. Unlike G1 and G7, the strand separation 
pathway is not possible for the intramolecular quadruplexes. Therefore, the emergence of 
base loss ions and the formation of an-B and w ions is diagnostic for the disruption of the 
quadruplex structures. In order to cleave the covalent bond between the guanine and the 
ribose and disassemble the quadruplex structure, both Hoogsteen hydrogen bonding as 
well as tetrad stacking interactions must be broken. The dissociation curves shown in 
Figure 6.7 demonstrate that G4 and G5 have similar gas-phase stabilities, with E1/2 values 
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of 1.20 +  0.02 V and 1.18 +  0.01 V, respectively, while G6 is significantly less stable 
with an E1/2 value of 1.10 +  0.02. The differences in the gas-phase stabilities may be 
partially explained by the number of tetrads per structure. The least stable intramolecular 
quadruplex, G6, contains four repeats of two guanines, allowing for only two tetrads in 
the quadruplex structure, compared to three tetrads in G4 or four tetrads in G6.  However 
the E1/2 values of G4 and G5 are approximately the same, even though G5 can form four 
G-tetrads and G4 can only form three. These results indicate there are also other factors 
governing the stabilities of the quadruplexes. As shown below, the structural and free 
energy analysis on the MD trajectories shed light on the trend of E1/2 values of the G-
quadruplexs.  




























Figure 6.7: Energy-variable dissociation curves for [G4]5-, [G5]5-, and [G6]5-. 
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Energy-variable dissociation curves were also constructed for the two-stranded 
quadruplexes G2 and G3 (Figure 6.8), both of which dissociate via strand separation and 
guanine base loss from the parent complex. Their E1/2 values are virtually the same within 
the margin of errors of the measurements. While both quadruplexes are two-stranded, G2 
is able to form four G-tetrads while G3 can only form three, so one would expect a 
greater E1/2 value for G2.  These results again suggest that other factors influence the 
apparent gas-phase stabilities of the quadruplexes, possibly strand orientation because G2 
forms an antiparallel quadruplex, while G3 likely forms a mixture of parallel and 
antiparallel structures.  



























Figure 6.8: Energy-variable dissociation curves for [(G2)2]
5- and [(G3)2]
5-.  
In addition to comparing E1/2 values amongst quadruplexes that have the same 
strand stoichiometries and thus fragmentation patterns, the E1/2 values of all quadruplexes 
were also compared relative to each other (Table 6.3).  The E1/2 values for the 
 128
quadruplexes fall into three main groups. G1, the parallel four-stranded quadruplex with 
four tetrads and three retained ammonium ions, has by far the largest E1/2. The 
quadruplexes with the next highest E1/2 values are two of the intramolecular quadruplexes 
with three and four tetrads, G4 and G5, respectively. The next grouping based on E1/2 
values include the multistranded quadruplexes with three tetrads, G7 with four strands, 
and G3 with two strands, followed by the intramolecular quadruplex with two tetrads G6, 
and finally the two stranded quadruplex with four tetrads. 








Number of tetradsE1/2 Value (V)Quadruplex
 
 
It is apparent that the E1/2 values are not solely artifacts of the DNA sequence. For 
example, G3 and G4 both contain four d(T2AG3) repeats, with all four on one strand for 
G4 and two on two different strands for G3. However, their E1/2 values are significantly 
different, with G4 having a greater E1/2 value. Base content alone also does not account 
for the trend apparent in Table 6.3, as both G1 and G5 both contain 16 guanines and 8 
thymines in the quadruplex, but their E1/2 values are significantly different. It has also 
been demonstrated in the discussion above that quadruplexes with the same strand 
stoichiometries have different E1/2 values. For example, G4 and G6 could be distinguished 
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by their E1/2 values, even though both form intramolecular quadruplexes. Therefore, we 
ascribe the differences in E1/2 values of the quadruplexes to differences in gas-phase 
stabilities of different quadruplex structures. 
6.3.6 Molecular Dynamics Structure and Energy Analysis 
To provide insight into the relative stabilities of the quadruplexes determined by 
the energy-variable dissociation experiments, molecular dynamics energy analyses were 
performed on the quadruplexes. The root mean square displacement (RMSD) is one of 
the key parameters used to evaluate the stability of a MD trajectory. The smaller the 
RMSD values, the more similar the MD snapshots are to the reference structure. In this 
work, we were interested in the relative stabilities of the G-tetrads in the gas phase MD 
simulations. Therefore, only the G-tetrad atoms were used in least-square fittings to 
calculate the RMSD values, with the final structures of a series of minimizations used as 
references. The RMSD of G-tetrads during the MD simulations are listed in Table 6.4. It 
is shown that G1-ammonium has the most stable MD trajectory and its mean RMSD of 
G-quartets is only 0.66 Å which is significantly smaller than all other model molecules 
including G1-no-cation.  
The molecular mechanical energies and the entropies, as well as the free energies 
of the quadruplexes, are listed in Table 6.4. There is more than one strand orientation for 
G3, G4, G5, and G6. According to the calculated free energies, the antiparallel strand 
orientation is more favorable for G4 and G6, and only slightly more favorable for G3. On 
the other hand, the free energy of parallel G5 is virtually the same as the antiparallel 




Table 6.4:  Root mean square displacements (RMSD) of guanines in G-tetrads and the 
free energies and their components of the final minimized structures and 50 
snapshots collected from the MD simulations. For a quadruplex, the 
energetically more favorable stoichiometry or strand orientation according 




 Energy (kcal/mol) Entropy (cal/mol/K) Free Energy (kcal/mol) 
   Minimization MD Minimization MD Minimization MD 
G1-ammonium 0.66  -1840.9 -1962.6 2132.7 2044.9 -2480.7 -2576.0 
G1-no-cation 2.32  -1680.6 -1795.6 2112.4 2038.9 -2314.3 -2407.3 
G2-antiparallel 3.22  -1779.3 -1868.3 2091.2 2049.5 -2406.7 -2483.2 
G3-antiparallel 3.82  -1593.8 -1782.1 2210.2 2041.7 -2256.9 -2394.6 
G3-parallel 2.96  -1625.7 -1782.5 2098.6 2016.8 -2256.3 -2387.5 
G4-antiparallel 3.09  -1645.2 -1818.0 2212.0 2034.5 -2308.8 -2428.4 
G4-parallel 2.23  -1668.4 -1803.1 2113.2 2038.0 -2302.4 -2414.5 
G5-antiparallel 3.96  -1719.8 -1917.8 2194.2 2053.1 -2378.1 -2533.4 
G5-parallel 2.56  -1773.4 -1921.9 2125.9 2041.8 -2411.1 -2534.4 
G6-antiparallel 3.58  -1174.6 -1534.1 2259.3 2042.1 -1852.4 -2146.7 
G6-parallel 2.70  -1225.2 -1514.6 2313.0 2034.9 -1919.1 -2125.1 
G6- T-tetrad 4.44  -1332.7 -1515.8 2083.9 2026.7 -1957.9 -2123.8 
 
The relative free energies between the minimized and the MD structures are listed 
in Table 6.5. The hydrogen bonding and stacking interaction analysis on the MD 
trajectories were performed (data not shown). The overall conclusion is that the number 
of stacking interactions and the number of hydrogen bonds among guanine tetrads 
slightly decrease in comparison to the final minimized structures, while the number of 
hydrogen bonds formed between guanine tetrads and other atoms increases significantly.  
To estimate the relative stability of the quadruplexes, one needs to consider many 
factors including RMSD values and relative free energies between the minimized and the 
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MD structures. It can be argued that the smaller the distortion of the G-quartets, the more 
stable the G-quadruplex and the higher the E1/2 value. This translates to the smaller the 
relative free energy between the distorted and the undistorted structures, the more stable 
the G-quadruplex  
If only the mean RMSD are considered, the rank order of stability is: G1 > G5 > 
G4 > G2 > G6 > G3, while the rank order becomes G2 > G1 > G4 > G5 > G3 > G6 when 
the relative free energies are taken into account. Thus, according to structural and 
energetic analysis, G1 and G2 are more stable than G4 and G5, and G4 and G5 are more 
stable than G3 and G6 according to the structural and energetic analysis. It should be 
noted that the above comparisons were made only for the energetically more favorable 
stoichiometry or strand orientation of each quadruplex, and the rank order may be 
changed if one considers the contribution of other strand orientations. 
 
Table 6.5:  The relative free energies between the last minimized and MD structures. 
For each quadruplex, only the energetically more favorable stoichiometry or 











The conclusions about the relative quadruplex stabilities determined by RMSD 
and relative free energy results correlate well with the rankings determined by the energy 
variable CAD experiments. One exception to the general agreement is the result for G2. 
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This quadruplex had the lowest E1/2 value, however it was determined to be the most 
stable quadruplex according to the free energy analysis and ranked fourth based on 
RMSD comparison.  This discrepancy could be attributed to the fragmentation pathways 
of this structure in the gas phase. Previous studies of the fragmentation mechanisms of 
single strand and duplex oligonucleotides have found that base loss and subsequent back 
bone fragmentation is initiated by protonation of the nucleobase, followed by covalent 
cleavage.50 In duplex DNA, the terminal ends of the duplex must unzip to accommodate 
this nucleobase loss. When high-proton affinity bases such as guanine are located at the 
terminal positions of a duplex, more extensive nucleobase loss and further unzipping will 
occur, leading to decreased stability of the quadrupelxes.29 If a similar fragmentation 
mechanism is assumed for quadruplex DNA, G2 can undergo more facile nucleobase loss 
and thus has decreased gas-phase stability since it is the only quadruplex containing G-
tracts on both the 5’ and 3’ ends of the strands forming the quadruplex. The gas-phase 
stabilities of the other quadruplexes do not appear to be affected by this anomaly. 
Aside from G2, the results of the molecular dynamics simulation support the 
general conclusions of the energy-variable dissociation study. Of the quadruplexes 
assessed, the parallel four stranded structure G1 was the most stable, likely due to the 
four-tetrads and stabilizing NH4
+ adducts that did not remain bound to the other structures. 
The next most stable structures were the intramolecular quadruplexes G4 and G5 which 
have approximately equal gas-phase stabilities. While G5 has more tetrads than G4 with 
four compared to three, the quadruplexes have different strand orientations as determined 
by the molecular dynamics simulations. The parallel strand orientation of G5 may negate 
the stabilizing effects of the additional tetrad compared to the antiparallel orientation of 
G4. The least stable quadruplexes are the double stranded antiparallel G3 with three 
tetrads and the intramolecular quadruplex G6 with two tetrads. G6 has fewer tetrads than 
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both G4 and G5 so it is unsurprisingly less stable. G3 and G4 have the same number of 
tetrads, however the antiparallel intramolecular orientation of G4 apparently increases its 
gas-phase stability relative to G3. 
6.4 CONCLUSIONS 
The CAD fragmentation patterns and E1/2 values for a series of quadruplexes have 
been acquired to assess their relative gas-phase stabilities. State of the art molecular 
dynamics simulations have also been applied to investigate the structural and energetic 
properties of G-quadruplexes in solvent-free environment. It is concluded that G-
quadruplexes can maintain their structures in the gas phase although the G-quartets are 
distorted to some degree. The ammonium ions were also shown to play an important rule 
in stabilizing the G-quartets for a four-stranded parallel quadruplex. Free energy analysis 
is useful not only in identifying the most favorable stoichiometry or strand orientation, 
but also for ranking the relative stability of a set of quadruplexes. The relative gas-phase 
stabilities of the quadruplexes determined by the molecular dynamics simulations 
correlates well with the ranking determined from E1/2 values of the quadruplexes, 
suggesting energy-variable dissociation curves are also useful as a means for rapidly 
screening the stability of quadruplexes.  
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Chapter 7: Probing Ligand Binding to Duplex DNA using KMnO4 
Reactions and Electrospray Ionization Tandem Mass spectrometry 
7.1 INTRODUCTION 
Electrospray ionization mass spectrometry (ESI-MS) has been established as a 
useful tool for the analysis of non-covalent complexes formed between small molecule 
drugs and DNA.1-3 The advantages of using ESI-MS in this capacity are low sample 
consumption coupled with fast analysis time, which make the technique adaptable to high 
throughput screening techniques.  In early reports, the binding of well-studied, 
commercially available drugs to duplex DNA was examined, with results indicating that 
the binding trends observed by ESI-MS such as binding stoichiometries, sequence 
selectivities, binding affinities and complex stabilities, can be correlated to known 
solution binding behavior.4-10 Recent accounts have extended the use of the technique to 
look at more novel types of ligand/DNA complexes such as those containing bis-
intercalators,11 ligands that are metal-mediated,12, 13 and quadruplex DNA,14-21 further 
demonstrating the capabilities of the method. 
While the success of using ESI-MS to screen binding affinities and 
stoichiometries has been established, one of the drawbacks of the technique is the lack of 
structural information that can be directly obtained; drug/DNA complexes are observed, 
but information about the drug binding site or alterations in the DNA structure due to 
drug binding can not be easily determined. Chemical probes that modify nucleic acid 
substrates in a structure-dependant manner22, 23 coupled with ESI-MS/MS analysis 
represent a promising technique for the structural analysis of DNA and RNA. Solvent 
accessibility probes (such as dimethylsufate (DMS), kethoxal, and 1-cyclohexyl-3-(2-
morpholinoethyl)carbodiimide metho-p-toluenesulfonate (CMCT)) that modify 
 139
nucleotides that are not base-paired or involved in binding interactions with proteins or 
ligands have been used with Fourier transform mass spectrometry (FTMS) to examine 
structural features of RNA24-26 and RNA/protein27 complexes. In these previous studies, 
tandem mass spectrometry or chemical digestion techniques were used to sequence the 
RNA and identify the site of chemical modification, thereby eliminating the need for 
polyacrylamide gel electrophoresis (PAGE) analysis of the products, resulting in a fast, 


































Diol (159.1 Da) Alpha-hydroxyl ketone (157.1 Da)  
Scheme 7.1: Mechanism of oxidation of thymine nucleobases by permanganate. The 
mass of thymine and the resulting diol and alpha-hydroxyl ketone products 
are given in parenthesis. 
 
In the present study, we have exploited the use of chemical probes with ESI-MS 
analysis by developing a technique that utilizes KMnO4 to detect conformational changes 
in duplex DNA and identify the ligand binding site in non-covalent drug/DNA 
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complexes. Under neutral conditions, KMnO4 oxidizes thymine and, to a much lesser 
extent, cytosine by attacking the double bond of the nucleobase to produce a mixture of 
the diol and an alpha-hydroxylketone products as demonstrated in Scheme 1.22, 23, 28 Each 
oxidized base results in a mass shifts of +34 for the diol and +32 Da for the  alpha-
hydroxylketone, which can easily be detected by mass spectrometry. Thymines in 
unstacked, single strand-like DNA are susceptible to reaction with KMnO4 while double 
stranded DNA is resistant to the oxidation.29 As a result, KMnO4 has been used to detect 
conformational changes upon ligand30, 31 and protein binding,32-35 determine the base pair 
composition,36, 37 uncover the specific structure of DNA (Z-DNA, hairpins, curvatures, 
parallel stranded helices, etc.),38-41 and ascertain conformational changes of mismatched 












































































































Echinomycin (1101.3 Da) Ethidium bromide (314.4 Da)
cis-C1 (1006.9 Da)
Actinomycin-D (1255.4 Da)
Hoechst 33342 (452.6 Da)  
Figure 7.1:  Structures of ligands used in this study with molecular weights given in 
parenthesis. 
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In past studies using the KMnO4 reaction to examine conformational changes 
upon small molecule binding, it was determined that the permanganate ion reacts with 
thymines around the ligand binding site as a result of the unwinding and extension of the 
duplex upon intercalator binding.30, 31 Therefore, ligand binding sites can be elucidated 
after determining the positions of the oxidized thymines. The site of oxidation is 
determined using a piperidine heat treatment to cleave the DNA at the site of the 
oxidation, followed by polyacrylamide gel electrophoresis (PAGE) analysis to sequence 
the fragments.30, 31 We have developed a streamlined technique to oxidize drug/DNA 
complexes in solution, analyze the extent of oxidation using ESI-MS and determine the 
site of oxidation using two tandem mass spectrometry techniques: collisional activated 
dissociation (CAD)44 and infrared multiphoton dissociation (IRMPD).45, 46 Our technique 
simplifies the experiment by eliminating the need for time consuming and labor intensive 
PAGE analysis and use of radiolabeled DNA, while also offering detailed binding site 
and sequence information. We establish the technique by examining the oxidation of the 
duplex DNA of different sizes and sequences as well as drug/DNA complexes containing 
echinomycin, ethidium bromide, actinomycin-D, Hoechst 33342, and cis-C1 (structures 
shown in Figure 7.1).  
7.2 EXPERIMENTAL 
7.2.1 Materials 
Single strand oligonucleotides were purchased from Integrated DNA 
Technologies (Coralville, IA) and synthesized as ammonium salts on the 1 µmole scale 
and purified by reverse phase HPLC. Actinomycin-D, ethidium bromide, Hoechst 33342, 
and KMnO4 were purchased from Thermo Fisher Scientific (Waltham, MA) and used 
without further purification. Echinomycin was purchased from Sigma-Aldrich (St. Louis, 
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MO) and used without further purification and cis-C1 was prepared as previously 
described.47 All solvents were of HPLC grade purity. 
7.2.2 KMnO4 Reaction 
Prior to the KMnO4 oxidation reactions, stock solutions of each single strand oligo 
were prepared at 2 mM in 250 mM ammonium acetate buffer. Solutions containing 
complementary single strands, each at 1 mM concentration were prepared in 250 mM 
ammonium acetate and annealed by heating the solution to 90 °C, followed by cooling to 
room temperature over a period of 7 hours. Stock solutions of the drug molecules were 
prepared at 1 mM concentration in water for actinomycin-D, Hoechst 33342 and cis-C1, 
and in methanol for echinomycin and ethidium bromide.  
Solutions containing a DNA duplex or single strand and were prepared at 40 µM 
in 50 µL of 90 mM ammonium acetate. Where indicated, a drug was added at 120 µM 
and the solution was allowed to equilibrate for 30 min. to allow for binding. To initiate 
oxidation 5 µL of a 5 mM KMnO4 solution prepared in water was added, and the reaction 
mixture was incubated for 4-30 min. at room temperature. After the desired incubation 
time, KMnO4 was immediately removed from the solution using a Pierce PepClean C18 
spin column (Rockford, IL). The DNA was eluted from the column using 40 µL of 50% 
acetonitrile solution and then diluted to 100 µL so that the final solution contained 50 
mM ammonium acetate. 
7.2.3 Mass Spectrometry 
Analytical solutions were directly infused into a ThermoFinnigan LCQ Duo mass 
spectrometer (San Jose, CA) at 3 µL/min using a Harvard Apparatus PHD 2000 syringe 
pump (Holliston, MA). Negative ions were produced using an ESI voltage of 3.5 kV and 
a heated capillary temperature of 110 °C. Nitrogen sheath and auxiliary gas flows of 40 
and 20 arbitrary units, respectively were used to aide the desolvation of the ions. Spectra 
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were acquired using an ionization time of 50 -100 ms and by summing 300 scans. For 
CAD experiments the desired precursor ion was isolated in the trap using default 
activation time of 30 ms and a qz value of 0.25. The collision energy was increased until 
the abundance of the precursor ion was reduced to ~10% relative abundance. The base 
pressure of the trap was nominally 1 x 10-5 torr. 
IRMPD experiments were undertaken on a modified ThermoFinnigan LCQ Deca 
XP mass spectrometer equipped with model 48-5 Synrad 50 W continuous wave laser 
(Mukilteo, WA) that has been described previously.46 Briefly, qz values of 0.2 to 0.1 were 
used and the laser was triggered during the activation portion of the scan function. 
Activation times of 1 to 3 ms at 50 W laser power were used to achieve dissociation. The 
base pressure of the trap was nominally 2.8 x 10-5 torr which corresponds to a helium 
pressure of 1 mTorr. 
7.3 RESULTS AND DISCUSSION 
The capabilities of the new ESI-MS method involving the the KMnO4 reaction 
will be evaluated by examining the oxidation of single strand and then duplex DNA. The 
oxidation of drug/duplex DNA complexes with varying duplex sequences, drug 
molecules, and duplex length will also be presented. The use of CAD and IRMPD to 
identify the position of the oxidized thymines is then demonstrated. 
7.3.1 Oxidation of Single Strand DNA 
To confirm that the oxidation protocol, subsequent work-up, and mass 
spectrometric analysis  allows effective monitoring and detection of the oxidation of 
thymines in DNA, the KMnO4 reaction was first carried out on solutions containing the 
single strand d(GCGGATATATGGCG), which contains three possible sites for thymine 
oxidation. Figure 7.2a shows the ESI mass spectrum of a solution containing the single 
strand prior to reaction with KMnO4. To obtain this spectrum, the reaction and sample 
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purification procedures were followed as described in the Experimental section, except 
the KMnO4 was not added to the solution. The 3- and 4- charge states of the single strand 
are present with very low abundance sodium adducts. The spectral region around [ss]4- 
(m/z 1070 to 1115) is shown in the inset of Figure 7.2a, and the sodium adduct ions are 
labeled with  asterisks. The corresponding spectrum of the single strand after a 5 min. 
reaction with KMnO4 is shown in Figure 7.2b. Compared to Figure 7.2a, new ions are 
present in Figure 7.2b and the m/z values of the new ions are shifted by multiples of +34 
Da compared to the m/z of the single strand ions. The m/z values of the new ions are 
consistent with the formation of up to three oxidized thymines on the single strand ions 
via the reaction shown in Scheme 1. The ions in Figure 7.2 that correspond to single 
strand DNA containing the oxidized thymine(s) are labeled with “a black triangle”, and 
the number of oxidation adducts is indicated by the number in parenthesis. The formation 
of up to three adducts is observed and is expected since three thymines are present in the 
single stand. The spectral enlargements of the region around [ss]4- also demonstrate that 
peaks pertaining to sodium adducts (again labeled with asterisks) can be distinguished 
from those containing oxidation adducts (labeled with black triangles). 
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Figure 7.2:  ESI-mass spectra showing solutions containing the single strand 
d(GCGGATATATGGCG) (ss1) (a) before reaction with KMnO4, (b) after 
4 min.reaction with KMnO4, and (c) after 30 min. reaction with KMnO4. 
Spectral elargements of the region around m/z 1070 to 1115 are shown in 
the inset. Sodium adducts are labeled with an asterisk. Ions containing 
oxidized thymines are labeled with a black triangle, with the number in 
parenthesis indicating the number of oxidation adducts. 
 
After 30 min. reaction with KMnO4, the oxidation of the single strand is more 
extensive, as demonstrated by the spectrum shown in Figure 7.2c. Up to three oxidation 
adducts are still observed, and the abundance of the ions containing the oxidation adducts 
relative to the single strand ions containing no adducts is significantly increased in Figure 
7.2c compared to Figure 7.2b. These results indicate that at longer incubation times, more 
extensive oxidation of the single strand DNA occurs. These initial results confirm that the 
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oxidation process, as well as the extent of oxidation as a function of time, can be 
monitored by ESI-MS. 
7.3.2 Oxidation of Duplex DNA 
After observing significant oxidation of single strand DNA, a similar series of 
experiments were performed with a duplex to compare the degree of thymine oxidation. 
The duplex d(GCGGATATATGGCG/CGCCATATATCCGC) (ds1) was used and 
contains the same single strand used in the oxidation experiments described above, then 
annealed with its complementary strand. The spectrum of the duplex prior to oxidation is 
shown in Figure 7.3a. The dominant charge state of the duplex is 5-, and the region 
around this ion (m/z 1700-1730) is enlarged and shown in the inset. After 4 min. reaction 
with KMnO4, two low abundance ions are detected with mass shifts  that are consistent 
with the formation of duplexes containing one or two oxidized thymines (Figure 7.3b). 
The abundance of these adducts relative to the unoxidized [ds]5- ion is significantly lower 
than the abundance of the oxidation adducts formed after the KMnO4 reaction with the 
single strand oligonucleotide d(GCGGATATATGGCG) (Figure 7.2b). After 30 min. 
reaction with the permanganate ion, the relative abundances of the oxidation adducts of 
the duplex do not significantly change, as demonstrated by the spectrum shown in Figure 
7.3c. Furthermore, no more than two oxidation adducts are formed even though there are 
six thymines in the duplex sequence. It is also interesting to note that increasing the 
reaction time from 4 to 30 min. resulted in more extensive oxidation of the single strand 
(Figure 7.2b versus 7.2c), while the degree of oxidation of the duplex did not change. The 
striking differences between the spectra obtained for the oxidation of single strand 
(Figure 7.2) and duplex DNA (Figure 7.3) demonstrates the resistance of duplex DNA to 
KMnO4 oxidation.  This resistance stems from the stacking of the nucleobases which 
sterically hinders the access and attack of the permanganate ion on the double bond of 
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thymine.28  Based on the results shown in Figures 7.1 and 7.2, a reaction period of 20 min. 
was selected for all subsequent KMnO4 reactions since this time allowed sufficient 
reaction of thymines on single strand DNA, while the extent of oxidation of the duplex 
did not change substantially at even longer times. 
 
 
Figure 7.3.  ESI-mass spectra showing solutions containing the duplex 
dGCGGATATATGGCG/CGCCATATATCCGC) (a) before reaction with 
KMnO4, (b) after 4 min.reaction with KMnO4, and (c) after 30 min. 
reaction with KMnO4. Spectral elargements of the region around m/z 1700 - 
1730 are shown in the inset. Sodium adducts are labeled with an asterisk. 
Ions containing oxidized thymines are labeled with a black triangle, with the 

































7.3.3 Oxidation of DNA Complexes Containing Echinomycin 
The KMnO4 oxidation of drug/DNA duplex complexes was also examined by 
ESI-MS to assess the ability to identify or predict structural changes of DNA upon ligand 
binding based on the observed changes in the oxidation patterns. Drug binding sites also 
can be determined from the oxidation pattern since the thymines that encompass the drug 
binding site are most susceptible to oxidation.30, 31 Previous PAGE-based studies have 
found that intercalators induce changes to the DNA conformation, and in doing so, 
greatly increasing the reactivity of thymines to the permanganate ions.30, 31  This effect is 
especially pronounced for echinomycin (Figure 7.1), a bis-intercalator antibiotic that 
binds to duplex DNA via the intercalation of two quinoxaline chromophores at CpG sites, 
with the central bicyclic peptide residing in the minor groove.  Intercalation of 
echinomycin causes considerable unwinding and distortion of the DNA duplex.48-51   In 
the present study, the duplex d(GCGGATATATGGCG/CGCCATATATCCGC) (ds1) 
was selected for experiments with echinomycin since this sequence contains multiple 
CpG ligand binding sites. Prior to examining the oxidation of the echinomycin/duplex 
complexes, the oxidation of the duplex in the absence of the ligand was assessed as a 
control. The results are shown in Figure 7.4a, and they are virtually the same as those 




Figure 7.4:  ESI-mass spectra showing solutions containing the duplex 
dGCGGATATATGGCG/CGCCATATATCCGC) (a) after 20 min, reaction 
with KMnO4, (b) with echinomycin (E), prior to reaction with KMnO4, and 
(c) with echinomycin (E), after 20 min. reaction with KMnO4. Ions 
containing oxidized thymines are labeled with a black triangle, with the 
number in parenthesis indicating the number of oxidation adducts. 
Figure 7.4b shows the ESI mass spectrum of a solution containing the duplex with 
echinomycin (abbreviated as “E”) prior to KMnO4 reaction. Echinomycin/duplex 
complexes are observed with drug/DNA binding stoichiometries ranging from 1:1 to 3:1 
in the 6- charge state, confirming that echinomycin/duplex complexes are readily formed 
in solution and maintained upon transport to the gas phase. Then the KMnO4 reaction was 
undertaken for twenty minutes on a solution containing echinomycin/duplex complexes, 
and the resulting mass spectrum is shown in Figure 7.4c. Compared to the oxidation of 
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duplex alone (Figure 7.4a), the degree of oxidation is significantly increased for the 
echinomycin/duplex complexes. Interestingly, the degree of oxidation changes with the 
echinomycin/duplex binding stoichiometry; as the number of bound ligands increases, the 
abundance of the ions containing oxidation adducts increases relative to the unoxidized 
ions. This is demonstrated by comparing the relative abundances of the oxidation adducts 
associated with the 1:1, 2:1, and 3:1 echinomycin/duplex complexes in the 6- charge 
state. It is expected that the unwinding, elongation and hence the distortion of the duplex 
should increase with the number of intercalator ligands bound to the duplex, thus making 
thymines in the duplex more susceptible to reaction with KMnO4.
51 
 To allow the semi-quantitative comparison of the degree of oxidation of 
DNA complexes, we calculate the percent oxidation of a given DNA complex, M, using 
the following equation: 
 
A[M + O] + A[M + 2 x O] + …A[M + n x O]                     
A[M] + A[M + O] + A[M + 2 x O] + …A[M + n x O] 
where A[M] is the ion abundance of the single strand, duplex or drug/DNA complex 
designated in the subscript bracket, A[M + O]  corresponds to each complex containing one 
or more oxidation adducts, and n is the maximum number of oxidation adducts associated 
with the particular complex [M]. For example, for the spectra shown in Figure 7.4, the 
percent oxidation of the duplex in the absence of echinomycin is 15%, while the 
oxidation values of the corresponding echinomycin/DNA complexes are 57% for the 1:1 
complex, 69% for the 2:1 complex, and 82% for the oxidation value obtained for the 3:1 
complex (all in the 6- charge state). The increase in the extent of oxidation with each 
additional echinomycin molecule bound to the duplex is reflected in the percent oxidation 
values. It is interesting to note that the percent oxidation of the single strand 
Percent Oxidation = x 100% 
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d(GCGGATATATGGCG) shown in Figure 7.2b was calculated to be 85%, which is very 
similar to the 3:1 echinomycin/duplex DNA complex. Clearly the multiple intercalation 
of echinomycin causes a dramatic distortion of double stranded DNA. 
7.3.3.1 Effect of Duplex DNA Sequence 
The KMnO4 oxidation of complexes containing echinomycin with another duplex, 
d(GTAGAGTCGACCTG/CAGGTCGACTCTAC) (ds2) was also examined (spectra not 
shown). The sequence of this duplex was selected from a fragment of a 265-mer DNA 
sequence used in a past study by Bailly et al. which reported the binding of echinomycin 
by DNase I, methidium propyl EDTA (MPE)·FeII , diethyl pyrocarbonate (DEPC), and 
KMnO4.
31 This former study identified multiple binding sites along the DNA fragment 
including one strong site at the sequence 5’-AGTCGACCT-3’ which is thus incorporated 
in our sequence, ds2. The KMnO4 reaction with this duplex in the absence of 
echinomycin was undertaken, and the percent oxidation for the duplex was 46% (spectra 
not shown). This is a higher degree of oxidation than the value determined for ds1 in the 
absence of  echinomycin (15%). While both duplexes contain an equal number of 
thymines, we speculate that the higher degree of oxidation of ds2 results from the specific 
location of the thymines. All of the thymines in ds1 are located in the center of the duplex 
and are flanked by G/C base pairs, while in ds2, there are three thymines closer to the 
termini of the duplex.  Therefore, a slight unwinding of duplex ds2 in solution, a process 
more likely to occur near the ends of the duplex, may make the thymines more 
susceptible to permanganate oxidation even in the absence of an intercalating ligand. 
While the variation in the degree of thymine oxidation in different DNA 
sequences is interesting, the change in the percent oxidation upon ligand binding is more 
important to the goals of this study. Echinomycin was found to form abundant complexes 
with ds2 with 1:1 and 2:1 binding stoichiometries (spectra not shown). After reaction 
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with KMnO4, the formation of one and, to a lesser degree, two oxidation adducts were 
formed for each complex. As summarized in Table 7.1, the percent oxidation values of 
the 1:1, 2:1, and 3:1 echinomycin/duplex complexes are 62%, 66%, and 70%, 
respectively. While the overall increase in the percent oxidation values for the complexes 
containing echinomycin with ds2 was not as great as the increase for the 
echinomycin/ds1 complexes described in the previous section, the increase was still 
significant. These results confirm that the oxidation of DNA upon echinomycin binding31 
can be determined by the ESI-MS technique. As will be discussed in the sections below, 
the specific sites of thymine oxidation on the duplex can be determined by CAD, and 
they correlate with the findings of the past gel electrophoresis study.31 
 
















aAll values +/- 5. 
bValues for the duplex alone were determined from the oxidation of solutions containing the duplex 
without ligand. 
cds1 = d(GCGGATATATGGCG/CGCCATATATCCGC)  
dds2 = d(GTAGAGTCGACCTG/CAGGTCGACTCTAC) 
eds3= d(GCAGTGA/TCACTGC) 
fds4= d(GGACAGTGAGGGCAGTGAGGG/CCCTCACTGCCCTCACTGTCC) 
gds5 =(GCGGGGATGGGGCG/CGCCCCATCCCCGC) was used in the experiment. 
hBecause the KMnO4 oxidation caused a loss of ethidium bromide from the duplex, the values for 
ethidium bromide were determined based oxidation adducts formed on the free duplex.  
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7.3.3.2 Effect of Duplex DNA Length 
The effect of duplex length on the KMnO4 oxidation reaction was also examined. 
Our previous ESI-MS studies of drug/DNA complexes typically employed duplexes with 
14 base-pairs because ion mobility/molecular dynamics studies have reported that DNA 
duplexes greater than 12 base pairs maintain the helical conformation in the gas-phase 
better than shorter duplexes.52, 53 It may, however, be desirable to examine the KMnO4 
oxidation of smaller duplexes for high throughput applications and targeted screening 
strategies. Since the oxidation reactions are undertaken in solution and mass spectrometry 
is simply used to detect the products in the present methodology, concerns about gas-
phase conformations are not a primary issue. Experiments involving a seven base pair 
duplex, d(GCAGTGA/TCACTGC) (ds3) were undertaken to assess the lower size limit 
of the duplexes that can be examined by the ESI-MS/oxidation technique. For this shorter 
duplex, the dominant DNA ions are detected in the 3- charge state. The percent oxidation 
value for the [ds]3- ion after KMnO4 reaction in the absence of any DNA-interactive 
ligand was determined to be 56% (spectrum not shown). This value is greater than what 
was observed for the 14 base pair duplexes in the absence of ligand, and suggests more 
extensive distortion of the shorter duplex in solution. This result is consistent with past 
studies that found that the B-form of duplex DNA is more easily distorted in shorter 
duplexes due to the reduced base stacking and hydrophobic interactions.54 For the present 
study, when the oxidation reaction is carried out on a solution containing echinomycin 
and d(GCAGTGA/TCACTGC), up to two oxidation adducts are formed for each 1:1 and 
2:1 echinomycin/duplex complex. The percent oxidation for these complexes is 100% as 
no unoxidized form of the duplex remains in the ESI mass spectrum (data not shown). 
These results reflect the greater distortion of smaller duplexes upon ligand binding 
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compared to longer ones dues to the smaller number of hydrogen bonds and stacking 
interactions, as well as the substantial degree of distortion caused by the intercalator 
ligand.  
 Experiments with a longer 21 base pair duplex were also undertaken. The 
oxidation of the duplex, 
d(GGACAGTGAGGGCAGTGAGGG/CCCTCACTGCCCTCACTGTCC) (ds4) was 
first evaluated in the absence of echinomycin (spectrum not shown), and the percent 
oxidation was determined to be 32%. After echinomycin binding, the percent oxidation 
value of the 1:1 echinomycin:duplex complexes was determined to be 53% and the value 
for the 2:1 complex was 67% (spectrum not shown). While the increase in the degree of 
oxidation for ds4 compared to the echinomycin/ds4 complex is not as dramatic as was 
observed for the complexes containing the shorter duplexes (7-mers or 14-mers), it is 
reproducible and consistent with the expected duplex distortion caused by intercalation.  
One of the main challenges of using longer DNA duplexes in an ESI-MS/KMnO4 
experiment is that at higher charge states, it is more difficult to distinguish the formation 
of an oxidized thymine from a sodium adduct which are always present in ESI mass 
spectra of nucleic acids. The dominant charge state for drug/DNA complexes containing 
14 base pair duplexes is 6-. The observed mass shift upon formation of an oxidized 
thymine in the 6- charge state is 5.7 Da, while the shift for a sodium adduct is 3.8 Da. 
The m/z values of the sodium and oxidation adducts in this charge state can be easily 
distinguished using a quadrupole ion trap mass spectrometer. However, complexes 
containing the 21 base pair duplex are observed in the 9- and 8- charge states, and at 
these high charge states, the m/z differences between the sodium and oxidation adducts 
are decreased. In the 8- charge state, the ions corresponding to sodium adducts are shifted 
by 2.9 Da, while those of the oxidation adducts are shifted by 4.3 Da. These peaks can 
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generally distinguished in the mass spectrum; however, for the 9- charge state, the peaks 
for the sodium and oxidation adducts overlap since the mass shift for a sodium adduct is 
2.5 Da, while the shift for an oxidation adduct is only 3.7 Da. Analyses of the KMnO4 
reaction with DNA present in the 9- charge state or greater require a mass analyzer with 
greater mass accuracy and resolving power.  
7.3.4 Oxidation of Complexes Containing Other Drugs 
KMnO4 reactions with complexes containing other types of DNA interactive 
ligands, including three other intercalators  and a minor groove binding agent, were also 
examined by ESI-MS. Actinomycin-D (Figure 7.1) binds to DNA duplexes via the 
intercalation of the phenoxazone chromophore, preferably at 5’-GC-3’ sites, while the 
two cyclic peptides bind to the minor groove.55, 56 As a monointercalator, the unwinding 
angle and elongation of the duplex upon actinomycin-D binding is less substantial 
compared to the bis-intercalator echinomycin,51, 57, 58 therefore the KMnO4 reactivity of an 
actinomycin-D/duplex complex is expected to be reduced compared to complexes 
containing echinomycin. To enhance the duplex binding by actinomycin-D, the duplex 
d(GCGGGGATGGGGCG/CGCCCCATCCCCGC) (ds5) was used due to its G/C rich 
sequence. The ESI mass spectrum of the solution containing the duplex with 
actinomycin-D prior to the oxidation reaction reveals abundant complexes with binding 
stoichiometries of 1:1 in the 6- and 5- charge state (spectrum not shown).  As 
summarized in Table 7.1, the percent oxidation value for this duplex in the absence of 
ligand was determined to be 18% (spectrum not shown). After 20 min. reaction with 
KMnO4, one low abundance oxidation adduct was formed for the actinomycin-D/duplex 
complexes (spectrum not shown). The percent oxidation for the 1:1 complexes was 
calculated to be 19%, which is not significantly different than the percent oxidation of the 
duplex in the absence of the ligand (Table 7.1).  
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For comparison, the KMnO4 reaction with complexes containing echinomycin 
with ds5 were also examined. Echinomycin/duplex binding stoichiometries of 1:1, 2:1, 
and 3:1 were observed in the mass spectrum, and the corresponding percent oxidation 
values calculated for these complexes were 51%, 67%, and 69%, respectively. The 
smaller duplex distortion imparted by actinomycin-D compared to that of echinomycin is 
reflected in the lower percent oxidation values for these actinomycin-D/duplex 
complexes and is likely the result of the monointercalative binding mode of actinomycin-
D. It is also possible that the cyclic peptides of the molecule hinder the access of the 
permanganate ions to the thymines. 
Ethidium bromide is another monointercalator that has been shown to induce 
KMnO4 reactivity in previous studies.
30 Like actinomycin-D, the DNA unwinding caused 
by ethidium bromide is not as significant as that of echinomycin,51 resulting in decreased 
thymine hyperactivity. The conformational changes induced by ethidium bromide 
binding were thus examined by our oxidation/ESI-MS protocol.  Prior to the KMnO4 
reaction, a solution containing ethidium bromide with ds1 was incubated, followed by C18 
spin column purification. In the mass spectrum of the resulting solutions, abundant 
ethidium/duplexes complexes with binding stoichiometries of 1:1 and 2:1 were present in 
the mass spectra (spectrum not shown). The spectrum of the solution containing ethidium 
bromide with ds1 after the 20 min. reaction with KMnO4 showed no ethdium bromide/ds1 
complexes (spectra not shown). However, the abundances of the oxidation adducts of the 
free duplex in the 5- charge state were significantly greater than those of the oxidation 
adducts of ds1 in the absence of ligand. The percent oxidation of ds1 in the absence of 
ligand was 15%, while after the addition of the ethidium bromide, the percent oxidation 
was increased to 40% despite the apparent lack of retention of the ethidium bromide by 
the duplexes after KMnO4 oxidation  
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These results suggest that ethidium bromide  reacts with KMnO4, causing it to 
dislodge from the duplex, either during the oxidation reaction. In the absence of KMnO4, 
ethidium bromide remains bound to the duplex after the spin column clean-up step.  The 
increase in the degree of oxidation of the drug-free [ds]5- ion in the spectrum obtained for 
the solution that contained both the duplex and ethidium bromide indicates that the 
ethidium bromide induced the thymine reactivity of the duplex prior to its dislocation. 
Thus, the KMnO4 reactivity induced by ethidium can be assessed by examining the 
relative increase in the percent oxidation of the free duplex. The percent oxidation results 
summarized in Table 7.2 indicate that the duplex distortion induced by ethidium bromide 
was greater than that caused by actinomycin-D, but not as dramatic as that caused by 
echinomycin.  
In a recent study, we examined the binding affinities of a series of new threading 
bis-intercalators47 for different DNA duplexes by ESI-MS/MS.11 One compound, cis-C1, 
demonstrated a high degree of binding specificity based on our ESI-MS screening results, 
and the bis-intercalative binding mode was confirmed by subsequent NMR studies.59 We 
examined the KMnO4 reactivity of DNA duplex complexes containing cis-C1 to 
determine how the degree of oxidation induced by the new bis-intercalator compares to 
that of echinomycin. An abundant complex with 1:1 binding stoichiometry in the 6- 
charge state is present in the ESI mass spectrum of a solution containing cis-C1 with ds5 
prior to the KMnO4 reaction (spectra not shown). After the permanganate reaction, one 
oxidation adduct was formed for the cis-C1/ds5 complex, and the percent oxidation was 
calculated to be 40% (Table 7.1). Compared to the percent oxidation of the duplex in the 
absence of the bis-intercalator ligand, 18%, a modest increase in the degree of oxidation 
is observed upon cis-C1 binding. The duplex distortion induced by cis-C1 is considerably 
greater than that caused by actinomycin with the same duplex (only 19%) which is 
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expected since actinomycin is a monointercalator whereas cis-C1 is a bis-intercalator. 
However, the percent oxidation suggests that the distortion of the duplex by cis-C1 is not 
as great as that caused by echinomycin, as evidenced by the moderately greater percent 
oxidation value for 1:1 complexes containing echinomycin with ds5 (51%). 
Hoechst 33342 (structure shown in Figure 7.1) is a well-studied minor-groove 
binder known to target A/T rich regions of a duplex. Compounds that bind to the minor 
groove of DNA typically do not distort the duplex as significantly as do intercalators60, 61 
and as such, do not induce KMnO4 reactivity. The ESI mass spectrum of a solution 
containing Hoechst 33342 (abbreviated as “H”) and 
d(GCGGATATATGGCG/CGCCATATATCCGC) (ds1) prior to the permanganate 
reaction is shown in Figure 7.5a. An abundant 1:1 complex is present in the 5- charge 
state at m/z 1795 and a much less abundant 2:1 complex is present at m/z 1885. The 
corresponding mass spectrum of the solution after the KMnO4 reaction is shown in Figure 
7.5b. The relative abundance of the Hoechst 33342/duplex complex at m/z 1795 has 
decreased, and a new peak is present at m/z 1791 that is consistent with a dehydrated 
Hoescht 33342/duplex species, not a typical oxidation adduct. To identify the new 
species at m/z 1791, CAD experiments were undertaken on the ion (spectra not shown). 
The ion dissociated to form an ion at m/z 1705, which is consistent with the m/z of the 
original duplex. Upon a second stage of collisional activation, the resulting ion of m/z 
1705 dissociated in a manner consistent with the fragmentation of native duplex ions in 
the 5- charge state (spectra not shown) These results suggest an unusual reaction between 
the bound Hoechst 33342 and KMnO4 but not the oxidation of the duplex The Hoechst 
ligand apparently reacts with KMnO4, dehydrates, and yet remains bound to the duplex to 
form the observed product of m/z 1791. This reaction also caused the decrease in the 





Figure 7.5:  ESI-mass spectra showing solutions containing the duplex 
dGCGGATATATGGCG/CGCCATATATCCGC) and Hoechst 33342 (H) 
(a) before reaction with KMnO4 and (b) after 20 min. reaction with 
KMnO4. Ions containing oxidized thymines are labeled with a black 
triangle, with the number in parenthesis indicating the number of adducts 
each peak contains. 
 
Low abundance oxidation adducts associated with the complex at m/z 1791 and 
1795 are present as shown in the spectral enlargement in the inset of Figure 7.5b; 
however, the percent oxidation for these complexes does not exceed 20% and in fact is no 
greater than the oxidation value of the drug-free duplex The significantly lower percent 
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oxidation value of the Hoechst 33342/duplex complexes compared to the 
echinomycin/duplex complexes is consistent with the low degree of distortion of the 
duplex by minor groove binder ligands.  
7.3.5 CAD of Oxidized DNA 
In addition to observing oxidation adducts induced by ligand binding to duplex 
DNA, another important aspect of the KMnO4 experiment is determining the site of 
oxidation. In traditional gel-based experiments, oxidation sites are mapped via a multi-
step procedure in which the oxidized DNA is cleaved adjacent to the modification sites 
by a piperidine heat treatment, followed by DNA precipitation, and then subsequent gel-
analysis of the products.30, 31 Rather than employing the piperidine treatment, our strategy 
entails direct analysis of the oxidized DNA adducts based on CAD to determine the site 
of oxidation, thus simplifying the analytical scheme.  
The CAD spectra of intercalator/DNA complexes have been previously 
evaluated.8, 62, 63 These complexes typically dissociate via the ejection of the ligand, 
leaving the drug-free duplex ion, or by separation of the single strands of the duplex with 
the ligand remaining bound to one of the strands. The MS/MS dissociation pathways of 
oligonucleotides have also been extensively examined,44, 64 and systematic interpretation 
of the fragmentation patterns has been used to determine the site of covalent 
modifications of nucleic acids based on diagnostic a –B and w sequence ions that result 
from the backbone fragmentation of single strand oligonucleotides.24-27, 65  
In the present study, the most abundant oxidation adducts were isolated in the trap 
and subjected to CAD. For example, Figure 7.6a shows the CAD spectrum of the [ds + 2 
x E + O]6- ion containing two molecules of echinomycin and duplex ds1 that was 
originally observed in the ESI mass spectrum shown in Figure 7.4c at m/z 1789. After the 
first stage of CAD, the complex dissociates by strand separation with one echinomycin 
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molecule remaining bound to each single strand. The mass of the ions containing the 
d(CGCCATATATCCGC) single strand (labeled ss2 in Figure 7.6a) is shifted by 34 Da, 
indicating that the oxidation occurred exclusively on ss2 rather than ss1. The [ss2 + O]3- 
product ion was subjected to a second stage of collisional activation (MS3) to gain 
information about the specific position of the oxidized base. As shown in Figure 7.6b, the 
MS3 spectrum contains many informative a-B and w ions, some of which contain the 
mass shift characteristic of the oxidized base. The sequence overlaid on Figure 7.6b 
summarizes the diagnostic cleavages (labeled with slashmarks) in the spectrum, with 
those containing the mass shift labeled with a “black triangle”.  
 
 
Figure 7.6:  ESI-MS3 experiments for  [ds + 2E + O]6- containing 
d(GCGGATATATGGCG/CGCCATATATCCGC) and echinomycin (E): 
(a) CAD spectrum of  the initial [ds + 2E + O]6- complex and (b) MS3 
spectrum of  the [ss2 + O]3- product ion. “O” is indicative of an oxidation 
adduct. The sequence structure in Figure 7.6b summarizes the sequence 
coverage. The fragments containing an oxidation adduct are labeled with a 
black triangle. The thymine that was determined to be oxidized is underlined 
in the sequence shown in Figure 7.6b.  
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Based on the cleavage pattern, T6 can be identified as the sole oxidized residue. 
The key fragment ions for making this assignment are the w8 ion that does not contain the 
mass shift and the (w9 + O) ion that does contain the oxidation mass shift. Because the 
echinomycin molecule binds to the G/C rich regions of the duplex, it follows that the 
thymines closest to this region, like T6, will be most easily oxidized. The clarity of the 
fragmentation pattern is remarkable, as well as the fact that the oxidation occurs 
exclusively at one specific thymine site. The abundant oxidation of T6 over T10, the 
other thymine in the sequence that is close to the G/C rich region of the sequence may 
occur because this thymine is flanked by two adenines and previous studies have found 
thymines adjacent to short A-tracts are more susceptible to the permanganate reaction.66 
The preference for thymine reaction on the C-rich single strand is not full understood at 
this time and merits further study. 
The sites of thymine oxidation determined by CAD experiments for the other 
drug/DNA complexes examined in this study are summarized in Table 7.2. In most cases, 
the CAD results confirm a single thymine oxidation, not a distribution or ensemble of 
oxidation sites.  Thus, the oxidation process displays striking selectivity that makes mass 
spectrometric analysis a natural fit for pinpointing the oxidation sites. The thymines 
identified in Table 7.2 are all with in 4-5 bases of the proposed 5’-CG-3’ intercalator 
binding sites or adjacent to G/C rich regions of the sequence that are likely intercalator 
binding sites. Future studies will be aimed at examining trends in the sites of oxidation. 
One result of note involves the complexes containing echinomycin and 
d(GTAGAGTCGACCTG/CAGGTCGACTCTAC) (ds2). As discussed above, the 
oxidation of complexes containing this duplex were examined to maintain consistency 
with a previous gel electrophoresis study of the binding of echinomycin to duplex DNA 
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assessed by chemical probes, including KMnO4.
31 The high affinity binding site of 
echinomycin on the duplex was determined to be the central 5’-TCGA-3’ site.31 Based on 
the strand separation products present in the CAD spectrum of the [ds + E + O]6- complex 
in our present study, the site of oxidation was determined to be located on the first single 
strand, d(GTAGAGTCGACCTG)  (spectra not shown). However, the MS3 spectrum of 
the [ss + O]3- ion resulting from the first stage of CAD was inconclusive since there were 
product ions suggesting that the oxidized thymine could be the T2 or T13. It is likely that 
the [ss + O]3- species consisted of two population of ions in which the thymine at position 
2 was oxidized in one population, while the thymine at position 13 was oxidized in the 
other, suggesting that the duplex can unravel at both ends. Unlike the other DNA 
sequences used in this study, d(GTAGAGTCGACCTG) contains two thymines (T2 and 
T13) that are located at equivalent positions from the ends of the duplex, and thus may 
have roughly equal susceptibility to thymine oxidation upon echinomycin binding. 
 















Sequence and Thymine Oxidation Site(s)aLigand
 
aThe site(s) of thymine oxidation are shown in bold.  
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To further ascertain the regions of DNA unwinding for this duplex, CAD studies 
were performed on the [ds2 + E + 2 x O]6- complex, the complex containing two sites of 
oxidation.  Upon the first stage of CAD, the resulting strand separation products revealed 
that the second site of thymine oxidation was located on the second strand, 
d(CAGGTCGACTCTAC).  Subsequent MS3 experiments indicated that T12 is the 
position of the second oxidized thymine (spectra not shown). This is the same thymine 
that was found to be oxidized in the gel-based study by Bailly et al. using a longer 
duplex.31 When the structure of the duplex is considered, the thymine at the twelth 
position on the second single strand d(CAGGTCGACTCTAC) is adjacent to the second 
thymine on the complementary first strand, d(GTAGAGTCGACCTG), which confirms 
that this region of the DNA is especially distorted upon binding echinomycin.  The sites 
of thymine oxidation correlate with the results of the past gel experiments31 and support 
that echinomycin is bound to the 5’-TCGA-3’ region, thus promoting oxidation around 
this site. 
7.3.6 IRMPD of Oxidized DNA 
IRMPD has also proven useful for gaining sequence information of DNA 
molecules and sites of modification.45, 46 During IRMPD, ion activation is independent of 
the RF voltage applied to the trap which eliminates the low mass cut-off problem 
characteristic of CAD experiments in a quadrupole ion trap.45  Ion activation by IR 
photoabsorption is a non-resonant process, resulting in increased secondary 
fragmentation of DNA and subsequently more a - B and w ions without the need for 
sequential stages of ion isolation, activation and dissociation that are common for CAD 
strategies.45 To explore the potential merits of IRMPD for the characterization of DNA 
oxidation adducts and determination of oxidation sites, several pilot IRMPD experiments 
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were undertaken in comparison to the CAD results described above.  Figure 7.7a shows 
the IRMPD spectrum of the [ds + 2 x E +O]6- complex containing echinomycin and 
duplex ds5 using 50 W laser power and an activation time of only 1.7 ms. The types and 
relative abundances of the fragment ions present in the IRMPD mass spectrum are quite 
different from those in the CAD spectrum of the same complex shown in Figure 7.6a. 
While strand separation ions dominated the CAD spectrum, they are essentially absent in 
the IRMPD spectrum because these ions have undergone efficient IR absorption and been 
converted into informative sequence a - B and w ions. The site of the oxidation can be 
determined readily from these sequence ions, as shown by the cleavages marked on the 
duplex sequence structure overlaid in Figure 7.6a, thus eliminating the need for a second 
stage of activation which is typically necessary for more complete sequence coverage in 






Figure 7.7: IRMPD spectra of [ds + 2 x E + O]6- using (a) 99% laser power and 1.7 ms 
irradiation time and (b) 99% laser power and 2.5 ms irradiation time.  
 
The relative abundance of the sequence ions produced upon IRMPD can be 
controlled by varying the irradiation time. This is demonstrated in Figure 7.7b which 
shows the IRMPD spectrum of the same complex that was dissociated in Figure 7.7a, [ds 
+ 2 x E +O]6- , with an irraidation time of 2.5 ms. The precursor ion has been totally 
converted to fragment ions, and the relative abundances of the lower mass a - B and w 
ions are significantly increased compared to those in Figure 7.7a. The ability to 
effectively “tune” the relative abundances of the sequence ions using different irradiation 
times during an IRMPD experiment is particularly beneficial for identifying the site of 
thymine oxidation without requiring more elaborate MS3 experiments. 
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An ESI-MS technique employing KMnO4 has been developed to assess the 
distortion of DNA duplexes upon ligand binding. Adducts consistent with the oxidation 
of thymine nucleobases are detected in the ESI mass spectrum, while CAD and IRMPD 
can be used to identify the specific sites of oxidation. Ligand binding sites can be 
determined based on the thymine oxidation pattern. The technique presented here 
represents an alternative to traditional gel-based KMnO4 experiments and is attractive due 
to the elimination of the need to use both radiolabeled DNA and the piperidine heat 
treatment required to identify the site of oxidation, while also offering excellent 
sensitivity and facile adaptation to high throughput screening applications.  
Significant differences in the extent of oxidation of thymines in single strand 
DNA compared to duplex DNA were observed, and the susceptibility of thymines in 
drug/duplex complexes were significantly enhanced, presumably due to conformational 
changes of the duplex upon drug binding. The bis-intercalator echinomycin caused the 
most extensive thymine oxidation, followed by the threading bis-intercalator cis-C1, and 
the monointercalator ethidium bromide. Actinomycin-D, another monointercalator, and 
the minor groove binder Hoechst 33342 did not substantially increase the reactivity of 
thymines with KMnO4. In addition to the type of drug bound to the duplex, other factors 
that influenced the extent of thymine oxidation were the size of the duplex, the number of 
bound ligands, and the proximity of the thymines to the termini of the duplex. The ability 
to assess the KMnO4 reactivity induced by ligands that become unbound from the duplex, 
either by reacting with the permanganate ion or as a result of the post-oxidation C18 clean-
up procedure, is also demonstrated. Multi-stage CAD experiments allowed confident 
determination of the positions of the oxidized thymines.  As an alternative to CAD and 
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MS3 approaches, IRMPD offers a promising option that results in more abundant 
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Chapter 8: Conclusions 
The results of this dissertation have contributed to the field of bioanalytical mass 
spectrometry by extending the use of ESI-MS to evaluate novel types of drug/DNA 
complexes, and by demonstrating how ESI-MS can be used to gain structural information 
about DNA and drug/DNA complexes. The clinical importance and structural diversity of 
DNA-interactive compounds is presented in chapter 1. In recent years ESI-MS has been 
developed as a tool for the analysis of drug/DNA complexes because it offers the 
advantages of improved sensitivity and faster analysis times over traditional, solution-
based techniques. As reviewed in chapter 1, most of the work done in this area has 
focused on examining DNA complexes containing well-studied, commercially available 
duplex-interactive drugs. These past studies were important because they demonstrated 
that not only are non-covalent drug/DNA complexes retained in the gas-phase, but the 
sequence selectivities, binding affinities and complex stoichiometries observed by ESI-
MS mirror known solution behavior. These reports laid the groundwork for the studies 
presented in this dissertation.   
In chapter 3, the binding of threading bis-intercalators with cis- and trans-oriented 
structures to DNA duplexes with different sequences is presented. The compounds used 
in this study were designed to undergo more specific binding interactions with DNA 
duplexes. ESI-MS was used to quickly screen the binding of the compounds to a series of 
duplexes containing different potential high affinity binding sites identified in DNase I 
footprinting experiments. The binding affinities of the compounds for different sequences 
as determined by ESI-MS correlated with the results of the footprinting experiments, 
further establishing ESI-MS as a screening tool. Specific binding was assessed in ESI-
MS titration binding experiments that determined the cis-oriented ligand exhibited more 
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promising specific binding behavior by forming complexes with well-defined 
stoichiometries, even at high ligand/DNA molar ratios. The trans-oriented compound 
formed ligand/DNA complexes with 2:1 and 3:1 binding stoichiometries even when each 
duplex contained only one high affinity binding site, which is suggestive of non-specific 
binding. 
The evaluation of metal-mediated DNA binding by ESI-MS is demonstrated in 
chapter 4. The binding of a series of benzoxazole analogs with different amide- and ester-
linking side-chains with duplex DNA is examined. These compounds are unique in that 
some of them, notably the ligands with shorter side chains, will only complexes with 
duplex DNA in the presence of divalent metal cations. The ligands form complexes with 
the metals and then bind to duplex DNA forming ligand/metal/DNA complexes with 
1:1:1 and 2:2:1 binding stoichiometries. Cu2+ was the most promising for promoting DNA 
binding, following by Ni2+. Another interesting result of the study was that the analogs 
with the most dramatic metal-mediated or metal-enhanced binding behavior were also 
found to be the most cytotoxic against lung and breast cancer cell lines.  
ESI-MS analysis of quadruplex DNA was explored in chapters 5 and 6. The 
quadruplex-selectivity of perylene diimides with different side chains was determined by 
ESI-MS in chapter 5 by evaluating the binding of the ligands to quadruplex, duplex and 
single strand DNA. Three ligands, one containing basic side chains, one containing 
anionic side-chains, and one benzannulated compound were determined to be the most-
quadruplex selective. The ESI-MS results correlated well with spectroscopic 
experiments, demonstrating that ESI-MS can be used to investigate the selectivity of 
ligands for different DNA structures which is increasingly important for developing 
compounds reducing the cytotoxic side-effects. 
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The success of ESI-MS for examining ligand binding to quadruplex DNA spurred 
interest in further examining the gas-phase stabilities of different quadruplex structures as 
detailed in chapter 6.  Energy-variable CAD experiments and molecular dynamics 
simulations were performed on series of four-, two- and single stranded-quadruplexes 
with different sequences and numbers of G-tetrads. The molecular dynamics simulations 
confirmed that the quadruplex structure is maintained with some distortion in the gas-
phase. Free energy analyses were also performed on the different structures and the 
stability ranking of the quadrupelxes correlated well with the relative stabilities 
determined by the energy-resolved CAD experiments. The results of this study suggest 
that energy-resolved CAD curves could be used to rapidly screen the gas-phase stabilities 
of different quadruplex structures. 
The seventh chapter of this dissertation describes the use of ESI-MS to gain 
information about conformational changes to DNA upon ligand binding, as well as 
determine ligand binding sites by utilizing the KMnO4 reaction. The ESI-MS technique 
was developed by examining the oxidation of thymines on single strand and duplex 
DNA, with the duplexes exhibiting a significant resistance to the reaction. DNA 
complexes containing different drugs were also subjected to the oxidation reaction. Bis-
intercalators were found to induce the most KMnO4 reactivity, while minor groove 
binders cause little to no increase in the oxidation. CAD and IRMPD experiments were 
also used to determine the site of oxidation based on oligonucleotide fragmentation 
patterns.  
The work presented in this dissertation demonstrates that ESI-MS is a useful tool 
for examining drug/DNA complexes.  My work has shown that tandem mass 
spectrometry can be used to map the sequence selectivities and relative binding affinities 
of new DNA interactive ligands in a way that consumes very little sample and is easily 
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adaptable to high throughput screening applications.  Ligands that are selective for 
quadruplex, duplex, and single strand structures can be pinpointed, binding 
stoichiometries can be determined, and non-specific interactions can be differentiated 
from specific binding modes.  Moreover, ESI-MS/MS can be combined with chemical 
probe methods to yield a complementary method for determining ligand binding sites and 
identifying conformational changes of DNA upon ligand interaction.   
Despite these inroads, there is considerable room for future work in this field. One 
major challenge that merits future work is developing ESI-MS techniques that are 
capable of analyzing longer DNA strands. The present method has proven to be 
successful for examining oligonucleotides containing 50 bases or less, however the 
ability to analyze larger DNA structures will make the technique more biologically 
relevant. The use of longer DNA strands will certainly necessitate more high 
performance mass analyzers with large mass ranges, or the use of chemical or enzymatic 
cleaving agents to cleave the DNA into smaller pieces more suitable for ESI-MS analysis.  
The use of chemical and enzymatic probes to gain structural information about 
ligand binding sites and binding modes is another important area of future study. In 
addition to the KMnO4 reaction present in chapter 7, there are numerous other 
footprinting and chemical probe techniques that could be used in conjunction with ESI-
MS including DNase I, the hydroxyl radical, and MPE-FeII. The use of ESI-MS to 
examine drug/DNA complexes is growing field, the capabilities of which are far from 
being fully developed. 
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